var title_f4_0_4096="Mechanism for humeral fracture from abuse";
var content_f4_0_4096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Humeral fracture from abuse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although the exact mechanism of injury may vary in child abuse, fracture of the proximal humerus may result from twisting at the elbow or forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4096=[""].join("\n");
var outline_f4_0_4096=null;
var title_f4_0_4097="Gadoterate meglumine: Drug information";
var content_f4_0_4097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadoterate meglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16424023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16424027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16424026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dotarem&reg;: FDA approved March 2013; anticipated availability is July 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16424029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance imaging (MRI) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity in the brain, spine, and associated tissues",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88898 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4097=[""].join("\n");
var outline_f4_0_4097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424023\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424027\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424026\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16424029\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4098="TM atelectasis";
var content_f4_0_4098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Collapse (atelectasis) of the tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Collapse (atelectasis) of the tympanic membrane is caused by poor eustachian tube function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4098=[""].join("\n");
var outline_f4_0_4098=null;
var title_f4_0_4099="Transabdominal preperitoneal hernia repair";
var content_f4_0_4099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transabdominal preperitoneal hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, DB, Maithel, SK, Schneider, BE. Atlas of minimally invasive surgery. Cin&eacute;-Med, Woodbury, CT 2006. Copyright &copy; 2006 Cin&eacute;-Med, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4099=[""].join("\n");
var outline_f4_0_4099=null;
var title_f4_0_4100="Nerve supply to leg";
var content_f4_0_4100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bony relationships of the nerve supply to the leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 519px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIHAWUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKxfBd7fah4YsLrVggv3U+cEXaAwYggD8KANqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKbLIkMTySuqRoCzOxwFA6knsKAHUVz39t3d9G0uk2kSWOzK3985jjY54KJjcyn1O0HjBINVVvvFOnwi4u7XTdbtict/Zm6CVV9VSRmWT/vtT6A0AdXXMeF3aw1zXNFnld2Ex1G23LgeTMSSoPfbIJPoGX1rQ0HxFpuuq4sZ2FxGP3trPG0M8X+/G4DD64wexNV/FQFi1prwLAadu+0AHANs+PMJ/3dqv/wAAx3oA36KbHIksaSROrxuAyspyGB6EGnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVma9rMOjWySSQXV1NI2yK2tIjJLIepwvoB1JIA9a5K5+KFhFaXDjRNe+1Qy+SbeS08s7vUuTtxnrgkjnigD0Cs3XNZtNGt45LrzHkmfy4IIULyzvgnaijknAJ9gCTgV5vdeM/ENr5Gqy219cWrMGMFnbLJbJHyrLK+DIp4LCQfL1DKvNJefEjzPE8epQ6bqx0HTrMG8ItlYr5x+WQYOGQBM7lJGMgZIIoA7K61HxbMwbTPD+mxw9cahqRjkI/wB2OKRR/wB9Gs++nEmsWdp4v1W2WSXbJFotijyK5ycNI2N0i5HAIVcjkHHHG658aEu2g0/w5ZXw1yc77eCSzeVWXGQr7cYbnBAyAT1yCK2vh/4V1CzvJ/FHjBFGozStKkEcas0RbA3uygE4XgL0Ubj1JwAdLdSW7Sf2l4l1FLbTVnZba1u40ijyMgO28ZJxkjJGBzj01JrW3nskttPZ7GMSDyZLbCDOzcGUdHXB6cjg8cZo1m1h1G1vIb9HNvEFnimgJEkbDPKkc7wVPTruwR1zyGifaPCviT7JqUh/s+UF42VWSGNnZR5iL0TcxCsnO1mDLgSMAAa2s2C3cUA8R6fcm6ify4tV0tmWRB135QiSMEjlfmX1JFWVuNR0JHi8QzLqekMuPt/khXiHOROijaVx/wAtFAA53KB81a1vdPHLa25QtcXG6eRHk5iT9ehKrgY7mr3nRNcPb71MyoHZO4UkgE+xIP5GgDlvClwdJ1Wbw1cOGtxGbrSZS+7zrYn5ox/1yLKo55VkPrXW1534mtU8PXuly20q29tZ30d3EDk7IJHWG4iB5wgMyOB26DAUV6JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDd3MFnAZrqVIYVIBdzgDJAGT9SKmpGUMpVgCpGCDyCKAAEMAVIIPII71U1TU7LSrY3GpXUVtCP4pGxn2A6k+w5rGn8C+GZnZn0e3G7qE3Iv5AgCpDYeGvClqbxo9O0qNPl+1SbUbn+He3Jz6ZoAyZtfSzvo9V16G4slud9rp8Dx8onBMkhAJQuQvB+6FXODmuU8L6Xeaxd2d3LaX+J7iWX7ZtjEaKR94Z+YHjsD8xOcDpuR614Mub/AMyI6tf6nAzKJo7S8kmDY+YKypxkYyBgEdsV6HAweCNlRkVlBCsu0qMdCO30oAi02zj0/T7azgLmK3iWJC7bmIUAAk9zx1rjtUso9O+IWm3EIksbe/RoXeNYzHczD94I2BBIJVHIIxyD179zXD/FiB7jStLFqXW/h1CGe1ZScLKG2jcB1X58H6/SgCjfT2x8W3OjRNOt1CiStsiXY5+aSNRtIdXKoxB+6TGOSdymXT9W1JtKtfEmpX8d7oV8m26sool2WUbcBwcB2KniTd0+YgLtwYfFVosiQ6zdzy20kD+WXUAshZ12Rsw6+XcBSCeNrn1JrV8P6jBf3zx/Y410bXLc3UCuM+YxVfMDL0G5XUlfVZOtAGg9xJBYtHIJRElpKu48rujYKD0zk5yOOR60zxfp632kyJ5fmSWqG4DOSMqchkx/tJvHoDtOOBipoU0KWV1pN9IqXulGWFW5P+jKUZCc8cxtFnPcGt+2BhcI5E3m58xpG+6qKFP15+n3ifqAVPDF4l3psd7cyRG7Ym1lkHAdo2ZTj2JDMP8AerTg8mK6lhj3GZ/30hznGeBn06cD0U1558LHig8JC5MTSTi6kjt/Mf72EUZ3HsArDPYA+tdR4a1MTS3KP5jMx83PlsXZccSP/c3DG2M/MFUdc8AHNfHC7itvDM4NzHHK1rcL5f8Ay0I2eYCv0aIfjivSRyK8Z8aC08Ua/bxxrKyy2REaee+4OzxxGOaM8qQZFI/3Se9ezUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXL6vop1Xxrpt5fxFtO0q3eaEl8I1w7AZK99ipkE9C9dRXG+JtCk8U+KbG01CPf4dsIxczwyxnZczk/IvowUAk9RyB64AOqhvbSeQJDdQSOeipICfyFWKyNNsNAstRki0y10u3v0Tc6W8caSqp7kKM4qHxtrP9h+GtQvU/10ULtGocB2IH8GQQTyMDHNAFXV/FEkWoxafpNmLiWR2h+13Mnk2iygH90XAYl+OgUjggkHivFviL8f7bStdttJHh27lvraVV1K3nuFhETplgkbFTuUsFbfgAhVx14774QahonjP4fz/wBkX+oL5qLHdW8sn7yzucZaRM5K7mxIOSM8gA7hXiP7WGiiGXS/Fq28DXN8h0u9V487J4WyJAQepCkc5BVRxQB6B4Y+MfgrxhYX+k3M95pWpy2joyai8YiuJPL2cSA4ZvlU5O0kgYrpfD2p22kabYyKSkcV0I40cYGTOY22jpnY7dOuOlfD3h/SZfEPiTTNIsI08+7njtU2bsMWbG856ep6fSvqX4d+NLnx5da/o+UuLCx1uKa1djl3t5btcKAAMBQjNuOT82PegD2qfSNOm8Z35upZle5ton8pZ2jWQncjA7SN3Eace1ZPi27n0XwVqt3pSy/brgm0tTMN5Zy7bnx0AJLkdsBT7VtXcqv41uVhhaWe20+NwGHyb2eQIpPYnLfhXnXxS1KC5/szRrCaVbxdhit5kPk8sAZCcgn92WYKeMgZ5zQB3Wh6TPYaBpWgW7KsqxtPeFkLrGzkvznr85OFzyBzwMG9rcx0Tw9eiwQfaTkRCX5i7YyXJJ+c859zha3LG1g0zT44IzthhTlmYnp1JLEk+uSTXnnxH1yxTR7rUXeedbiBrLTLeM5+1zsCN6oeCoJTD+2f7uQCtoukRwNb6l51zcTX2rQRlpIyHVV/eHOcEbpBkk87QoP3a9WridB0KXQPAHh/T7+QSX1tNavcSIBhp3mUyEdsFnb8K7agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4/wAUaFc+KtftbDUEmj8NWiCedRJtF9MSNqHad2xAuTnhiwHY12FcYdJv/EPie+n1O4vrXR7KZYrWC2vJIftBCAl32EHG5mGCTnap4A+YA6SHTtO01JJbSxgt8DLG2g2sQDnGFGTz2715v41e2W2uLqW5uL2BZd88N9ZyxFFCnCo6oACDgBipPPJNdbrcNvomjzW8D3E094DFm4vtzsOc4Mu7OATwqsfauEWwtba6trnyYtMjh+b7VqTR2oUkEDCtDGx75wRjPfpQBzHw70hPh346vvEVheyTeCNYtd12fNFw9tcD5gZAgzwTIPu8bufa5+0tZWmrfDbXZNOkEybrfWopEO+NyrC3k2noMIyH8/etPUvFvh68CafpV94futQkYxGRb6CaWdiQCIyJMqGx93aw56HvyvijT/CY0jU/7aujZXM0IjurWwvzGqxFhmSfChSSVQBcFmI9M7QD578E6jc+DrLUvEEMhDzRzafp0ij5XmK4eUA4OER+CR96RPQ16h+xjodzfeNNR1YF0sdPt9rkE4llk4RWGcHaFc8DIJHqKjb4aaP4i1KO6h1G81Dw9YItnBaaJHBM546IRJmQ7m3O2wHlidoxXt3hu40XwH8Pp4dLKwXmqvI2nWtrBiaQ7dkbBOT/AAbssT15JNAGpY6xDeal4h1OBXisvtBL3srqsUfkL5SlgTkgtllAH8Oe4rjdQvI/E/j+3nsmu0FrC0SOIGwyGUSZcgExrsUjozAsCQvGLfiLR9QmsLe9165NjJCif2do1uN0m2NSPMfBHIUt8z8Akfczg+deK5NVt3tNMgkngindvOs7KbY3k+Uylyw+c4K7jjHToQM0AfTXiVYW0L7NfW8twxVSUt4GddykE9wFHH8TDiuK+H/hy0bxjqN3eWDwS2scdzbQysHKedJOQ7nJYvgAAMcr1wCat2/w8gGkWv8AwiGvapo9pKFkkgaR5o5QVwwZWYFWP8XI5HQV2ugaLBosNwscs1xPcSmaeeZtzu2AAPZQAFA7AUAUviBKtt4P1K7cZW0Vbs9ePKdZM8f7tdCDkZHSqmr2aajpN7ZSrujuYHhYeoZSD/OoPDU5uvDulzs29pLWJi3qSgzQBpVBb3dvcS3MUEySSW0gimVTkxuUVwreh2up+jCp64Pytd0+/wDG6WOhy3Emp3P2ixuXlhFsx+w28QEg8wSAeZEwOFzjkUAdvcXMFt5f2iaKLzXEaeY4Xe56KM9SfSpa8Wg8F6qY5/N0O6k05L6wvU0+VrSIsyCVZvLSJxGpwyfebJA+8TV+Pwrrq65qVzLBqJupJL14bqGS2WKSGSOQQwuxbzcIGjULjaGQMDjNAHrVVrO+tr2S6S1lEjWs3kTAAjY+1W2/kyn8a8i8XeDNaPhmCx0fS55LlNKd4biOaGS4j1AoOWluHJQZC/NH82c8rgE+jeFdPurG98RyXUXlpd6m1xAdwO+PyYlzweOUYYPPFAHQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVzPxQnltvhp4tntpXhni0i7eOSNirIwhcggjkEHvXK+IbrVPClvp1vGbTTIr6eTz70XpaOPagKJ5lwrKhYluo5C4HJGAD1CivJrjxR4jktpbhdTskktLbSnZbSJZYJ3uZjHIwY8lMDK7SO3JHBml8T6jbajNpmp6+mnWVtdXcJ1eaKIM7Rx27xRMCAmWE0h4AJEWBgnNAHqdFeVweLNek07UtT1OY2ENlp1nNNZw2ymSOaeEF8u5wqoxycjAAJORxVfw1r99rPiHR4768t7wWWu3FrHcW8yyrLGdNEwJdERWIMpGQoHA64yQD1yivPPGev6vYa7rIsb0Q2ul2On3gh8lW85prmeN1diCQu2Ifdwc856g4cnjbX1udela806GW0j1H/iWzSp50QhVzC6xbQ5yEViWYqwfK4GKAPX6K811TXfEmjGwtJbuG+utdt1hsJktNiwXZcbsqCcqInMmCekD880aB4o1m98ePYXV5YQRi+urZ9NmnRZhBGH8qVI9vmEttRyxYptc4AIFAHpVFYN9deJ0u5VsdH0Wa1B/dyTarLE7D1Ki2YD/vo1B9s8Y/8AQC8P/wDg6m/+RKAOlqO4kaKFnSJ5mA4jQqGb6biB+ZrnvtnjH/oBeH//AAdTf/IlH2zxj/0AvD//AIOpv/kSgCWx8VWdzcm2mtNVsrkKW8u5sZFyB1IYAqcZHQms7U/iJolnOsEIvbycnG2C3KqPcvJtT/x6seezvLzxPK114R8KyaxsExM2qzZkUALvGbTDYyASM4yM4yKoWUGp6nc6j/Yng3wsrQy7PtcmpSvatMuMgILdd5UjBIwAwxnIOADe+0XXjD7LdaLp8ulwzIY5tXuFjFwsOcmO3ALHLHgscBeo3EDHgf7XHhhtM0/RtS062jW0jlktpz5YkfLRR7WkkOWdj8+GY5Bxjmvf/D1t4t0bTVtU0Xw9JIzvNNINXlQPI7FnYKLTAGScDsMdetcz4o0nVfGk17pt3ougxzSJtuLd9auUaZFO3dtNsAV+bG8DP3cMMCgD4o8H3L6d410K9liupTbX1vO0dqm6QqHVgEAPJI4A47V9pJFfajBqHirUXC79Pvjbwg7lG1FxKpIyNuGRccEFm/5aGvB4PhlffDzxYb2aODU5rfCxwWlxKHt5HZsOSYRwESQ7sYHDZ6A+4+IINZ1nSY73xJp2j6T4YtIREtk+uzWisuBuEki25LoQFAUY6H72RQB4j+zPpfjgapfz+GtFt1027j+S/wBURxBbODxJGQMu20sNq4zkbiBXql9qekfCrSIToFvceJfEVwy2B1m8lxCsiK42hyT90bvkjB/uk54pfF3iLxjqGl6Xovhyy0rw/ptxcJZKsN2/myL5ka4QtEhRCJADhS3XpjBsfH82iyeEtLniisvJiln2QKWijYBFSJSFBG58KrYXkjjtQBsy3Dto93e3SXbSb4VuJhbpNcXRZt2xcgr8qrtKABAWbHIyeIn0/VdL8Rw+K9R0RxeopeCGV23yIflcyjYNp8tjHgLwAD169JbXOreFrm2tdP2alq2pMr2MLxNuWMIqtcTKHxsGMKoIJ+UZADGs7x3pmpafbxnxPenXr5yZlgvJSYhGQct5SbRGwOApAxwcnI5AO7+Gfi2zvLQCOS5Nrc75YhcbmnV1zuQqARn5W4XPzq/XK56X/hNNL/59fEH/AIIL/wD+M1iNYWGt/DXSrzw1bxWaQQrdWsMDCIREfM6ZHQhgfT51GTjNN8NfE2z1KKJLyxvFnG1ZZbaFpockAhhjLbWBBHGcEZxQBu/8Jppf/Pr4g/8ABBf/APxmsLwR4osdO8NW1ncWuv74JJoxjQ75vlEr7eREf4ccduh5rvbS5hvLWK5tpBJBKodGHcGs/wAPy7or6LOWgvZlP/Am3j9HFAEmjazbausrWkV/GIyA32uxntSc+glRd3TtnFc/qvjKaytPEOoRaUZ9I0SO4NxP9oCyO8MJkYJHt5XomSwOe2Oa7GsK58J6NdXd7PNbSMb0MLmIXEohm3R+WxeINsYlPlyVzwOeBQBj+JvF95Y6kLDSbCK4uY9QtbSUTybFZJkZsqR0I2gc561HdeP47XXZbGayWSEC4VJ7aV5B5kMbO8bnywithGGA7MCOQO2qngrQ1t54vIunM8kUzyyX07zb4/uMJS5cEdMgjjjpS/8ACE6D9ra4NpMXLzSbDdzGNWmVllZU37VLb3JIAyWJ680AYMvxHFtCy3mlNDeSx2k1rCsxkEiXPm7N5VCVI8iUsAGwAMbs4p//AAsJ3sJriHRZ2eztZb2+jkk8oxwo7pmPcoMhby3ZchAQBkqTiuhuPCWiXAbzbI7jBb24dZpFdEgZ2h2sGyrKZHwykN83JPFRXXgzRLuGOO6gupgiPGWkvp2aVGOWSRi+ZEJ/hcle2MUAQQeMraee0jitpnFzqk2mIQR96O3kn349CIiAPUineB/FQ8UW9zIbeG1lh2Frfz980O4EhZoyqmNxjBHI64Y4NVbOx8J37y+KIWdYLeaS8N1LPPFbK3kGN51ViIypidsyAbTknJIzWnoOnaNpWr39ppzTNqf2eCS4NxcS3EnklpREN8jMduVmwoPB3HHPIBvUUVRv9X0/T4LyW7u4Y1s4xNcDdlokOcMyjkA7TjjnBoAvUVFNcQwSQRzSKjzuY4lJ5dtrNge+1WP4Go9RvrbToEmvZRFE80UCsQTl5JFjRePV3UfjQBZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzdc0r+1bdUS9u7CdCdl1aFBKgIwQCysMH6dgeoFYWn6pf3NxHYeFtNgXRbYeV/adzIDG5UlWWNFO5yCCCxKg4PJ611N6XFncGMkOI22kDJBxxXK/Dm3g0XwTYJJLDHAi7AxG3JyQSTwGJOTkAcEDnGSAX5rfxVGjtBqOi3D5G2OSxliGM8/MJW7e1c/d6XqOu6xcs9poUFzDAUedTLJIZMEL8rxhCvHU7sYHBrrbnxBpdtcWcM17GrXi7oHwTHIME8OBt6D1rkfFL+HLu6uIrTX9Osbvb5d6scoLFJcgbgD8uSevGe54FAHBwmz0TUmvJ2ttU8QIyMCjhIS24xIjySPh2GGwq7VGzAKjNQ+OrqF7uO81m/e7Nzbu0LvIqonzINkalQrAHqEJLcgs1auueFNW0nQmu7LVdP1S2mlRIbiT5PIQkIrBg43DaqgjJyfxNcb4rkUWdxf+JvEEGq3SpKkzy6fcXNtajzEBEbxcKoTAIypLkZcjigDuPBumzalqsV7NpzK/2q3QG6j5gijLSqqnoXONzY4GV75qx8T9FW/+Knh2fUJZFsnsXitokIxPcrKpCuSMYwwYDIyyrzXOfCHX7jxLrOk6hpfl6V4Osb65tbWySDa90y2p/fysWPQZAAGB6kg1o+J9di1nxNYX9rfJIJLe3vdMtHmMci+ZEdwPVSHV1xjnfHtHLCgDcstRhi1zxA0Uz2hSX7LF5Ual447dNgSJX+U/NuZcggFmGT0FSa8h1fQ7ZLvR11NZCd011MfMNypGzKcnJ24IAAHIU46X/CHgXTdb0vUtR1OXUpn1K5uXik89oQsbzMwZEXHUnPzA5wOMcVXVNY0fW30W5ihexsIRJZ3MMiQMYWICqF+7lXUDHbqOCFoAj0zwCt3DG2ma1e6Il6/nX1jaSsILhSMMQrcrliFz8pKrg5xWxpNjaeGfHkMSyXbWd1ZtJDJ57eSHUEtlB8pJxI2TnGRjFbfiyA6T4N1O5jJuL4IsrzNJ5bSOGBGGJ+UAk4Xt0Fc14V1L/hMrGCTUJ2fWNNS4CwSIqpfRyqQjsAOQVwDsOM7ucUAb/wAJmtH8Ih9MWVdPe7uJLdZJN5VWkZsA+mWbHoK2PDrA3euoAQU1Ag5PXMUTcfgwrk/gRNb/APCG3NjbeUBYahPCUT+AswkwR2P7zp29TXTeFwBqvikgsc6mOvT/AI9bccfl/OgDoK86vvDGqSeJtQ1WC3K3R16Ca1uTIpKWf2KGOTAzwpkEmU4LYzg8GvRaKAPF9M8F6/Hoc9tNBqqajLFbRXci3MEcd063MbSSiSNxIz7RIQ7hWwcdcAdTJ4W1C18V29ppisnhWaSG/uf9IOY5oAQIwCdxDkQN6funB+/z39FAHmvwy8N6to2qCXWY78XgtHhu7ktb/Z72beh835G8124YqXUbQzD0qaTw9qcnjB55LCQu2pGc6r5ybDZGHb9n27t/Xjbt2Z+fO6vRKKAPObLwdcx/AVvC8dnFBq02gfZJIS42i6NsEOWBI++OoyOKo6t4Ru7681LULDQ3s5RpunR6dHJLEJIJorq5kkwVchSFkQ7s8hiAfvCvVKKAPNfCvhvVrLxnJfanHftN9pune8ja38ieF2Yxq53ecQoKAKVwpXg46x+NPCl7far4vms9Ja4l1XSYre2ukljULIvmhkbcwIJDJggEe4r06igDy/UvC+tWmoXKeH0Gn2C6o9zA6yqscSNpUsXmFc5x9oZCRjJPzY6mud0PT08SR6pb6FpyrY48PmZYrqGWOSSK+kluX8yN2Vn8oKxO7eRtyMkV7lRQBzvgnS59Hs9StJIBb2o1Cd7SJSNqQsQVCgcKMlvl4x6V0VFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXium+KvC+l+DbPw/rouLu2ui1vdoJXkljuM5aPy1O9AGAwVxg4PHU+1VleINU0zw/Yy6rqZjiCAIGC5kkY/djQdWYngKOpoA+fLjwHcaT9li8L+JdcihkYrb2N5fNG/I6rA42OQOAv6enKXz+NTqFquvawsmn2rq94ptkSZYIlLv5cpVypxGxwCMHkDvX0voGk32r6TqM3jFN/9qMGXTWOUs4QPkj4/wCWg6s4P3uhworyrxL4fQ6pqWg3V0xuPNTz5JXdPtFi/Cb3JwW2faFZsdU5x1oA+efBfjbXtc8WaTod1dQy2WqalbwStLbxebseVQcS7dynBPzAg8nmvqv4tWtrc6fbeDdKL2drexCyneyj3ixSSaJgzopyS+xlAHUsSeATXD+HvgZ4b0qW28R363cSxTwskf2p/wB2/mAbgIVJHPIIcgcdOa6TxDFZeGPsV5ElpbrGwm8mSKaO6RTIQSuCzHeyjLSEsx+UbcgAAltdA0nQfFGn2Ph9me2sop7aNX3bYQtrLlc9CS3JY5z2AwSdf4Y6Yks2oW+q6GdN86wgtRaO4cRrA8gChl44SSFgV6bhzxU2l+Fnh0211rW4hHqLTxLFC7D/AESKQiMjHTzCHJY8gfdBwMlftl9pNhomryW80hgtR9oiQE7WjUJcLwOSUXeo7mDHegDe0/Qtb0jWYP7PvoZtLklZ7nzzhypB/hC4L5x84K553Bj81czeiXxT41XXYbmxWw0IyJpomkKRzS4VZJmkU5KbmCqvQlCe4rPOr3vjbSV1qy8UmDRJblYDp8RS3ZgwIEZYqXy2V6MuRyMdDb+FOlPBvtbiZJZIWEbNCAIsRkbY1AAXIwCcKOAvuSAdxFDpNxp09k8hu7W6JjnkmlLgyZVQvJ+Uk4IAxyM9a89vvh/a+GZp/EPhjVb5L+z4gtmiWbcVJRkIODtO9QSMEAA89/RrOC9BjgkllZYne4MsiBFfJYIrAYzz85wBziue+Id++g+Ekl+027SMjbjIOZXbGXx2C5Zs9sL9KAM74Sz6bP4g1640e2+wpfRW93c2IYkQSkMMgdBuGQQMDMZxnrXb+Go9v9qvuUmS/lYgDGMYXn/vnP41y3wY8PPpegz6rdKUutYMc4iLlvJgVAsSZPfblj7se+Ses8Lyi40ozBNm+5uDjOf+Wz80Aa1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZF94l0axv/sV3qNvFcgqrKzcRlvuhz0QtkY3EZ7ZrXrznWdG1gaX4x0W20k3g16WZob3zoxFGJYVjzMGYP8mDwqtlVXGDwADvbO+tr2S6S1lEjWs3kTAAjY+1W2/kyn8aktLmC8tIbqzmintpkWSKWJwySIRkMpHBBBBBFeZ2fhXUF8WzyHSpULav9qbVnliIktfsqRtHgOZDuYY2lQP4s5ArK07w14h0fwdp2n2GhXa3Mfh2fSZo4bqBR9rKQhZ8mQDYxRsH7w7qM0AezVFLcwQzQRSzRxyzsViRmAaQgFiFHcgAnjsDXnlz4a1Xb4nvlsvtWoTJBFZR3FxvjaPyIllCxlwgYkSfexuIGTt5rH0jwfqUF5ZTXmi3U9hZ669xb2sr2qyRW72KJuVI2WJVE+87QQe+GzkgHsFFePx+FPEI8P3dtBYT2uonRJrO8nF0gOqXrNHtnVg+QRtlO59pAlA6Lx2/ijQZB4Gu9I8PxShyAIlE5D8yBmPmM2c/eOSc0AdTRXkuseDtWW+vIbOxdvDq6o80Wn2/kMGja0twHWOVhHgTLOSrEHLbgDxm9YeBrq+N6upyanGRpFtaWN1cXe6WKYLKruyoxQyDchLEEE9CeaAPTKK8lvfDfijVdMtNQ1m1Zru5vTNqOlwSQzKsaxeVEqiQiJwCPMIJHMhPJUCu40fSbxfCFhp41HVbC4iRV89zBJcgA8BiVkjJxgHGfr3oA6Kob2SaK1ke1hE84HyRl9gY+m7BxWB/wjmqf9Dp4g/782H/AMjUf8I5qn/Q6eIP+/Nh/wDI1ACzXniueF0tdI0u0mPSW5vWlQf8BRAT9Mj61l+F9F87xZrF/r9yNV1ewnEdrMyFI7aJ4o2KxxZIU5LDdyxGAWNaf/COap/0OniD/vzYf/I1Ztp4f1Jdd1GBfF2vK3lQzNIILHLlt68/6P2EY7d6AO3rzbxFpKeLvGOo2thq9xp9/plvGDLborLlg21JAR8yHdJlQQfcV0qeHdTDAnxlr7AHODDY4Pt/x7VS+HUKka3ekxtNdXrPIYwQOVDgc+gcD8KAOA1zwPrtpPpcm3RbeWS7iiNzbXE8bgk4AClGUggDhtxBPUgCtS08MXK/EbSb3XLhLme2uykQAD+dm2lYTTttXdICuFAUKgzgZOa73xf00UFygOpwZx3xkgfmBVfUoVi8XaZKrhmlul3Kf4R9muB/7KPzNAEnxAjSbw1LDJjy3ljLAjOVVw5+nCnmuO+HVlf2ng++0C/Jlu4bdLm3uy+7znMakPgcghgjH1LHrXZeOkifR1WcgLvdxnOCVikbnH0rJ8RG38Oa14dv2EyK7R6ewjY+UAflG72+fdk/88xQBy3wn163yFsm00C/mjM0kc7NErENhI8jOGw3l57IyN8yjPqXnpHck+Sq/vPKjJG0uT8zke2Bn3Kn2riP+EJ02Xwz5toLWHUAvneYzlFCth9jMpyuMKysvKMqsM4OeotkvX0KOPV3gTVEixO8DkhI2bBIYgDdtXrjGQccUAPsIo5zZra3Fy9tGBcbtxHDKfLU55wBzg/7JPU1xOvTDxd4vsdBiN1JZQMWurhWUK6RkFlOBzubapAxww9OO01+caPpF3JFIy3F1IdshBbDsMDp6ABR749ay/h3o8dnb3N8IokaY+REY33r5SE8g+hYuR7bfSgDsaw/BELQeEtKR4/LcwK7Lu3YLfMefxq74g1BdI0HUtScEpZ20lwQOpCKW/pT9HUppFirKFYQICoGAPlHGKALlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVxM/jC4TxjLo7NpdkEuYoIob+V4pbxGVWaSE42tjcwCjcSUIJXtbfxnBJZJd2tndfYpLq3tobuZAsM/m3McGUwS3V+NygHqPl5oA6uiuF1v4k6fpq61ClnPLqOm2sl2LUyxZmSN1Rj8rMUwXX74U4PAODjQm8ZQW9/LaTWdz9qIt1gs0UefJJKJTswSEGFhdslsAKSSMUAdVRWRqGvW+m6D/AGrfwXUEQKI0JjzKrO4QLtBOTuYdCaxbr4haVawqJ4LuO+86WBrJzEsqGMKzkkuEwBJGeGOd6gZPFAHY0Vx7/ETQ9jzQi+ns47eG7ku4rZjDHDKoZHZzgAbTk9wByKn1fxzpGm3E1u/nTXMdwbURpsTe4jWR9rOyrhVdckkcnbyeKAOporMtdbsbvw/BrVq00+nzwLcRtDA8jsjAEYjUFieegGazf+E00v8A59fEH/ggv/8A4zQB0tc15E0XxIE/zfZ7jSdn3uN0c2enriXrR/wmml/8+viD/wAEF/8A/GaxtW8a6bD4g0OdbbWwrvNatv0S9UkNHvAUGIFjmIcDJxk4wCQAdhrskkOiahJBnzkt5GTHXcFOP1rL8AWIsPC9snl7JHLO+erHcQCf+Ahaz9Z8a6aNNmCW2vhnwgzoV6vLEDGTDjvUfh/xxpj6VFutdc3KzxsE0S9cAq7KRkQ46jp2PB5FAG14shWWHTGZipi1G3cY7neBj/x6qmr26f8ACW6RcMV3i4UD1x9nuh/M/wCea424+IWneLPEml2nh6C4vrGzvoTcTy2NysayFwoyQnylcnG/AyM/wjPXa6HbxTZ/MwSNraQAc5+aZD9B+8X9KAKfxK864k0fT4nVUupmSTPXaxWI4/CY9O2au/E+zN54K1IKkjyRxl0EabnzgrleRgjcSG7Yz2pL+S5uviHp9ssCNZW1s0zyluQx4wB+MZp/xJjnufCN3Z2dwLe6uisUUhkKYbO7GRzkhSMDrmgC74WEEOhaYsSsjT20RUP94gRKATz6AVYnt2DeUQztdzDzWB4VFX0PY7QCPVzXP/D/AFePW/DmmJIqmRHlyASQBE+AQfxTr7+ldDG4k1l3KynYDDHz8vADO3uMlV+q0AYHjHU3fULTT7GBpLzzNgdztSNnGFc5HzbeXwP7me1dXZW0NlaQWtrGscEKLHGi9FUDAH5VyOgQz6t4wvNSu7Tbb2Q2W7Tf6xJXUblCjgBUwMnJJc+nPaUAZXimFLrQbq0lbbHd7bVzjtIwjP6NWqBgYHSsLxSlxPLoltbOqCTUY3lz3SNWkI/NFFbtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/qnhhdUuy17qupSWBniuDp5MXk742V158vzMblVsb8cemRVWLwTaxWEenjUtSbTYbiC5t7QtFsgMVwk6Kp2biu6MDDMflJAI4I6qigDh4/hrpa28lu99qUlqbG60+KFmiAhiuHjd9pWMMWBiTDMWPXO6r1z4Ktrm9+3y6nqX9pqYHS8UxCRHiWVQwHl7MlZ5FIKkEHoK6qigDJ1DQ49R0RNNvru6mUSRStOSgkdo5FkBOFC8lRkADjpism98DafcahLfxXd7bX73EtwLiPynK+YkSOgV0ZSp8mM8gnK8EV1lFAGHZeGbK3GorM012uoQR29ys+3Dqkfl9FAxkE57emKy4Ph/ptvpOl2dteX8c+nNK8V8zRyzuZSTJv3oyNuOCcrxgYxgV2FFAEFhbfY7KC382SbykC+ZIFDPjuQoCg/QAegFT0UUAFYni1YFs7K7uGKC0vreVWAztLSCM/hiRgfYmtusrxXB9o8NapHzn7O7Lhtp3AEjntyBQBS8eXDW+hxiOdIJZbqBY3cE/MJAwAA6klcAe9Z3w9nkQ6zot/LJcXdncFpWlAHmeZklgvozBnx0+fFXfFFudQ1Xw6qkNALn7RkDJymGUj2xnn3qSLZD48mTy4w89j5ocPhmw4Ugr3xxg+5oAlfTdP8O+HJLfSLW30+0hYSBIYwqqdwJbHfp+lQ+LWW02agF+aCMO7bsARrPCzZ/AE/nV/xUpbw1qirHJK7W0gSOP7zMVO0L7k4xWN8Rry3tdDkivXhWO9hms9kpGx9yFmzn0RHb8KAJfBs0OqXerazBdNcQ3E3kxErhQidNoPrkZ9cVL4otWv9W0K2MkyQx3H2thFjLGMrtBz/AA/Mc/StTQYmh0azWRY1lMSvIIxhd7ctj2yTVQXUh8YS2+12iSzjIP8ACrM0mfxwi8fSgDZXAyFGMH0xz1/rWFfX1rpk11e3ErRQwfuy0mSoGDLIw/Dj6qBW5GxeNWKlSRnB7VyHia2lv7ddHNwRJcPHHI6Ds8oeUZ/3FIA64YmgDW8G2Daf4etllRluZ83M+85cySHc249yM4z7Vt0UUAY18rzeK9LUZ8qC3nmb03Eoij8mf8q2ay7SdZvEmoxqoPkW8Clv9pjISPy2n8a1KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqK6hW4tpYXJCyIUJHXBGKlooA47wnBe3ujeDrxhGPslqY7oSsd+7ywmV4OfmXnJHHrXTnT7U6ouomFftqwmAS5OQhO7Hp1FYvgaZmtNVtHieP7Hql1Cu7+JWcyKR7YkA/CukoA5XxvfXeyDTdGk26rMd8RK7lVh9wuM52hvnPqsbDuM4ni97XWF8MaNqkP21rwI1w4ACqHQqWI9G+dcf7VdnaaRFb6td6gZJJZp8BQ4XEQwAQuBnnaCck9BXmWi3V02o3+q390Daac9lpsKBAAmLoRu2Tjk7SfowxQB6L4S1CO90eGEzRvfWarbXka4BimVRuBXt6j1BBHBqzYndquonC/fWPOeeEU9P+B9awdE8MCO8tNTF/dpdQs8ci+aZFZQzAplvmKk4OCSBgbQtP8J332nWteaTKD7a0EYLkhmQEHAxxwgoA6kBIIcDCxxr64AAFcbp32mfxla2l8AZrSKW9d16Mzfu1GPZXcZ/2e9dVqrqtk6OpfzcRbFZVZ93BAyQM4zXOeB5Pt+p67qbL80kscCMVK/IqCTAB7ZlbnvQB11FFRXc6WtrNcSnEcSNIx9gMmgDP0CSO6Oo3cSjEt3Im718rER/WNq1aw/A0C2/hHStieWZYFuHXP8AHJ+8f/x5jW5QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGTo8UVvqmtRx8PJcrcMP96JFz+aH8jWtWBbsIvHd+mxQZ9Ot3Dd22STA/lvX8636AI7iaO3t5JpmCRRqXdj0AAyTXnnhuxgvfhrOyP9o/tG6LuXIky/nhCOeOqfnXS/EK8Wy8Ham7yiISRiDce3mME/8AZqy/CdnBpng6O2ihS1gj1EEIDkAtchj+bMfxNAGz4S1Br/SJLmWNokMrSpv67JAJV/ISAfhUXhWTzNPsXuUMc0vmThSSOZGLZxnvluvpWPLqsem2XiMShY7C0tJAATgq8ZcEY64MbQY+tdDE8LX1s9vtCHaoG0qVRYmIyDyP9Z+FAFrW7xLGweWUfJg5OcbQFJJz24B5rI+G873fg2wu5YEge43yFEfcAC7bef8AdAq/4ie3e0mt72NZLR4JPNUjdkHCYx3yHP5VL4atVsfDumWqIEWK2jTaO2FFAGlWZ4lKf2BfRynCzRGDrjl/kH6sK06yfEMIul061Ztqy3sTHjOfLJlx/wCQ6ANVFCIqoAFUYAHYUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHC+KtItbnx34d8w3IW8+0+eqXUqK+yIbeFYDj2ribzxBNbakbx9bTS7mKDXlt9+1/PeLUiscYV8lshQNq4Y9FxxXuFFAHkl74r1CG71W2kuv7JvJtUSJZJJ444YyNOtJDG0kqSAHdI2FVMtg4xgmtf4Xavca7qE+qXm1Z77Q9Iu5ETIRXkSZm2jsMmvQpHWONnchUUFiT2ArAg8Z6BPazXMWoKYolickxOC6ynbGyArmQM3Clc5PA5oA4w+K/EVuk19A/8AaMksmtw2+nCBQpa0mlWAKVG4s3lhTzg7uACMmvpvivXru1SO013Sro3F7Z26XCNHcvF5vmeYHRAgUfIpUH5gS27OOe9n8YaHDZ29y98THOJTGqQyPIfKOJBsClgUP3gRlcHOMGqcnjaxj1OW22b4FZBHPFIrCUNbS3GVHf5Yj0znOemaAOd1LxR4lsNQ1PRbeEahq2mwz6kGFuQLu1EJ8lABwHac7ODnETY68avw01y+1htQF3qun6lBGkLxvbzxySo7b96uEVQq/KpUEbhlgScCtC18d6DPo9hqT3MsEF5B9oVZYH3Rx4BLyAA7EXcMuflHrV+58SadBfPZNJKLoKxRXhkRJWVC5VJCuxm2gnAJOATjg0Ackby7t7JruzuRDqOq+IZLC4nKB2SJJpIkVQeBhI1IzkZYtg7jnJfxX4lsdON5FcHVLg/2xax2ptlAd7OWRIpMIAxdvLywBwd2FVa7fS9T0i10BPFE4/s+LVo7a5n3yMy+ZIqIgx03Hci5AGcDPQVK/jDQ0sorprx/LkaRdgt5TKpjOJN0e3eoQ43FgAuRnGRQBwlh4v1J47eO58RacNNnvI4pNVguIJntVMEr7XIQRJudEVSyn7xBySprN0PxJPpPh6xZrqYIdMBFyjKNrvemPzGL5jVRnJYqcD16V6fN4w8PxX5sn1a1+0gxAorbseaVEZJHADb1wehzUl94o0exeZJ7zdLFMYHihieVw4RZCNqAnhXUk4wARnFAHB+DNcvta8T6E9/cwXLwf2pbie3kEiTKrW+1tyqitw33gqg9QK9WrIstbjutZ+xKqGKa1W8s7mOQOlzFkBiMDjaWT1BEikHkgaspcRuYlVpADtVm2gnsCcHA/A0AOormvtnjH/oBeH//AAdTf/IlH2zxj/0AvD//AIOpv/kSgCfUJkg8Z6MpVd1xa3UQbHJIMTAZ+gat6uE1y48Ti80e7utG0GNre7xERrMxDM8bxhT/AKL0O/8AMCtb7Z4x/wCgF4f/APB1N/8AIlAFD4q28l9odhp8bMpvb+G3JEZcAHPLDBwAcHPQYpniG68nwrq8kcabrXVI2Idsg4uI3J6ccH3rA8a3Xim48R+FbeXRdHSX7WZo/L1WZkJTaxDH7OuMgHs3fitG5iv7jwd4xGqW9vFeR3bTGG3maZPljikA3MiE5AHbvQBi/G4GO50+1aS28rVpo7YwMxWSdDJH5qqQP9iHr23V6HEjLHaTAI/nBtxDD5g8kftyAvf2Fcd8Yraw1eSx0+5Ly3VrFJfw2qjIlcFURWx1DEldvcsPSt3wp5+qR6deTXkLeW8rzRQAhRMoMRXnBAAI4IGNo+tAFnxcftuiakLfc3+iBlAGN29ZFUDPQ5Kn8q6WJBHGiLnCgAZrlPETi21KBA+Fu7uBGAHo8O1eQR03nFdbQAVkXsJuPE2mEsdltDNLt/222Ip/IyfnWvWRZ28jeKNSvG3eULeC2QE8ZBd2I/7+J+VAGvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV9QjaawuY4xl3iZVHqSDivPdC8B6m+i6PPq2owQ6zY2VlDbCO1Pl2xhIYq48w+aSflJDKMDK4PNelUUAeey+E9ctNc0m40y+thcY1CW8vpbXdGsk7RFQkXmggfJgfM2NvOSalsPhxb2Fzpf2e/cWlgYAkRjyxSKxmtAu7PUibdnH8OMc5He0UAecSfDaSS101Z7/AE27ntNPXTG+16a0kUkKfcOwTAh+Wyd2Dn7owKnb4du/iO31OTUreQW91Ncxs9kTcBZLaWHyfN8zAjXzchQoGFAOT81egUUAc1J4X3+D9G0L7Zj+zn09/P8AK/1n2WaKT7ueN3lY6nG7POOcPUfhwlzqT36Xlq9y09zJsvLMzQ7JjGSpUSKdwMYwwYDBII6Eeg0UAcnbeCrZdL17T7iZGttVjjiKQw+UIAlukI2cnGNgYenA7ZrKm+HO+y0hm1CC51Wz+0tPc3ln5kV09w6vKxiV1Knei7cP8oG3kV6DRQBzGj6RcWuuWANtFb2Gk6Z9ggaJVRJmcxltiBiURBCgAP8AePYAnp6KKACiiigDE8YrJ/YTSQgF4Li3nGemEmRj+gNbdZXi2RovCusyR43pZTMuRnkISKv2c4ubOC4UqVljVwVORgjPBoA5jV4Yrr4g6MsqktaxGZPmwMssgz7kbR+dOliYL41R1+WX51A/iBtUX+akVR04tc/FjUySClrahMAEYJWIrnsfvPW3dGOK+17d8oNlHK+emMSjP5L+lAHIazd2a/E4X5u1W4sofIKS8xIgUEtwQQxaXYM9z04rc8K26aNq+s2sSXy6dBGjq0ixiFW+YuU2/MScjO7P3OtZ/gfSzdeGRqWoxWyaxrLxaldRAlwFD+YiAE84z1wOSeKd4r0mHSbRNZuWklaztxaqqswXaU2BmP8ADgvLk4wdwzjGQAbOqyNf6rophx5BuEkw4weI5Hzg+xH4/Sumrmpjbz+IdFeC5R1O64iIORIhhZcg9+qn866WgArJ8PLKyX9zLKJBc3cjoBnCouI1A/BM/jVzVbr7Dpd5dEqPIheT5unAJqLQLR7DQ9PtJceZBbxxvjoWCgE/nQBfooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCpq9oL/Sb2zckLcQPCcejKR/WqnhGQy+FNFkZCheyhYqRgrmNeMVrVleF7j7TokJIIMTyW5BOeY5GjPP1WgDn/CqQS/ETxjcxwkSD7LEZd2VYhCCAOxG1QfoKq+ObyWbWLnQbOFJ7q/s4WMZm8o+SrzGQ5HJH3Vxjoxqv4a1nR9AbxZq2sXltZGXUXZg0mZGRQNvydSeSAADn3qPQZdS1PxJLrurqsNlPbv5du/WCKJ1YYPctuG7PGcgZHUA63w8rPoulPcygNNbwuoiOMNgMVGOiYUDHpnPWtG4kaWzuIskTskoURsQ2ASAQR0PT8ax/CLz3FjBeXbQzObdX8+HhG3AY2DAwNqoeg+9U4WS4sLoBss+nJhBx8zB8nHbJx+VAHL6ZNPp/iHRbLUo7yVEmeK0u5Y2beHhLEMw+UDjA57EDGAD6NXnfjXRItQ8NWEtzqYsZ9OmWaO6R8bFEiurY6EKArcj+HHQnPc6Vdm+0+GdkMcjArIhGNrqSrD8CCKAMnxvifS7XTtxVtQvILcYPJXeHcf8AftHroawNVjjufGGgRyBy1vFc3iYOAGASLJ9flmcfjW/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3g5Xg/ty0YgrBqk2wA5wJNs2PzlNdDWVpfyaxrMfHzSxzfnEq/wDslAHiHh/QrK/13UbzVpJvtmo3ywQGNSVljCyRkkAdducEY6gZ5r17TdPgs7rTbW7SR5YbdraNpGLK+BHIx6c8jqcfcrzTwGJIfFunTm6k8jTrKeSWHaWJjdQwB46rgAfU+tegDWbiHSdP1XXLqKygtrtllMZdhcoY3VcKq5JLsp2gEDae4oA3fD9j9l0aOGW3W3eRcyQq2VTIxtHPAAAH4VcRAl6xUYzEo/InHv3NecaprfjTUrOzf4daZZPphZ3a81K5UmX5j8qKrEgA5BLEHgcV0kWseKY9N8++8PadFcgY8hNULGRsfwnysevU0AS3CQPHJDfRCVbhJLNYJD8km4BGVuPukxrz/wBNKqeAr26ivtW0PVrhpdSszFMSybQ0TrtVlPQ5MbMeeGYj0rV0XWTrlorQRmzu4XUXdpcqGZARyMqcHPOGGQcY9QOE0+W4034saZDdYa5uoZo5QAVMcRRShfB2u26DAIxgEAjoaAPQprQHxTaXnVls5oevTLxH+n6Vq1iaxctbeIvD6jZi5kmgO48/6oyce/7v8s1t0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYtm7DxlqsW0hDZWsoOOCxedTz9FX862qw2Hl+OEJXHn6cwDZ6+XKMjHt5o/OgDyTwbrCaP8WvFEN3HeXFtOIY4mXaVSQJGjRgbsk7ougH8xXQ+PLBdZ+IegLcvDc21gbaSG3mZyHkkeVXcomAcIh5bjPGOTWdrunwWXi3UbSW3ka51C/Wa0u4ro20loWU7mV1VupMYwQQSctjFR3GiaxoWs6f4kuv7e1K1tCEuAbi0wkIfIcCMKZMc8HHBPBNAHq3h+OK1tLm3hSwht7e4kVI7QBUjXO7DAcBucn6571FNc3Nvb3s0wWWFf38RhAGV6gcnGQF5+oNVtN1S1uYr6708K8EssVyzJuzJE8SDzPXIweBj7n5rqmovH4fD3EPnLLD5Mn2Yl9khG08/wB3Jxuzx1NAHhPibxG/h3x5pWsaJNNbGc3EU1id0zOoAGWUEcAlTg92DDPJrrPBF1PcatdeIb+dWvFWGzuIQNzbxcI+4HOfuT7ccYA5ry7xgdJ8VeInstW/tM6XaSTQi7Eok8tySA8oIJZlUKOASSQD90V6BolxouleFpNH0mbUHvbfc08l9sV94Ea/wDBCmMJgdx3oA9e1yyS78T+GpWchrOWe4VR/EfJaP+UprfrHjaWfxdL/AM+9pZKoOOryOSR+AiT/AL6rYoAKgvru3sLK4vL2ZILW3jaWWWQ4VEUZZiewABNT1z/xC0+61fwD4l03T4vOvbzTLm3gj3Bd8jxMqjJIAySOSQKANLStW0/V4pJNMvILpI22SeU4OxsA4Ydjgg89iKvV5n4s8FahJPDeRXF3rDT3CnUYiluDLGkbrEFjcLGyqzE4Y5y27JKqKrDwZq88GpMrailzH4fgtNMmu73DpchrsNvETlQ4WSEb8HGflJINAHqtFeXxeFr26vLcRaLJp2gvqMEkmlyyx4VFgmWR2VHZSrs0QKgnO0kjk1lX3g3X5bOxgure/lsoYLmCGGykt2ltGNxIY5FMrhVPlGMKyncm3GBk0AexyyLFG8kh2ogLMfQCorG7gv7G3vLSQS21xGssTgEBkYZB59QRXl8/h7xDN41g1A6dJFi6nSe4hNssU9qbSVY97Z8528wxZU4QHkDADVv3Og6jL8MfD+jCBxewHSkuolmCkJFPAZxuBwQESToeegzkUAdxRXj+q+DNZMot1sp5NCiub7ybG0NuTGJGjaKRElYIAMSgYIZC3AwTjVTwXqF3Fr9xcSXiaoUtjplzcXZYrJFBEQzKrbcmZDu4G7nqMUAel0V5LqnhfxDqNrp19qVpPM11NdXWo6ZDJBM0UkgjWAASsI28qOMoSCPmYsuetel+H7eW00HTba5e5knhtoo5HunV5WYKAS7LwWz1I4znFAF+iiigAooooAKKKKACiiigAooooA5bQPFp1qWSW209/wCzEkmia6FxGzRmMsCZIgdy5KnA5bpkDnFpfF+iG3kma7ki8uVIWimt5Y5d7jKARsoc7sHbgc44zWFf+A7jUtTa+utTtLa7WO4jjvdN0/7Nd/vYmjHmS+Y28Lv3YCqN6I3G3FZMvw/1PTpY7nSp9Ma7mvrKWTyLAwxRLD5u6RlMxaQnzBn588d6AOkuviBotteWiyTMbG4tJ7r7Usbt5flSKjq6Bdy7Szbi2Nu0hsVsf8JFpX9rjTPtYN2W8sAIxTeV3hN+Nu/b82zO7HOMVzQ8AE296smpgz3lhf2s8gt8AyXcokaRV3cKpGAuTxjLZyS7TvAEdhr/APaEU1jNE1wt0wuLIvMkgQKfLk8wBQdueUYjJ56YANiz8aeHry0murfUozbRQJcmRkdVaJzhXQkDeCRjK55468VasvEek3uwQXi+Y4l/dujRyL5e3eGRgGUruXIIB5FcvD8OvK0jSbMaofN03S7Owil+z8GW2ljlSUru6FolymemRuqWTwRfG+fU49Yt11aeWd7mU2TGJllhhiISPzcqQtvFglm5DZHPAB0Fr4o0e7vYLW1uzPLOiSIYonZAHXem5wNqll5AYgkY45p2teJtI0ScRaneCGQx+cV2M+2PODI20HagPVjgDuRXOaX4Cl0/U9FuYtTijTToYIZGt7Z4pboRw+XtkYS7GU9cMjEdA3AI0fFnhH/hIP7Z/wBO+z/2jo02kf6rf5fmZ/efeGcZ+7xn1oA028SaSuqNp7XgF0pKHKNs3hS5TfjaXCgtszuwM4xUGmeMfD+pwyzWGq208MULXDyKTtEagFnz0IG4ZI6ZrEj8ARw67d30U1i0Nxcy3f7+yL3EUkikNsl8wADLEjKEgEjPTD9U8AxahoPhzTXv3jOlQpaTSrEP9LttirLCQT8qybEJ5ONooA3YfE+jzajFYxXga4lwF/dvsLFN4TfjaHKfNsJ3Y5xitmuLh8DR2/iqfVopLGSKa8F6yXFkZJo5NoB8uXzAFHGeUYjJ56Y6ifS9PuNQgv57G1lvoBtiuHhVpIxzwrEZHU9PWgC5RRRQAVzWs3bWfjvw2pRzFewXdruzwrgRyr+JET/ka6Wuf8caXPqeh77Dd/aVhMl9Z7SAWljOQmewcbkPs5oA86+KAvLbxi/2YRMs1otwGcZ8o70iZ8DBO0fNxWzYSXw8I3L6oYDLFDE0tvCFjdNk5PfK9RJkYHYd81H4svIL7XvAuri0M+naur6fcQSj+CePhZF6cfMCD34qrZPeeGrfWLW63TyWEos4JpIfOlvI2VTb7wOXwG2MQMnyM8c0AXAU+H+o69daPo899pDTxy3kNvgTWu5BgwqcK8Q/uKQVOcZBwML4oeI9Rk0rWDpemCy09LKS6a8v4HtmMwA2IY2G+TLAcBQMgZJwQew+IEp/s7XYpNVWGBrObcgYgwk20o556E4YdOVrxfXRcar8Pbi4vHV3l1C1hAO1BKTMNzkMSRwnQjnJ5oA5z4RW02k3C3+vxreXBuDBLdvN5kls5cSO4PQAAsGJ+bcxGcE16PZ6SmkN4O1J5rZL3Xitkbad/nWOSWGXdEvAwPKUkAD75J5yTT0DwiR4ZF3cai1tpEt19maQskQEauz3FwSw4YhGjUZIUM2M5qu+uWXi/wCMqSNeyQadoYgk0yIKIXupVdCU5G5kVWkO3PPB6DkA978OmaU6nczjHnXsgjHoiYjH57CfxrYrH8GpJH4T0cTkmZrSJ5CxyS7KCxz9Sa2KACqHiDURo+g6lqbRmVbK2kuTGDgtsUtjPvir9V9Rs4NR0+5srtN9tcxNDKucblYEEfkTQBxd34g1LQNSW11W8trp4tKSeQykQJJcNOEwCFJA5wqgMTwOSeYdN8fXupatpEFvpaRQSm8S+E7OjwmBogWTcqsRiQnDIpPHTvvnwnZ31nbjX2OoahHAkDXiM8DsEcOjDa/yuGAO5SDnOMDin2vg/RbV7Z4LedZbed7lJftcxcu+N+5i+XDbVyrEg45BoA5mz+J6XOmS366JetC0MM9sEJzKssqRqrF1VFk/eKdoZlxn5uDWhdeOXstasrC901VM00NtP5M7TPbSy8IH2x7AOV+84JDZAPfUg8GaHBbG2jtrj7J8m23N5M0UQSRZFEcZfagDKuAoAwMdOKivdC8O3PigG5jlGqylNR8sXEyRytCUVZdgYRsy4jBOCcbQeMUAVdL8UTW/w1bxHqaNcywQyzSLGApcK7AAdhwBTf8AhM7r+1G0YaQn9uify1gN3+5Mfleb5hk2ZAx8uNpO7/Z+ar+veG7GXwLqOg28y6dYS20kZlYlhCrZLMSWB4yT1FZ2j6d4R1qGWDTJpp5UmW8aYXtwtzuZNiyCUsJCpT5QQ20jjpQBWf4jI1vJdW2lSvaWthb6jeO8yq8Mcsk0bKqgEO6GByRkAgcHOAcnU/HmradY6o8Sw3NzAmrzQpKmEK2t1DGgJBB4WU8d/Ud92XwjoMXiyD7RI4WbT7e2tNNSSVI9lpJI5ZgrbZBm4Thwcbc85ONOXwx4curq7tZLSOSd4LgTxmVyfKu5A0pIzxveHIPbYduOaAMu78eNa66umPpMzywyQRXfks8hieUjGzCYYKGVmJK4B43EYrK134iyiz1uCxgjjuYdPub2yvIWaaKQQuiNktGqE5lThC465I4z2H/CKaULuO6Vb1bhVRWkW/uFMwQ5XzcP+9xkj593Bx04rPtPBfhW4S4+zQGeExT6eyLfTSRxI7qZYlXeRGN0a/KoG3bgY5FAHW0VFa3MF3As9pNFPC2dskTBlODg4I461LQAUUUUAFFFFAHO+O9UuNI0SOe2mW1WS6hgmvHUMtrE7hWlIPHAPU/KM5OQDXHXnjmTTnu7WLXbO/J+wfYJ28vddCS6eKYqFwH2qoBKjAIzxmvU653xd4mXQJtKtkt/tF3qVwYIVZmVBtQuzMyqxHAwODyR0GSADg5vEt1pk2t2tx4iliupdckgiWaaGJbOMoZE3ySI/lxsBhTtbJwFHJNQzeNfENx4TfU476GCey8Oz6vIIoVZZ5oXcbSWHCME5wAeeCK9Ej8ZaA8FxP8A2lGsMKq5kdHRXRm2K6EgB0LEAMuRk9aLTxloN1cxwR3xWV2ePEsMkWx1UsUcsoCPtVm2tglRkDHNAHE3PjDxAnijU4YZLDzLae4ij0iadElnjSJmjeOPb5jM7BW3btm0kYBGaSz8bXkDxSjW7XUtJWSwa71BkjRLZpmkWWJiuAuNseA3zLuwxORXbp4y8Ptp9xfNqcUNrbmLzZJ1aIKJW2xt8wHyMeFb7p5weDU0PijSZru1t0uJQ91t8l2t5FjcspYKJCu3cQCduc+1AHnV1481AwWN8dTgFlJe30SxWZh+0XAjvnhiKxyf61PLQAiMhyTkdQK6T4lXcVnrHhKS41ddHgN7OHu2eNQn+iy45kBXrjqDW9pXiazuvCFp4hvStjZzQLO/mNkRhvU496QeLtFNp9oF1KR5xt/JFtKZvMChivlbd+QpDfd+6QenNAHE6d4s1+eC6vL64MNrp/h+21OeC3sg01w8jXa7l3N8gIhRtpBxnGQM5raL4u1u/uF06PV7aZZNVgtVvrd4rlvKktpZGG5Y0jLBo+ykDod2K7yfxr4bglijk1i03ywLcoFbdmJgSsmR/CQDz0q1qHiTSrCWaK4uszxSLE0MUbyyF2UuFCICzHaC2ADgDPSgDg9F8W317d2ttrGvQ6SkcLGKdo4x/aMy3U0LL8wxwsUZKpgkzDBAGKl+Hl9qNtqGl2kl609lqDas/kPGoELRXeFKsBuOQ7ZySOmMY59Hsbu3v7OG7spkntpkDxyIcqynoRWBH4pe58R3ul6fpz3IsbiO3unFxGjoXVW3iMnJQBwSeCcHaG7gGH4h8TahZ+K5rSK+jgliubOG00woha/ildRLICfmO0M/KkBfLJbINL8O7GdPB+r3v2l5tSvri9LXAiUSllmlReQMtjAxnOBgDAAFdFqvirTbLRrq+hnjuTHbXVzHErYMv2fIkAOOzcH61AnjXSZLKGeKRzI9zbWpidGjZXnZVQneB8pySG6NjCknAoA8ztNV1JtH0jVLHxE9xe2vhO5vJJ9scpaVPIYxyZB6Nw2fn68g810Wn+LdavPGwtZbrT7SEXaQjT550R5YGiDeYiFfMdixyGDbMAgjIJrs28W6Es11HJqMUf2ZZHkkkVkjIjOJNrkbX2nhgpODwcGq8XjXSJdb0/S0+2/ab6OaSPfaSRhfLaJSrhgGUnzlIyMYByRxkA6WiiigAoorN8StIvh7UvIbbO1u6RH/AGypC/qRQB4Hp1/q3hHQdMsdbeS5hutTGsae+CHit2lcyIeu4ruRxjr5mOwr1nxTCZtbvWN21tFbWcN0/wAuRtVp1Y9udrdPYV5/8ZbeW80iy0TQrGa9l8NxxNd3AZYlhDIFRQxySxADYUHAxk9q05fGi6trEqvbXWn6w1jFbvppO93ZpQ+EYAhlaPOG6c845wAb/wASLWW6S7so7No0vpNPtZb0R7yyyTSI3B+X5AQT7P8ASuB8d6Fpq+PtI0bQJ2hZZUuEto4jLHFcFx++Yk4Y7TJhSSBknnGK9I07RbAxy+H9ZukvrF7SO3WwuJ2m4WaYqxJ6nCqM/ezH6gVleGbDTx8UNQh0qBIYNO3ySMZJHeWZ0RSSXJ4+YjA7r9aAIvjl9j07wdo0F00qabDep52xyr7FhkCHcATnzDEc4615b4i8PypomtXS2emfYHhhuY3nmMFzBM8ZSNF2xH5mkzNtypIZMlR19i+KqPey2lqHc2dtBPdXsCthbhCuyOBjyQsjnnAztRgMZrlPCHgHwm3hXXdTTTjceUZjEZfMKq4t1V2WJyVzuDY+XIG0dqAO/wBKk8YWmmWdt/YugSeTCke86zMN2FAzj7Lx0q19s8Y/9ALw/wD+Dqb/AORK6OJBFEka5woCjPXinUAYFndeKXuolvNG0SK2LASPFq0sjqvchTbKCfbI+tO8e2d7qPgbxFZaSrNqNzptzDbBXCEytEwTDEgA7iOSRit2sPx3q1zoHgnX9YsI4pbrT7Ce6jSXOwskZYbsEEjjoCM+o60AcN4h8H6qt/eR6TZt/YTX8Fy9lC0TfaV+zujnZIdjHzPLZg+N23dywGbOkeB5by5EWtJqn9nrpAtITcXgEkchlnzlYnK7lR0AbnAwAetb1x4uubXVbmwudJWI2dhHqF5cPeRrBbo7TqoLHBPMB5AwAecY5q6F4+TUdRttPudOkt7ua/Fl8pfy+bWW4VwZERiCIWX7oGSCCRzQBzt14a8W6loq3Wsq0t+byCK7s4ZInFzaQROgwrnyyXmcz7WI+Xap5GK2dGtDaT+D9JIu/t9pPdXskd00ZmhtSkyAN5ZKhd0sSqoJ4Uddhwt78RxDpj39vpMk0EGnTapc7pwhSCJ2Vwowdz/KSBwD3Iq3deNZ7UX1vcadbw6nb3EcKW7XTMJhJGZF2lImdnwGyio33Tgkc0Abl5HJrPhK8h1PSH33drLFNprzLlwylTGXU7RuHGc8ZriDpvisxMYY9alsLaeyuIrTUri1a6YpOGlVJI22lTGP+Wj5JHXHXrbHxTb3ngiPxGsYt4ng83yrqTygrZxtZscfNx0z7Z4rnrPx9qGo6jplpZaTGsr6nLp17HM8ibdtqLhWjLojYKup+ZBnBA6hqAMmfw9qt1c2F3rPhm51OAT6q72bXEBaNZ5UaHcWkC/dU/dJ2kD0FZyaVq1/Lqmm2N//AGjfWmmaJFqrQTK32meJ7kXKZY7PMKiMlWxkbQ2Aa9I1vWtQs/F+g6VZ2kE9rfRXEk7vIVeMRmIZXseJDx345FclovxIubXwxY3XiGxLXFxYRXMEkMgY3DNNHCAyhRszJLHjG7gk8EYoAhs/DF7btZC+0LUtW0mOO4WKwnltUe1lZ1ZXCLIIwuNwUqxZOwG446nwDor6LPr6TaabZ7jUZ7lbkOhW4jkkd0xhiwKhsEMByeM9a0fCWutr9jcTSWclpLbzmBwQ+xyFVt0bMqllw4GSo5DDtW5QB5FpPhG707TNLtLnwxLeWVp9sjuLKOeECeV3Qw3KkyAYVVdRnDKXyBkZr0vwxa3tl4b0m11Wf7TqMFpFFczZz5kqoA7fiQTWlRQAUUUUAFFFFABWPrWiLqmpaRdPMUWwllkMYXPmB4XjxnPy435zz0/GtiigDzjTfhktjpi2CXdgI4kgiiuE08rcFIpo5AJH8whiREAdqqMnOO1aeq+A4tTS8iub5vIutTfUJFWPB2tam3MYO7rg7t34Y712lFAHEHwRdXKmTU9Xinuw+nBJIrQxKIrS5FwFK7zl3OQWyAOMLwQU1HwLJe+LI9Yl1CB0jvor2NZrQyTxBECmKOUvhIzgtgJ1JyTWj8TpbuD4feIJtOuJ7a6is3kSaAkOm0ZJBHTgHmuYHiu9Gt+Rb65b3jpf2dta2iLEf7QtZRF5tyCvJ2b5eVIUeQcg54AOkXwjj4fW/hj7b/qoY4ftPlddjA527u+PWs3Wfh6moazd6ot5Abma+a7SO5tTLEqtbQQMjKHUsf8AR1cMGXGcYIzlnxR1iazA09tSGk2dxpt5L9pwmZpkCBIAXBAyHc4HzHb8pGDXPQ+Mb201TQLG0vVVEbTrOezuZI1MyzRx5kiTYZHA8wfPvVQysMNg0AdrpHg22tI9ShujbTWl/p8Gny2sNv5UQSMSBgo3HCsJSNvYDqax1+G3/En06KfVFvdVtbmS6lvLy18xLpnTy/3kaup4RUAIYH5B1GQcaDxB4kurW1l/toxG80nUdRwlrF+5e1liRFXIPDCX5t2T8vy7c0r+PdRl8S6WtrcRgSz29vcabNJGjP5sAk3xR7DIVywHmM4XII2nrQB6FoGk3Okx29uLm0FhDbiMW1taeSok3El1+diFwQNvPTOTmsjX/B8uuazBdXlzpvkW9xFcQyLp3+mxbGD7EuPM+UErg/JnazDvmuJh8eaydKluLPUodRu30u3vLiERoBp0sk6JMCFG5REjMxV8sNhz6V2PhbXdSufCGtX32iz1me0aX7IbS4SczBYldUdo1Vd+4kfKBxt75oApyfD25kS4t31mL7F9m1K3t0FmQ8YvH3ku3mYfaemFXI/OotW8K6sGhLEalfXV1pSS3EES20FtbWV2s/zK8rMWO6Xlc5JAIAGa57TvE8trrmparHr8OpQPaaELq6byxFbpJdXSyj5QAgAPVskdycVu2PifV9cutLh0vUrWGG81HUYftCwCUNDAx8vbyBkgD5uc+lADh8L4Uingju7NYd7y28/2HN1E5k8xcyGTayhgMjYCwABPUnol0HVZNd0rV7vVbN7uziuLaRY7FkjkhmaFmCgykqwMC4Ylh8x+XpXAXHirXINA1W5s70W403TNR1QIIxJ5zw3UwVGL5IQhADjB9CK3YfFV6/jiwsZNTjjkn1m40+XSSqbkt0tZ5Um6b8sY0bOduGwB3oA9IrnJfB2mSyvI11rwZiWIXXb5Rk+gE2APYV0dFAHNf8IXpf8Az9eIP/B/f/8Ax6szW/BmmM2n2wvNcHn3aAh9cvmBCAyHgynB+Tg9j0wea7isi9t1n8UaXIxP+j29xIo7biY1B/ItQB5X4i0VPCd/4ia9t9fn0rUfLltr1Ly6u0VtqI8c0YdiT8o2uyt1xkYApNFu9Wk8TQ659ik0+O80dLO0juFAmaKEhjIy/wAJZnOAecAcDPHq3ivzBoF08MMszx7ZPLiQu7BWDEKo6nAPHeuf1nTprq00VFBW+azETb/lbHmQb8jsQM/jQBV1OzmbxVYvDZQpbl8/apf3jswumLJgngDeGBxxu4PHHNfDrUru5+NHiSOa5drN7OSeKEyI6ovnjawxyu5TnBz9eCB18k9lYXWs317dTT3EVuzjeMR7VnmaNVJGS6sCvpgLivOfAUFt4bvvFtyrzyw2ml2dkN/LmWV5pSFPoDKvAoAi1O+k1Tx1d3oDQXcNzbC2kR1YSNN5nlcHjcEij4Pdn6cmu6t7KWz+FN7aCY3Uk80sQL/IT5lwUI7dya8z8Qxta+M00hbPbYI1lNqUUZ/eYMMztjng5Z/xx2Net+GLgXfgTRJA/wAt5dpIm48lTcGQDnr8ooA7iiiigAqjrkdhLomoR6z5X9ltbyLd+ccJ5JU79x9Nuc1ernfiNplxrXw/8S6ZZQ+feXem3EEERYLvkaNggySAPmxyTigDPtYfCdzbvE3nS/2pDHpUiXrXBllRfOdEYS/OOHmIY4JBHOAtXR4I0Pa/7m8MrzJcG4bULgziREZFYSmTeDtdl4PIJB4rk9f8KXg1jNvor3+iw6jazpZxyxYaJbeZHwsjqMb3XIJGc9xVCbw94qs9Dv7W10+7ma902W2to4ruIfYT9pnkjjYtIPuxSxoCm7/V+mDQB21j4a8L3djqGmWlqJLeO3k0a5j82XiNxveIknPIkzuBzz1q9qPhXSNQvHu7i3lF28iS+fDcywyBlQoCrIwK/KzAgYyDzmuD8SeGNau7rVYjpP2mwvNQuLgPF9meZSYLdInUTHYq5WUE4LjC4HJNdJqWkavffDrRNOnSWTU1k0s3o88BisdxA1xl88/IsmcHnkDOaAN1fDelL4dGhLa40sLtEPmPlfm3Ah87gQ3IIOQQCCMVQk8KeH9PtpbmSK5jEVydSe5a9naUSiERFzJv3n92oUjOCByDXE6p4P1jEVvHYyy6HBfXrJp1t9nbCSGMwyKkrCMKuJhjIKmQEDirKeGtSWLUItR0e+1a8ls4YrDUbi5haS2UWqo0chLghjKJHYoCrGTk4HAB38+n6drUmmamwd3t/wB9azxSvEQGAODtIypwuVbIOBkVUPg7QTZwWraerQQWhso0aRzsiLK2Ac5yGRCG+8CoIIrF+F+javoltdW/iCF5b1lhP28SqY5ECALEse4mPy8FcDIb724lmA7mgClpOmW+lW7w2rXToz7y1zdS3Dk4A+9IzNjAHGcVdoooAKKKKACiiigAooooAKKKKAK01/awX0NnNOiXM0TzRoxwWRCocj6b1z9azYfFWjzS2KR3Tlb1Y2t5vIkEMm8ZQeZt2AsOik5PpVbxz4WXxVp9vbi8ksZopCfPjQMxidGjlj7Y3Ruwz2O1sHaBWTq3gE3/AIjj1EX1sLeK7tbuGKWzMktuIdn7qGTeBHG2zJAXOWY5IwAAa8HjTQ7q4hSy1C3uI2keKSVZAEiKI7tknGcCNs4zjHOKP+E10H7Mk5u5Qj8optZg7rjcXVNu4pjneBtxzmsm8+HsN74b03Rrq/c29ql3HIyRbWlWeKWM45O0gS5zz096tS+HdelvbLUW12xGp2kEtqko01vLMUvll8p53390UZBBAGCNvNAGvH4l0iTUY7KG8Eszqrhoo2eMBl3LukAKKSoyASCRgjqKfo3iDTNaeRNNuvOZFWTBjZNyNna67gN6HBw65U44NcpF8N44bjTUtr8W9hZ2sVmywxOlxcRJD5QSSQSbXGOfmjJHYjgjS8EeDv8AhGH/ANbp82y3W2SWGyMMzKp48x/MYMeP4VUZycdAADYbxHo628U76jbpDI0yK7ttGYd3m5J6bNjZz0xVeDxVply9slrI7vNcralJEaF0Zo2dSUkCtgqpIwOeoyM1i3vw7tL2/wDEctzezfZdWt5YIrdEC/ZDMFE7oeclzHG2CMAhuu40aZ4Fa1uLKeW401Jba8ju2ay09oPNCRSptbMrn/lqSD0GMY5zQBb8Fz+GLq7nn8P3U91cy28cpmuJp5meBixQxvMTmPO77h2g9ea0ZPFeixz3scl5tFmHM8pifyk2Y3jzMbCy5GVBJHcVR8J+Ef8AhH/7G/077R/Z2jQ6R/qtnmeXj95944zj7vOPWsvVvh6+pX2synU47S31GC4haK0t3jDNJjDygyFJGXHUIrHueuQDptT8T6LpYmOoajBb+TMts+84xKyb1T6leQO9Rr4r0VtRjsRejz3YopMbiMsIzKU8zG3cEBYrnIAzisi18HXZ1X+0dR1WCe6Opx6k4gtDEh2WxgCAGRiODuzk+mKwr/whqWo+I1094pk8ODULu/llkWNWPn2s8TrG6ysx+a4JAaJcAHk4GQDrx408PfYpruTU4obeEx73nRohiQkRsNwGUYghWGVODgnFVbOXwzd6lb61FdvPcPc+RB5tzM6JO8XRIWbajmMk5Cg7Wb1OcvTfh6bSGCN7vTg8M9pKJrbTzFJIIJd+2QmVgScdgoBJODnAvxeGZH+Jlzrjq8dhHbRtHGXBSW7IaNpgo5DLCFjyeoY+mSAdhRRRQAVjI+/xjMhH+qsEYHP9+R+3/bMVs1hW4P8AwnN+ew063/8ARs9AG7WFq+3/AISLSi2NwimIycf8tIc1u1z/AIjntrO/tby9eNbe3t55W3HBOGiOAMjJ4/PFAHE61qdzDo+s2csFvPa4eCK4gQMpYSySMGbfn/V7Tg5+Y8nk1z3gyeSbSLhIkAfVPEsiGVrcQF4YxHCSUOcckkDPrWANXutd1C8tbS2vtL8QWyQwPJEyNBLHIxYs2CQsnlyOCASB2Jzmu3+FiQxaX4cimuVu5Lm9v54psjMiea5DHGATiMdvSgDj/H11bxfFLxNdQLNLsa2iuyBuVRHAr8YxgYcZ5ySeK9k0+w8m28HWDfKbKESlGBJOyAx9+esoOTXk9vp8ereNdbN4wkttS1iSEYBjcKTAhUeuY4359GyK9qCyy+MXc/6i3sAF56tJIc/pEKANmiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArBh3L48u8qQkmmw4bPBKyy5H/j4/Ot6se/uo7bxPpKSK267inhRgONw2vg/wDAVc/hQBsVxHxMtjdvoEIvbuyWa8eFpLWNWdgYZDsyQdoJVee2BXb1xHxTdILXQLqWd4I4dVjLOpxw0ci+o9QfwoA4HxXqwsNG1G2lvp7hVisoY9PSBgLMeWw3Fj8pJYNkjOcD8JfhvpT6do3hm6iARtP8MrNGGbAEroXbK/WYVU+LlvPdaLrd3GLWGAK12l4qHzdywySRbgTnABAAxgEnueOm8Vww2OhahFGhgCQQWmNwB2f6MCuc9NuefY0AYXgDS4o/GumQyq01zbTT3LvIQPvxkZA/3lHbvnNet6IskmoaxdSMpSS5EUOOyRoqkH/gfmfnXlvwSiF54m1fUpEOUWVEYqVCoZiFxkkj5Y89e9eqeFVkGgWkk5BlnU3Dbc4zIxfHP+9QBq0UUUAFFNkdI13SMqLwMscCjenmGPcu8Ddtzzj1xQA6iiigAoqOaeKHZ50qR72CJvYDcx6AZ6n2qSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArA8ZGaGwsr62VXls72CUgj+Bm8uTHv5cj1v1U1ixTU9JvbCRiqXUDwsw6gMpGf1oAt1558cbH+0fCdlbAqHbUoGQNgKxXc2CSQFGAea7Hw1cyXfh/Tpp5FluGgQTMO8gGH/8eBrmfi3Lbx6NpaXLsnm6gscZVdx3+VKRweO1AHCfFaCY+DNbuiTFFDZ2sUMkZbEW8IhhIKkEHeCCD/Gc9KveJdR263rREnzR30AWMsRuO4gDJx1MWOuOMetUvHl/dajofi6Awvbyx2NkNoiPly7l35643BlKn5RwFqn4xnXTvEFxc3jGKObU3SORDtOY1uG5YcNjzM49qAIPAVxrSx+MYPDdtpcpdbe0S7mvmjdTKZPLYBYmDHMucZXoOua9dguPF0EMcUegeH1jRQqj+2puABgf8uleX/AzRbSDS0eKbI1DWTcoFxh47aAJk4/6aYJ/p0r3igDmvtnjH/oBeH//AAdTf/IlH2zxj/0AvD//AIOpv/kSulooA4r4h6bd6/4FisNSsFaa41HT1uba0kadRGL6EuQ2xSQEBYnaMAHsM1yM+ieJdF1e+1OaSe+1Z7C3E15ZwOweOO6jBRRgksYVZigydzvjORXqWv6vb6HppvbxZWi86GALEm9meWVYkAHuzqK528+I2j2dtG1xFdx3RedJLNvKWWLySBIWJfYcblwFYltw2g84AOV1/UNeu7e/vIBrn2dNRnNtZC1u4GuIxBFsAeJDJGA5fG5dpJO7pirWpy67NaeJzjxDB4k+z3A0qKJZDbBfsuYvmUeSW8zPLHdvGB8uAemfx/owkm8tb2a2h8gy3cds3kRrMEKMXPGMSKT3AyTil1bx5o+nTSQN581wk8luI02LvMao0jKzsqkL5iqec7vlAJoA5zUbrVNc1gzWlpqRsYtVsZLUXVnLCFAjfzG2uoYKGxkkVnWs/ib+yYzAfEJLWtr/AGyZ4pPOSczRif7MGXn9353+qyvClPmxn1fS7+21TTLTULCUTWd3Ck8MgBAdHUMp59QRVmgDyrXdS1WwtdVTQl8Sy20+lY04yWlzLItyJZN2Syl1OCmDJjIHGcUy6hvdMuvFaxW2ttJe6wjl4xdGOO3aKL96nk/M+GUqVjYMO+ACa9YooA8bgXxXeeHytxNrqzW2m6s8LRxzQPJNFdFbQsDlyTGAQrFiw67uTV66l8WSeKp5DcXltKJoTZR/Y7iS3khMK7lcp+6XMhky0nzrgY42g+rUUAeS2d14hh00z2f/AAkLpEmmS3wvIJTN5wukN0IlK5YeSH3LGCnQIMk1Dr1/4huLOW9gXXXRb28NvYLbXdu9wmI/JPmRoWjx8wUSLsO47vu17BRQA1CWRSylCQCVPUe3FOoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxfDUUVmdUsYXUrBeyPtAA2+biYjH1kNcj8c8/2HoSoGaVtWjWNFUszMYZsAAD/ACM11llBHbeMdUZWbdeWsEpUnjKGRSR+BSsz4gIGm0GeSRY4LG7e+lOMttS3lUYHf55EGPegDkfEukTS6H48ntZLeY3lyskREYDqsCAGP1IUoSD6MccVleLF/trS471YYLmIX9zJsuIBKoVrfAfaeAVaQHI5+Wug1xZj4bvr6a0tdOmnluYvMi2tujmh2CYFc4OQucEAleetcN40tF0zwf4Z0eeX/Sr65uI7V0LRyAKEUn5erbFbjkHIGDQB3fwegWS1sZPNjl+y21zIpVNgxcXkhGFPIwsCivUK87+DunPaWN68kvmGOK0sxgYH7uBXJx2y0rcV6JQAUUUUAZ+uaVBrNlHa3TypHHdW92DGQDvhmSZByDwWjAPtnp1rBufAmnyXrXtveXtrfNNPN58Yic4mKF02yRspXMaEZGRjryc9dRQBhQ+FrBLXWbedprmLVkWO6WUr8wEKw8YAxlVGfcnGOlZw8BafHp+lQW95fw3WnLKsd9mOSaXzWDTGTzEZGLuA5O3qOMV11FAENnB9ls4LfzHl8qNY9743NgYycADJ9gB7VNRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYV4rR+NdLkWMFZbG5jd88gh4WUf8Aodc943kupfEJhiTzLVNNeGRYn/elp5UX5VzyR5a9SOGPNdJfsx8W6PEAdv2a6kJB6YMI/wDZq8sXV7HWfFXiL7ULyTS7icia4t03ARwhVVRlT8uUYnbyTIuPYA251utA8D3OnLaLZ5tvJjjLmTYZGRWAGOmCzdeK848Y6jKt34NZbhZYdL0aDULqWSLzMee6l3U8lCFUnPTB5IA56zxZquoi0e50rSrqa5lxCIb5fKZIowYwVIRss7yliM8BO1eU3F/4huNUuxLoaxxIx0u202C42yRpbwsRHG4U5/1sZyfQDjOQAfQ/wbuYr7wvdXsMnmC5vZJCdwPRUXHHThRxXeV458F/+En07wpNZ2mkaTKsVzuc3OqSRSBnijkwQtuwJw45z/LJ777Z4x/6AXh//wAHU3/yJQB0tFc19s8Y/wDQC8P/APg6m/8AkSprO68UvdRLeaNokVsWAkeLVpZHVe5Cm2UE+2R9aAN53VAC7BQSAMnGSegpa87+K2j6v4nn0/R9JtkMUUc169xPK8Mcc4XZBhwj7mVnaTbjrGpJHGaF1c+I9TeTVUh1qzljh0mWGzVZERZHmIukZMfPhOGByAOeODQB6nSMwVSzEBQMknoBXjT2mtaeL22tBrUNvJrl1LfERXTjyXaV4WjMWGKsSNxiJIO3dgZq/Na+I7yw1n7Rf6xcrbeG4zbqLQwpeXTfbFbdGy7i+0Q5Tj7ykryKAPVwcjI6UV5rp0muDxJbLINXW7F8qshjkFkLDyBnnHl7t3v5m/j7ldB8PLTUR4Rs5dcvNSm1G7hV5xdna8LEfdUBRtx+frk80AdLcXMFshe4miiQDJaRgoAzjv7kfnUhZQygsAW4AJ614Lb6VqkXgDSdPSx1ovbeHVt7lJLSVpI7hJLUNGmVyQArlQuVIUkZxXSSS65DP9p02x1i/wBOgvbqSxiukkW4ZBp7HbvlG9A0+5VZ+cnA+XbQB6nNPFDs86VI97BE3sBuY9AM9T7VJXjukR65c38UUyapdafFqen3MLT2l0nl5Eol5uCZCBtTJOAM8AZ59ioAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzfx74mh0jUdVu4pRHe2VktpCzsAqNMfMkc57IkaMTz6dcZ5DwPDaafpmlX1lr9uG1U+bGIo5LMSJvKRg5Y8ZLE5GSFxgHFXPHhsX8HS+L9RjMxku7mLaqFyYHkWNSAvX5beMn/Z359K4jR9Rgl1F7GNLjVbOJzBJBPaRwSyogXaFlkdXwzP5nKBPnwMnmgDtbzxIknjm08N6tL5iRQsge+IkjkmHmRh/oXC9TxjrXDQ6dZRfGGw0mD5V0u1vJ2/0f5d2x1aUhefMzDGxBzuzj66fiCe3kMEt9pq2TyGdLVXSO4cpGIyv/AC2AdiXfuQSRwOtclD4gPhX4iXFxcx3Tg217E3l2oEzyrGB8o3sNqo4bqc7fegD3X4J6l9ustRIbKuIZ8eWYwCFaDhTyo/0YHB9a9LryH9nHT9nh3UNXju7i5t7+VFjNxy+Yw3mE44/1jyDjj5a9eoAKKKKAMHxL4otdAnigmtb26uJLae8EdqisRFCYxIxLMAMeavGcnoMnANH/AIT/AEJtbh02OdnaWSKATgrsEsiB0TBbeSQy8hSoLAEg8Vqav4ftdV1BLy4knWVLG508BGAHlzmIueQfmHkrjtycg8YzdO8E2emaglzp97ewJmJ5YAIWSZo0VAxLRllJVEB2MoOM4yTkATSfHmj6kLaRVvLW2uYZZ4bi7tzDHIsYUvgn0BJ9wrEZAzUMfxF0N7+ztSbhHuDboxkCp5Mk4UxRuhbfuO9OikDcNxFTX3gTSb3wppvh+4e7NlYFPLcSBZGUAqysQMFXRnRgAMq56dasy+E7b/hIJdWtby7tZJ5Y5riGJYmjndFVQTvRmX5URTsZchR35oA6KiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOE+Jq6lJqHhaPRbiWK8F7LLHGspRZ2jt5HET9irFdpz0znqBXGrrfiHQ73VYbu8NvJd6qhu7ma5UR2O+0SUQo8isiLuOwErg7f7zA17bRQB4rr3iXUNR02K31XWLO2mQ6ZJFDZMjR6iWulEkiMw3Mg2j7hGOckgineI/G2oaXpuoiyvls72C41SeI3EsaQziGcqseZFdnb/pmm04P3l4r2ise78S6RaaqunXF4Euy8cRXYxVGk4jDMBtUseF3EbjwMnigDG8DXTTal40uJAx/wCJpE4RctjOnWZwB9Sa4aw8f6xcRXrWepQTxzQWk8DSNFNLbNLdJEySLGiqhCv9wl2BHLdq9DsvGmmyadDd3wmtFkmmiyYpJI0EczRbnkVdqAlc5Ygc1Zm8XaLFeT2hvC1xD5isqxORvjUu0YbG0uFBbZnOBnGKAOFv/EupR3N5o+o639jtIZ72D+1JI4leVkit3ihOV2BmE8nRQSIuMHJrQvJH/wCFLeHn3tvMOk5bPJzLb5robXxxok+h2OrNLdQ2d3CJw8lpLiJMAkyMFKoBnlidvXnHNalnr2l3msXWlWt7FLqFqMzwJktH9373p95fzoA8i8Q+M9Yv4PE9rpWpS4l0jVZIYUlj+2Wk0GAgCRoGjJyQNzsx4I2kYOxqPi/VI9egtrDXNMezWK3kt7i5nhjj1EO7CTBCnfgDaBGQQ2C2dwFd/F4n0eXVjpkd6puxI8W3Y23zFUsyb8bd4UFtuc4BOMc1VHjbw6LSa6k1SKK3i8smSZWjVlc7UdSwG5GPAdcqexoA4+58T6tHo8l5e6wlst3rN5p1qypFbRWyQXFwgMs0gdRuWIDOwknAAySas/DXWLzXNeiv9QZDcTaFbGTys7CwuLhSwHHXbnoPwrs4PEmjz2wuIr+IxGeO2ycgiV1VkQgjIJV0P0Oado3iDTNaeRNNuvOZFWTBRk3I2drruA3ocHDrlTg4NAFnVdUsNItDdatfWtjaghTNcyrEgJ6DcxAzWN/wn3g7/obPD/8A4Mof/iq6WigDmv8AhPvB3/Q2eH//AAZQ/wDxVH/CfeDv+hs8P/8Agyh/+KrpaKAPHNS1LTNZ+GMuk6VqNpPPpcE0e+0kjuWCwxsokVQcNlDuAPfjsa6jTfhX4VtlMstrPfXkknny3lxcu0s0nBLswIzkqGx0B6ADArjvHkc15a6l4j06+ksfJ1kxxyvlkKwrHFKSvdSIp1IJwR+Fdp8PfEnnvP4e1UmHVrA7VjlK7njGMfd4yuQvuNrdGoA84vLfTl8eXukanol3H4ajvG23MUsoEruiCQOVbPyNGj8nG0ue2K1PiJ8M9CTxFpuqywXf9myXUPnRW0rKYXAKmTOT8pTG4dwnqa9Cj8GWqaDf6a17eSyXV1Jem7kYGVZWOQeABgDC4xgqMHrXKa/YeIV8G6homqi2aNBCLK6WXe7hSXlBUjJVY1OCfmOcHP3iAdh8PrGHS/DSadboI47S5uYQgGNoE7kfhgg/Q10lc1pt0Lfxje23nB7bVLZNQtcDglAscuD34MJ/4Ea6WgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4S88LalqfivWnnnht9EuZrGcr5W+WcwEPhXD/INyqDlCSM4I6ju6KAPMtW+F0l/YS2Z1eB4JIpo9tzYmYQs88s3mQjzAEf96FLEMSEXG3nO+3gxXuoJXvjtj1e41QqIsFhLbTQeXnPGPN3bsfw4xzkddRQB5jrPwxvNW8Nw6Pd63ZyxRaU2lKZtNaRYxt2rMiGbCygdW5zgY29+50PSP7LudXl8/wA3+0L03eNm3y8xxpt6nP8Aq85469K1aKAOPn8ER3EsZmvSYl1a41N0WLBYTW00BjB3cY87du/2cY5yMzSvhuLGGzi+16f/AKJLauk0OnmOaRYJVcLI3mEEnb1UKMknHQD0OigDktT8E22o+LG1ee6kFrJblJLJVADz7HiWfd1DCKV0xjn5T/DyngjwcPDD/wCt0+bZbrbJLDZGGZlU8eY/mMGPH8KqM5OOgHXUUAFFFFABWf4jv/7K8P6pqAKg2lrLPlug2IW59uK0Ko67pyavomoabK5SO8t5LdmAyVDqVJ/WgDJGhxnwTa6dGYrh4LeNopJFyryKAwc/7x6+xNcVYWHh3xLpkWk+JBE17assFjqEmFmKjBjQvgYlXOCh+9jcAQxx2S3sqfD6OY3aLdCzWF7j7wSbARm/B88e1effEDSLTTvDOg309tHcajI4Vo/N8kz7iXEbY5IG5l4B5K8GgCtL4i8XeCtXlsL6QXMLSK1vHch5FnUkgiJ8kjouAWO3fgjpumh874geM7W08Swz2scO9p9JkV0VUCjA3OB5gYtztAyME44AqXnh+80vTo9T11Bq2nXEcbw3NtcNJJYylgVZNx2kbiuMbVGDgKT8254O0uz8TabdW2sSTr4iBW9t9RIC3CxsMRujA5wMcjtkZwegBsaZZ3em2F3p0HnXN14enFxZ7ZA8k8DgkwncM8qWUc4yE54rudNvYNS0+2vrOTzLa5iWWJ8YyrDIOPoawYNMvrPWtFuJlN/cC2a2vb+MJDuwAQzpnnJHQZwewBq54SiS2sbu1hAWC3vZ0jUHO1S5bH0G4gDsABQBt0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUNe1FdJ0a9v2UP9niZ1Tdje2PlXPqTgfjV+uX+JkTP4J1GVEaQ2nlXxRRksIJUmIA7nEZ479KAMnUPDM6+BNN0S5unW4nu1lu3jIIaSSRpZFUkDC72OOOgA5rZl8NRatqt/ceIra1u7fiGzhI3rHFtGWOQMOWLcgnAxg1sTQWWsWVs80aXFuWS5iJ6ZGGVhSa1qUWk2P2u4H7kSxxu2QAgd1TcSew3ZPsKAOK0eyvLmLxB4Ula6tmtZ0nt7q4j86OWFzuAHIzyrZGeCfQVvaT4L0jSNShvtOSeGaNpCP3hfKuADGS2TsyNwGeG59qu6xrX9mazolnLEPI1KaSDzycBJBGXVfq21sfTHelvrt7bxJpccjSC2uopolAHymYbXUH32rJj6H1oA1PNj8tpPMTy1zubdwMcHJ9sGue+Hcl5c+FLa91KJYru+klu2RQRhZJGaMYPcIUH4Vy8lwLOx8WeGJdQiDS3vkWAkmVZSt2FYxgYz8rSSAHk7celelRoscaogCooAAHQCgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEBgQwBB4IPelooA5Xw5enStXk8MX4KFFabTJT924tgRlB/tRblUjuu1u5xbhtr3WdNmN7dRpDdB0NssIZVQ5XY5bkn16dwKt+INEtdctEhuvMjmhcS29zCdstvIOjo3Y8n1BBIIIJFcddaJ44t7wtpd5pe+QqZrpZ3gE2MZLW7RyoGIHLIRnjigDMttUsNX8AXmhaxqccGvaPM8Cs9yvnLPbNvhkDHqSAhzjnLD1q94s8Qrqmk+Gry2tddgla/inhEFgXkYrGxYeWxDbcMRuIx35FWdN8CarHZ6lZ33iFGstUunubyO3sgskiuoVovNZm+UgAFtu7Hcdug8N+DdD8OTebpVrKsojESPPdS3BiT+4hkZti+y4B49BQBh+CPCcrXl14i8TC6k1e8ujcpa3EgMdqFHlxMI1JQSeUFy2SQScEV3tFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Patten, J. Neurological Differential Diagnosis, 2nd ed, Springer, London 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4100=[""].join("\n");
var outline_f4_0_4100=null;
var title_f4_0_4101="Anisotropic reentry";
var content_f4_0_4101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anisotropic reentry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A is an activation map of a single reentrant circuit at the epicardial border zone of a myocardial infarction. The large arrows represent the general activation pattern which occurs around a long line of block (blue arrow). Parallel isochrones 130 and 140 which are adjacent to the block suggest that activation is occurring across the block, resulting in a smaller circuit (shaded area) shown by the small black arrow. Panel B is an enlarged representation of this shaded area; the dark black rectangle represents an area of block around which there is a reentrant circuit (small arrows). Rapid activation occurs parallel to the long axis of the fiber orientation (isochrones 10-40 and 130-150), while in the transverse direction activation is slow (bunched isochrones 50-120).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4101=[""].join("\n");
var outline_f4_0_4101=null;
var title_f4_0_4102="Evaluation of the child with hoarseness";
var content_f4_0_4102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the child with hoarseness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Craig H Zalvan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Jacqueline Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4102/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/0/4102/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the child with hoarseness will be presented here. The etiology and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link\">",
"     \"Etiology and management of hoarseness in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Hoarseness\" or \"dysphonia\" are the terms used to describe a change in the quality of the voice. The voice quality can be breathy, strained, fatigued, rough, tremulous, or weak; it may have a change in pitch or abnormal resonance. The prevalence of hoarseness in children ranges from 4 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The causes of hoarseness in children vary by age (",
"    <a class=\"graphic graphic_table graphicRef73274 \" href=\"UTD.htm?0/42/686\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/4\">",
"     4",
"    </a>",
"    ]; most of these disease processes are benign and respond well to medical and speech therapy.",
"   </p>",
"   <p>",
"    The history and physical examination, including laryngoscopy, and if possible, stroboscopy, will determine the etiology in the majority of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx is part of the anterior hypopharynx. In newborns, the larynx is situated at the level of C3-C4, where it facilitates simultaneous respiration and swallowing during infant feeding; it gradually descends to the level of C6-C7 by the age of 15 years. The hyoid bone, a mobile, crescent-shaped bone, forms the anterior upper limit of the larynx, which is divided into three regions relative to the level of the vocal cords:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The supraglottic region encompasses the area above the vocal folds and includes the epiglottis, arytenoids, aryepiglottic folds, and false vocal folds",
"     </li>",
"     <li>",
"      The glottic region includes the vocal folds and the region immediately below the vocal folds; this region has the narrowest diameter in adults",
"     </li>",
"     <li>",
"      The subglottic region refers to the region starting 1 cm below the vocal folds and ending in the upper cervical trachea; this region corresponds to the cricoid cartilage and has the narrowest diameter in infants and children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The larynx is formed by the articulation of the thyroid and cricoid cartilages (",
"    <a class=\"graphic graphic_figure graphicRef79855 \" href=\"UTD.htm?24/1/24599\">",
"     figure 1",
"    </a>",
"    ). The ring-shaped cricoid cartilage is the only cartilage that completely encircles the airway. The epiglottis and the anterior commissure of the vocal folds are attached to the inner aspect of the thyroid cartilage at the thyroid prominence (also called the Adam's apple).",
"   </p>",
"   <p>",
"    The arytenoids, which help to position and move the vocal folds, articulate on the posterior edges of the cricoid cartilage (",
"    <a class=\"graphic graphic_figure graphicRef56206 \" href=\"UTD.htm?15/23/15733\">",
"     figure 2",
"    </a>",
"    ). The aryepiglottic folds are formed by mucosa that runs from each edge of the epiglottis to the arytenoid. The lower portion of the aryepiglottic fold creates the false vocal folds (also called the false vocal cords or vestibular folds), which are protective in normal phonation function (",
"    <a class=\"graphic graphic_figure graphicRef79855 \" href=\"UTD.htm?24/1/24599\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The true vocal folds (the vocal cords) are comprised of the thyroarytenoid muscle and the vocal ligament and extend from the vocal process of the arytenoid to the inner surface of the thyroid cartilage anteriorly. The vocal folds undergo age-related changes, lengthening as the child grows.",
"   </p>",
"   <p>",
"    The muscles of the larynx (",
"    <a class=\"graphic graphic_figure graphicRef56206 \" href=\"UTD.htm?15/23/15733\">",
"     figure 2",
"    </a>",
"    ) act to open and close the glottis and to regulate voice quality (",
"    <a class=\"graphic graphic_table graphicRef62687 \" href=\"UTD.htm?20/58/21419\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nerve supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superior and recurrent laryngeal branches of the vagus nerve innervate the laryngopharynx. The recurrent laryngeal nerves branch from the vagus in the upper chest and reenter the neck (\"recur\") in the thoracic inlet, extending to the larynx superiorly, traveling in or near the tracheoesophageal groove. The right and left recurrent laryngeal nerves travel underneath the right subclavian artery and around the arch of the aorta, respectively. The superior laryngeal nerve descends along the pharynx and divides into internal and external branches.",
"   </p>",
"   <p>",
"    The superior laryngeal nerve (SLN) supplies sensory innervation to the epiglottis and false vocal folds and the motor innervation to the cricothyroid muscle. The remainder of the larynx receives motor and sensory innervation from the recurrent laryngeal nerve (RLN). The interarytenoid muscle is the only muscle that is dually innervated by both RLN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx has three main functions: phonation, airway protection, and cough production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Phonation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phonation occurs as a result of the interaction between the true vocal cords and the exhaled column of air from the lungs, which creates oscillation of the vocal fold mucosa relative to the deeper vocal fold structures (thyroarytenoid muscle and vocal ligament).",
"   </p>",
"   <p>",
"    The intrinsic laryngeal musculature adjusts the tension and location of the vocal folds to produce fine changes in voice production (",
"    <a class=\"graphic graphic_table graphicRef62687 \" href=\"UTD.htm?20/58/21419\">",
"     table 2",
"    </a>",
"    ). Changes in pitch and frequency are mediated by the tension and position of the vocal folds, which are controlled by the cricothyroid and thyroarytenoid muscles. Contraction of the thyroarytenoid shortens and contraction of the cricothyroid muscle lengthens the vocal fold, resulting in lower and higher pitch, respectively.",
"   </p>",
"   <p>",
"    Voice is articulated through fine motor control of the tongue and lips, and resonated by the airway above the vocal folds. The size of the pharynx, oral cavity, nasal cavity, and larynx increase with age, resulting in changes of resonance, particularly in boys. The loudness of voice is directly related to subglottic pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Airway protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The airway is protected from ingested material during swallowing by laryngeal elevation, epiglottic deflection, and closure of the false and true vocal folds. Contraction of the paired lateral cricoarytenoid and the interarytenoid muscles results in adduction of the vocal folds and closure of the airway. Contraction of the posterior cricoarytenoid muscle causes rotation of the arytenoid and opening of the airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient glottic closure causes increased intrathoracic pressure that results in cough. Rapid glottic opening during cough facilitates the expectoration of tracheal air and mucous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the child with hoarseness begins with a complete history and physical examination. Additional information can be obtained from laryngoscopy, radiographic studies, and voice evaluation. Children who have rapidly progressive symptoms, stridor, aspiration, pain, or respiratory distress may require urgent otolaryngology evaluation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Specialist evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history is instrumental in making a diagnosis. The first step is to determine in what way the child's voice has changed. Descriptions from the child, parent, or teacher are helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Voice complaint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following questions may help to determine the cause and type of voice complaint:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is there a problem with the vocal quality?",
"     </li>",
"     <li>",
"      Does the child complain of breathiness?",
"     </li>",
"     <li>",
"      Is the voice rough or strained?",
"     </li>",
"     <li>",
"      Does the voice resonance have a hypernasal or hyponasal quality?",
"     </li>",
"     <li>",
"      Is the voice pitch too high or too low? Does it change or break?",
"     </li>",
"     <li>",
"      Is the child's voice too loud or too soft?",
"     </li>",
"     <li>",
"      Is the child's voice ever normal?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The responses to these questions can help to pinpoint the location of the voice problem. Breathiness of the voice, due to leakage of air through the vocal cords, may indicate vocal fold paralysis or a lesion preventing complete closure of the glottis. A change in resonance may indicate a mass lesion, nasal obstruction, or incomplete palatal closure. A change in pitch or quality of the voice may indicate a mucosal irregularity of the vocal fold. Difficulty with loudness may indicate a pulmonary or effort-related problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the exact nature of the voice change has been determined, other factors relating to the dysphonia must be elicited, particularly the onset and tempo of the problem:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Was the onset related to a particular event?",
"     </li>",
"     <li>",
"      Was the onset gradual, or has the dysphonia been long-standing?",
"     </li>",
"     <li>",
"      Are the symptoms intermittent or chronic?",
"     </li>",
"     <li>",
"      Has the voice complaint been progressive or static?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute problems are more commonly related to vocal abuse and result from injury to the mucosa overlying the vocal folds. Acute problems may also be caused by an infectious or inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/6\">",
"     6",
"    </a>",
"    ]. Chronic, progressive problems typically indicate a structural abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional important questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the voice worse in the morning or evening?",
"     </li>",
"     <li>",
"      Are there factors that alleviate or aggravate the dysphonia (eg, vocal abuse, upper respiratory tract infection, allergy, or environmental problems)?",
"     </li>",
"     <li>",
"      Could the child have gastroesophageal or laryngopharyngeal reflux?",
"     </li>",
"     <li>",
"      Does the child have dysphagia, sore throat, difficulty swallowing, or pain with swallowing?",
"     </li>",
"     <li>",
"      Does the child have stridor or wheezing?",
"     </li>",
"     <li>",
"      Does the child have a cough?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Details of the birth and past medical history also should be obtained, particularly if the voice problem had onset in infancy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Was the quality of the newborn cry normal?",
"     </li>",
"     <li>",
"      Has the child had any respiratory distress or feeding difficulty?",
"     </li>",
"     <li>",
"      Were forceps used in the delivery?",
"     </li>",
"     <li>",
"      Has the child ever been intubated?",
"     </li>",
"     <li>",
"      Does the child have any other medical problems?",
"     </li>",
"     <li>",
"      Is there any history of speech, language, or developmental delay?",
"     </li>",
"     <li>",
"      Is there any history of hearing loss or chronic ear disease?",
"     </li>",
"     <li>",
"      Are there any behavioral problems or psychiatric disorders?",
"     </li>",
"     <li>",
"      Is there any history of trauma or surgery, particularly involving the heart, chest, base of the skull, or neck?",
"     </li>",
"     <li>",
"      Does the child have a history of voice problems? Has he or she had any prior voice evaluations or visits to a speech pathologist?",
"     </li>",
"     <li>",
"      Is the child taking any medications (eg, inhaled glucocorticoids, antihistamines, anticholinergics)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Review of systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, detailed questions regarding the remainder of the head and neck are important:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the child have ear pain or other symptoms of ear disease, particularly hearing loss?",
"     </li>",
"     <li>",
"      Does the child have nasal obstruction, rhinorrhea, postnasal drip, or change in olfaction?",
"     </li>",
"     <li>",
"      Does the child have any problems with tongue movements, difficulty swallowing, pain in the neck, or pain in the throat?",
"     </li>",
"     <li>",
"      Has the child had any weight loss?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete head and neck examination should be performed during the initial visit. Otoscopic examination, including pneumatic otoscopy, should be performed to rule out middle ear pathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .) Other pertinent components of the physical examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the skin for any cutaneous lesions, hemangiomas, or lymphatic malformations",
"     </li>",
"     <li>",
"      Examination of the nose for patency, obstructing lesions, foreign body, or evidence of allergy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Examination of the oral cavity for mass lesions, mucosal abnormalities, tonsil size, and motor function of the palate and tongue",
"     </li>",
"     <li>",
"      Palpation of the neck for mass lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic evaluation of children with hoarseness is not usually necessary. This is because most causes of childhood hoarseness involve the mucosal surface of the vocal folds or a functional problem of the larynx. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link\">",
"     \"Etiology and management of hoarseness in children\"",
"    </a>",
"    .) However, radiologic evaluation can be helpful in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computed tomography (CT) or magnetic resonance imaging (MRI) is useful when a mass lesion is suspected either within the larynx or along the course of the recurrent laryngeal nerve in the event of a vocal fold paralysis.",
"     </li>",
"     <li>",
"      A chest radiograph or fluoroscopic evaluation may be helpful in evaluating the presence of a foreign body; a chest radiograph may demonstrate an intrathoracic mass causing impingement on the recurrent laryngeal nerve in patients with vocal cord paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"       \"Airway foreign bodies in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A soft tissue radiograph of the neck may be useful in evaluating the child for edema associated with an infectious or allergic process (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"UTD.htm?2/56/2959\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64512 \" href=\"UTD.htm?2/43/2751\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A modified",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow may help to identify those children who are aspirating from a vocal fold paralysis or laryngeal cleft.",
"     </li>",
"     <li>",
"      Airway fluoroscopy can help in the evaluation of the vocal cords and trachea [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIALIST EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation by an otolaryngologist, speech pathologist, or other specialist may be necessary depending upon the suspected etiology of hoarseness. Children who have hoarseness and rapidly progressive symptoms, stridor, aspiration, pain, or respiratory distress may require urgent otolaryngology evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link\">",
"     \"Etiology and management of hoarseness in children\"",
"    </a>",
"    .) The indications for referral in children with non-acute hoarseness include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration greater than two weeks",
"     </li>",
"     <li>",
"      Unexplained hoarseness (eg, not associated with an upper respiratory tract infection)",
"     </li>",
"     <li>",
"      Progressive hoarseness",
"     </li>",
"     <li>",
"      Socially unacceptable hoarseness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laryngology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete evaluation of a child who has hoarseness and any of the above indications includes visualization of the larynx by indirect or flexible laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/7\">",
"     7",
"    </a>",
"    ]. Flexible fiberoptic nasopharyngolaryngoscopy is a valuable tool in the examination of the larynx in children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/5\">",
"     5",
"    </a>",
"    ]. After adequate anesthesia of the nasal cavity, the flexible scope is used to examine the nasopharynx and larynx, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The closure of the palate and adenoid pad in the nasopharynx",
"     </li>",
"     <li>",
"      The prominence and architecture of the base of the tongue",
"     </li>",
"     <li>",
"      The presence of pooling or mass lesions in the pyriform sinuses",
"     </li>",
"     <li>",
"      The architecture and function of the larynx",
"     </li>",
"     <li>",
"      The presence of mass lesions",
"     </li>",
"     <li>",
"      The vocal folds for symmetry or lesions of the free edge",
"     </li>",
"     <li>",
"      The patency of the airway and completeness of airway closure",
"     </li>",
"     <li>",
"      Evidence of reflux",
"     </li>",
"     <li>",
"      Laryngeal mobility during speech and swallowing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The older child is asked to perform a variety of tasks under direct visualization:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Voicing the letter",
"      <span class=\"nowrap\">",
"       /i/",
"      </span>",
"      permits visualization of the adductory movement of the vocal fold",
"     </li>",
"     <li>",
"      Deep inspiration or a \"sniff\" permits visualization of the abductory movements",
"     </li>",
"     <li>",
"      Pronouncing",
"      <span class=\"nowrap\">",
"       /i/",
"      </span>",
"      with a low pitch upscale to a high pitch permits testing of the cricothyroid muscle",
"     </li>",
"     <li>",
"      Fluency of speech is determined by repeating phrases and connected speech; this demonstrates normal neurologic control of vocal fold movement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The stroboscopic examination is another useful diagnostic tool in the evaluation of hoarseness. During phonation, the vocal folds vibrate more than 100 times per second. The stroboscope sends out bright flashes of light that are timed to the frequency of vocal fold vibration, a process that visually \"freezes\" the image for the observer and permits evaluation of the mucosal edges of the vocal folds for irregularity or subtle changes. The endoscopes used for stroboscopy are usually a rigid telescope with a 90&ordm; prism (which allows visualization of the larynx through the oral cavity) and the flexible endoscope. Stroboscopic examination is usually well tolerated in children older than six to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4102/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct laryngoscopy may be necessary if the larynx is not adequately visualized by nasopharyngolaryngoscopy or stroboscopic examination; if the child's hoarseness is not responding to therapy; or if a suspicious lesion is detected with the above examinations. Direct laryngoscopy is performed in the operating room. The laryngoscope is placed within the oral cavity to directly visualize the larynx; a microscope or telescope can be used to enhance visualization. Complications of direct laryngoscopy are rare and may include dislocation of the jaw, inadvertent removal of teeth, discomfort, small mucosal tears, injury to the larynx, and the risk of anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Speech and language",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of a speech language pathologist (SLP) is crucial in the diagnosis and treatment of a child with hoarseness. The SLP performs an acoustic assessment including pitch, loudness, voice quality, and phonation time. Glottic airflow, subglottic air pressure, and glottic resistance are evaluated during aerodynamic assessment. Hearing evaluation is performed when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Hoarseness\" or \"dysphonia\" is the term used to describe a change in the quality of the voice. The voice quality can be breathy, strained, fatigued, rough, tremulous, or weak; it may have a change in pitch or abnormal resonance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of hoarseness in children vary by age (",
"      <a class=\"graphic graphic_table graphicRef73274 \" href=\"UTD.htm?0/42/686\">",
"       table 1",
"      </a>",
"      ); most of these disease processes are benign and respond well to medical and speech therapy. The history and physical examination, including laryngoscopy, and if possible, stroboscopy, will determine the etiology in the majority of cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link\">",
"       \"Etiology and management of hoarseness in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The larynx has three main functions: phonation, airway protection, and cough production. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with hoarseness who have rapidly progressive symptoms, stridor, aspiration, pain, or respiratory distress may require urgent otolaryngology evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include determination of the manner in which the voice has changed, the pattern and time course of the voice change, associated symptoms, past medical history, and review of systems. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the physical examination of the child with hoarseness include the head and neck examination, otoscopic examination, cutaneous lesions, examination of the nose and oral cavity, and palpation of the neck. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiologic evaluation is usually not necessary, but may be helpful in specific circumstances (eg, suspected mass lesion, foreign body, aspiration, etc). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for referral to an otolaryngologist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a speech language pathologist in children with non-acute hoarseness include duration greater than two weeks and unexplained, progressive, or socially unacceptable hoarseness. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Specialist evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/1\">",
"      Silverman EM. Incidence of chronic hoarseness among school-age children. J Speech Hear Disord 1975; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/2\">",
"      Duff MC, Proctor A, Yairi E. Prevalence of voice disorders in African American and European American preschoolers. J Voice 2004; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/3\">",
"      Carding PN, Roulstone S, Northstone K, ALSPAC Study Team. The prevalence of childhood dysphonia: a cross-sectional study. J Voice 2006; 20:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/4\">",
"      Cohen SR, Thompson JW, Geller KA, Birns JW. Voice change in the pediatric patient. A differential diagnosis. Ann Otol Rhinol Laryngol 1983; 92:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/5\">",
"      Chait DH, Lotz WK. Successful pediatric examinations using nasoendoscopy. Laryngoscope 1991; 101:1016.",
"     </a>",
"    </li>",
"    <li>",
"     Levitsky SE. Hoarseness. In: Primary pediatric care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1156.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/7\">",
"      Kenna MA. Consultation with the specialist. Hoarseness. Pediatr Rev 1995; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/8\">",
"      Nastasi KJ, Howard DA, Raby RB, et al. Airway fluoroscopic diagnosis of vocal cord dysfunction syndrome. Ann Allergy Asthma Immunol 1997; 78:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/9\">",
"      Shao W, Chung T, Berdon WE, et al. Fluoroscopic diagnosis of laryngeal asthma (paradoxical vocal cord motion). AJR Am J Roentgenol 1995; 165:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4102/abstract/10\">",
"      Hirschberg J, Dejonckere PH, Hirano M, et al. Voice disorders in children. Int J Pediatr Otorhinolaryngol 1995; 32 Suppl:S109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6304 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-217.117.136.88-353D9881C8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4102=[""].join("\n");
var outline_f4_0_4102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nerve supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Phonation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Airway protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cough",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Voice complaint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Review of systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIALIST EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laryngology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Speech and language",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6304|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/56/2959\" title=\"diagnostic image 1\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/43/2751\" title=\"diagnostic image 2\">",
"      Subglottic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6304|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/1/24599\" title=\"figure 1\">",
"      Laryngeal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/23/15733\" title=\"figure 2\">",
"      Laryngeal musculature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/686\" title=\"table 1\">",
"      DDx hoarseness child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/58/21419\" title=\"table 2\">",
"      Muscles of larynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=related_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4103="Disorders that cause hyperthyroidism";
var content_f4_0_4103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders that cause hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4103/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4103/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4103/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4103/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/0/4103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different disorders can cause hyperthyroidism. It is essential that the correct cause be identified because appropriate therapy depends upon the underlying mechanism of the hyperthyroidism. From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthyroidism with a normal or high radioiodine uptake indicates de novo synthesis of hormone. These disorders can be treated with a thionamide, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      , which will interfere with hormone synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"       \"Thionamides in the treatment of Graves' disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism with a near absent radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation or an extrathyroidal source of thyroid hormone. Thyroid hormone is not being actively synthesized when hyperthyroidism is due to thyroid inflammation; as a result, thionamide therapy is not useful in these disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the main causes of hyperthyroidism and outline the therapeutic approach to the less common conditions. The treatment of Graves' disease and toxic nodular goiter and the diagnostic approach to patients with hyperthyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism is more common in women than men (5:1 ratio). The overall prevalence of hyperthyroidism, which is approximately 1.3 percent, increases to 4 to 5 percent in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/1\">",
"     1",
"    </a>",
"    ]. Hyperthyroidism is also more common in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/2\">",
"     2",
"    </a>",
"    ]. Graves' disease is seen most often in younger women, while toxic nodular goiter is more common in older women.",
"   </p>",
"   <p>",
"    In one prospective cohort study of adult women, the overall incidence of Graves' disease was 4.6 per 1000 during 10 years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM WITH A NORMAL OR HIGH RADIOIODINE UPTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune thyroid disease and autonomous thyroid tissue are the major causes of excess new hormone synthesis by the thyroid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' disease is the most common cause of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/4\">",
"     4",
"    </a>",
"    ]. It is an autoimmune disorder resulting from thyrotropin (TSH)-receptor antibodies (also called thyroid-stimulating immunoglobulins), which stimulate thyroid gland growth and thyroid hormone synthesis and release [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/5\">",
"     5",
"    </a>",
"    ]. Stressful life events may be a risk factor for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/6\">",
"     6",
"    </a>",
"    ]. Another risk factor may be a relatively high iodine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/7\">",
"     7",
"    </a>",
"    ]. Ophthalmopathy and pretibial myxedema are additional autoimmune manifestations of Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     \"Hashitoxicosis\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Hashitoxicosis\" (a neologism that combines \"Hashimoto\" and \"thyrotoxicosis\") is a term used to describe rare patients with autoimmune thyroid disease who initially present with hyperthyroidism and a high radioiodine uptake caused by TSH-receptor antibodies similar to Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    .) This is followed by the development of hypothyroidism due to infiltration of the gland with lymphocytes and resultant autoimmune-mediated destruction of thyroid tissue similar to chronic lymphocytic thyroiditis (Hashimoto's thyroiditis).",
"   </p>",
"   <p>",
"    The initial therapeutic considerations are similar to those for Graves' disease. However, hypothyroidism may intervene, making further antithyroid therapy unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Toxic adenoma and toxic multinodular goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic adenoma and toxic multinodular goiter are the result of focal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diffuse hyperplasia of thyroid follicular cells whose functional capacity is independent of regulation by TSH. Activating somatic mutations of the genes for the TSH receptor have been identified in both toxic adenomas and nodules of toxic multinodular goiters [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Similarly, activating mutations of the Gs-alpha protein have been identified in toxic adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/9,11\">",
"     9,11",
"    </a>",
"    ], but it is uncertain whether they occur in toxic multinodular goiters [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/11\">",
"     11",
"    </a>",
"    ]. Other mutations must also play a role because in one study mutations in neither of these genes were found in 15 toxic adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of the TSH-receptor gene are most common; they were found in 15 of 31 toxic adenomas in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/13\">",
"     13",
"    </a>",
"    ]. The mutations are usually in the transmembrane domain of the receptor, but can be in the extracellular domain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The mutant receptors activate adenylyl cyclase in the absence of TSH.",
"   </p>",
"   <p>",
"    Toxic multinodular goiter tends to be more common in areas where iodine intake is relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/7\">",
"     7",
"    </a>",
"    ]. In comparison, the frequency of thyroid adenomas is not related to iodine intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Iodine-induced hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, iodine-induced hyperthyroidism can develop after an iodine load, as an example, after administration of contrast agents used for angiography or CT or iodine-rich drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . In iodine-induced hyperthyroidism, the radioiodine uptake will be high only if sufficient time has passed for most of the administered iodine to be excreted. By comparison, the uptake will be low if iodine continues to be given or if the original preparation has a long biologic life because, despite the increase in thyroid activity, a recent exogenous iodine load will dilute the radioiodine tracer used to determine the uptake. These disorders are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Trophoblastic disease and germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism can occur in women with a hydatidiform mole or choriocarcinoma or in men with testicular germ cell tumors via direct stimulation of the TSH receptor. It is uncertain whether this process is mediated by high concentrations of human chorionic gonadotropin itself or by other placental proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/15\">",
"     15",
"    </a>",
"    ]. Therapy is directed against the tumor. Thionamides are useful adjunctive therapy, since hormone synthesis is occurring within the thyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H12187099#H12187099\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'hCG-mediated hyperthyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link&amp;anchor=H7#H7\">",
"     \"Serum tumor markers in testicular germ cell tumors\", section on 'Hyperthyroidism and hCG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TSH-mediated hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism caused by increased TSH production is rare. Two forms, neoplastic and non-neoplastic, are recognized.",
"   </p>",
"   <p>",
"    TSH-producing pituitary adenomas are macroadenomas by the time of diagnosis, and some are locally invasive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Almost all of these patients have a goiter, 40 percent have a visual field defect, and one-third of women have galactorrhea. All patients have high serum thyroid hormone concentrations.",
"   </p>",
"   <p>",
"    Therapy is directed at the pituitary tumor. Although not perfect, surgery is reasonably successful (two-thirds are improved or cured), particularly when the serum TSH concentration falls to a low level (&lt;0.2",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    one week after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/18\">",
"     18",
"    </a>",
"    ]. Radioiodine or thyroid surgery has been used when transsphenoidal surgery, external beam radiotherapy, or somatostatin analogues do not control the hyperthyroidism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    and the longer-acting somatostatin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    have been useful for suppressing TSH production in patients with these adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/17,19\">",
"     17,19",
"    </a>",
"    ] and, given preoperatively, may permit more effective surgery of locally invasive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further information about the clinical manifestations and treatment of these tumors can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"     \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-neoplastic TSH-mediated hyperthyroidism is due to resistance to the feedback effect of thyroid hormone on pituitary TSH production. This condition is usually due to mutations in the nuclear triiodothyronine (T3) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. Treatment is rarely satisfactory. T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/21\">",
"     21",
"    </a>",
"    ] and 3,5,3'-triiodothyroacetic acid (a derivative of T3) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/22\">",
"     22",
"    </a>",
"    ] have been effective in a few patients.",
"   </p>",
"   <p>",
"    Another rare form of \"TSH-induced\" hyperthyroidism results from an activating mutation in the TSH receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This disorder is transmitted as an autosomal dominant trait, and affected patients are hyperthyroid with appropriate suppression of TSH release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epoprostenol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a single report, 3 of 45 patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    (prostaglandin I2) for pulmonary arterial hypertension developed hyperthyroidism with an elevated radioiodine uptake and negative thyroid stimulating immunoglobulin levels after more than 1.5 years of therapy; confirmation of these findings is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM WITH A NEAR ABSENT RADIOIODINE UPTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism with a low radioiodine uptake can result from thyroid inflammation leading to release of preformed hormone, exogenous ingestion of thyroid hormone, or ectopic production of thyroid hormone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term thyroiditis has been applied to a group of heterogeneous disorders that result in inflammation of thyroid tissue with transient hyperthyroidism due to release of preformed hormone from the colloid space. This initial presentation is followed by a hypothyroid phase and then recovery of thyroid function. The definitions and clinical features of this disorder are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the term subacute thyroiditis is used without modification, it usually refers to subacute granulomatous thyroiditis (de Quervain's thyroiditis), which is a viral or post-viral syndrome characterized by fever, malaise, and an exquisitely painful and tender goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/26\">",
"     26",
"    </a>",
"    ]. In comparison, painless thyroiditis (silent thyroiditis or subacute lymphocytic thyroiditis) is part of the spectrum of autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/27\">",
"     27",
"    </a>",
"    ] and has a particular proclivity to occur in the postpartum period (postpartum thyroiditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of thyroiditis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct chemical toxicity with inflammation, which is one mechanism by which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can cause hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .) Preliminary data suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      may also be associated with a destructive thyroiditis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link&amp;anchor=H17#H17\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Sunitinib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation thyroiditis, from external radiation or after radioiodine therapy.",
"     </li>",
"     <li>",
"      Drugs that interfere with the immune system, such as interferon alfa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of thyroiditis\", section on 'Drug-induced thyroiditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=see_link\">",
"       \"Lithium and the thyroid\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Palpation thyroiditis occurring, as an example, during parathyroid surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with thyroiditis usually have a radioiodine uptake of less than 1 percent, making radioiodine therapy impossible as well as inappropriate. Thionamides also have no role in treatment, since new hormone is not being synthesized. Therapy consists of beta-blockers for symptomatic control and antiinflammatory drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or nonsteroidal antiinflammatory drugs, or, in severe cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/31\">",
"     31",
"    </a>",
"    ]. Ipodate is also useful, as it blocks both the conversion of thyroxine (T4) to T3 and reduces the tissue effects of thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4103/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Exogenous and ectopic hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous or ectopic hyperthyroidism (hyperthyroidism resulting from excess thyroid hormone originating from outside the thyroid gland) can arise from external or internal sources of excess thyroid hormone, and can occur in several clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factitious ingestion of thyroid hormone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute hyperthyroidism from a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      overdose. This disorder can be ameliorated with beta-blockers, drugs that block the 5'-monodeiodinase (such as ipodate) and, in severe cases, plasmapheresis or dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Struma ovarii, in which functioning thyroid tissue is present in an ovarian neoplasm. Treatment consists of ovarian surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=see_link\">",
"       \"Struma ovarii\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functional thyroid cancer metastases, in which large bony metastases from widely metastatic follicular thyroid cancer cause symptomatic hyperthyroidism. Treatment may require a variety of approaches including thionamides, radioiodine, surgery, or external radiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of follicular thyroid cancer\", section on 'Metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25013079\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several different disorders can cause hyperthyroidism. It is essential that the correct cause be identified because appropriate therapy depends upon the underlying mechanism of the hyperthyroidism. From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake (",
"      <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of hyperthyroidism with a normal or high radioiodine uptake is Graves&rsquo; disease. Other causes include Hashitoxicosis, toxic adenoma, and toxic multinodular goiter. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hyperthyroidism with a normal or high radioiodine uptake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Iodine-induced hyperthyroidism can occur after an iodine load in a patient with underlying autonomy in a nodule or nodular goiter. The radioiodine uptake will be high only if sufficient time has passed for the administered iodine to be excreted; iodine uptake is frequently low in patients with iodine-induced hyperthyroidism, but is usually not under 1 percent unless the source of iodine is continuous (eg, a daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      tablet). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Iodine-induced hyperthyroidism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"       \"Iodine-induced thyroid dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthyroidism with a near absent radioiodine uptake can result from thyroid inflammation leading to release of preformed hormone (thyroiditis), exogenous ingestion of thyroid hormone, or ectopic production of thyroid hormone. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hyperthyroidism with a near absent radioiodine uptake'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/1\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/2\">",
"      Asvold BO, Bj&oslash;ro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/3\">",
"      Holm IA, Manson JE, Michels KB, et al. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005; 165:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/4\">",
"      Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008; 358:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/5\">",
"      Davies, TF. New thinking on the immunology of Graves' disease. Thyroid Today 1992; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/6\">",
"      Radosavljevi�� VR, Jankovi�� SM, Marinkovi�� JM. Stressful life events in the pathogenesis of Graves' disease. Eur J Endocrinol 1996; 134:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/7\">",
"      Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991; 229:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/8\">",
"      Fatourechi V, McConahey WM, Woolner LB. Hyperthyroidism associated with histologic Hashimoto's thyroiditis. Mayo Clin Proc 1971; 46:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/9\">",
"      Duprez L, Hermans J, Van Sande J, et al. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene. J Clin Endocrinol Metab 1997; 82:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/10\">",
"      Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/11\">",
"      Holzapfel HP, F&uuml;hrer D, Wonerow P, et al. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 1997; 82:4229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/12\">",
"      Pinducciu C, Borgonovo G, Arezzo A, et al. Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. Eur J Endocrinol 1998; 138:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/13\">",
"      F&uuml;hrer D, Holzapfel HP, Wonerow P, et al. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/14\">",
"      Kopp P, Muirhead S, Jourdain N, et al. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281--&gt;isoleucine) in the extracellular domain of the thyrotropin receptor. J Clin Invest 1997; 100:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/15\">",
"      Norman RJ, Green-Thompson RW, Jialal I, et al. Hyperthyroidism in gestational trophoblastic neoplasia. Clin Endocrinol (Oxf) 1981; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/16\">",
"      Wynne AG, Gharib H, Scheithauer BW, et al. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med 1992; 92:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/17\">",
"      Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/18\">",
"      Losa M, Giovanelli M, Persani L, et al. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81:3084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/19\">",
"      Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993; 119:236.",
"     </a>",
"    </li>",
"    <li>",
"     Golsman, J, Wietecha, K, Rock, J. Thyrotropin-secreting pituitary adenoma: Reduction of tumor size by octreotide therapy into the sellar confines allows surgical cure by transsphenoidal hypophysectomy. 10th Internat Cong Endocrinol, San Francisco, 12-15 June 1996, abst. no. P2-482.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/21\">",
"      R&ouml;sler A, Litvin Y, Hage C, et al. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab 1982; 54:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/22\">",
"      Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G. Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC). J Endocrinol Invest 1983; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/23\">",
"      Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994; 7:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/24\">",
"      Farid NR, Kascur V, Balazs C. The human thyrotropin receptor is highly mutable: a review of gain-of-function mutations. Eur J Endocrinol 2000; 143:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/25\">",
"      Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. Endocr Pract 2009; 15:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/26\">",
"      Volp&eacute; R. Subacute (de Quervain's) thyroiditis. Clin Endocrinol Metab 1979; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/27\">",
"      Nikolai TF, Coombs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1982; 142:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/28\">",
"      Roti E, Emerson CH. Clinical review 29: Postpartum thyroiditis. J Clin Endocrinol Metab 1992; 74:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/29\">",
"      Lambert M, Unger J, De Nayer P, et al. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest 1990; 13:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/30\">",
"      Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008; 69:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/31\">",
"      Volp&eacute; R. The management of subacute (DeQuervain's) thyroiditis. Thyroid 1993; 3:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4103/abstract/32\">",
"      Arem R, Munipalli B. Ipodate therapy in patients with severe destruction-induced thyrotoxicosis. Arch Intern Med 1996; 156:1752.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7871 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4103=[""].join("\n");
var outline_f4_0_4103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25013079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPERTHYROIDISM WITH A NORMAL OR HIGH RADIOIODINE UPTAKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      \"Hashitoxicosis\"",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Iodine-induced hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Trophoblastic disease and germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TSH-mediated hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epoprostenol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HYPERTHYROIDISM WITH A NEAR ABSENT RADIOIODINE UPTAKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Exogenous and ectopic hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25013079\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/45/32476\" title=\"table 1\">",
"      Causes of hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=related_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42453?source=related_link\">",
"      Lithium and the thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=related_link\">",
"      Overview of follicular thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=related_link\">",
"      Struma ovarii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=related_link\">",
"      Thyrotropin (TSH)-secreting pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4104="Diagnosis and classification of cerebral palsy";
var content_f4_0_4104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and classification of cerebral palsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4104/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/0/4104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) consists of a heterogeneous group of nonprogressive clinical syndromes that are characterized by motor and postural dysfunction. These conditions, which range in severity, are due to abnormalities of the developing brain resulting from a variety of causes. Although the disorder itself is not progressive, the appearance of neuropathologic lesions and their clinical expression may change over time as the brain matures.",
"   </p>",
"   <p>",
"    The diagnosis of CP is discussed here. The epidemiology, etiology, clinical features, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=see_link\">",
"     \"Management and prognosis of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cerebral palsy (CP) depends upon a combination of findings, including motor delay, neurologic signs, persistence of primitive reflexes, and abnormal postural reactions. A diagnosis rarely is made on the basis of an isolated abnormality. Infants with normal functional development and behavior who have mild hypertonia or hyperreflexia should be observed. If these abnormalities remain isolated, they will resolve progressively after the child reaches nine months of age in most cases.",
"   </p>",
"   <p>",
"    Infants with an abnormal obstetric or perinatal history may be at increased risk to develop CP, and should be monitored closely. Clues to an early diagnosis include abnormal behavior, psychomotor delay, and abnormal oromotor or oculomotor patterns. The infant may be hypotonic or have increased tendon reflexes and clonus. Developmental (primitive) reflexes may be asymmetric or persistent, and postural reactions may be delayed. In many cases, spasticity may not be identified until six months of age. Dyskinetic patterns are not typically apparent until approximately 18 months. Ataxia may not become obvious until even later.",
"   </p>",
"   <p>",
"    Although the lesion in CP is static, clinical signs evolve as the nervous system matures. Thus, a definitive diagnosis usually requires serial examinations, and often is not possible until later infancy, especially in preterm infants. This is illustrated by a report of infants at high risk for CP who had serial examinations for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of three or more abnormal signs at eight months of age was highly predictive of CP. However, CP often was missed at one month and sometimes overdiagnosed at four months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neurobehavioral signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurobehavioral signs suspicious for CP are excessive docility or irritability. A typical history includes poor feeding in the neonatal period. The baby often is irritable, sleeps poorly, vomits frequently, is difficult to handle and cuddle, and has poor visual attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Motor abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tone in the extremities may be normal or increased. Persistent or asymmetric fisting may be present. Abnormal oromotor patterns include tongue retraction and thrust, tonic bite, oral hypersensitivity, and grimacing. Poor head control may be an early motor sign. However, increased neck extensor and axial tone may make head control appear better than it actually is.",
"   </p>",
"   <p>",
"    In addition to the neurologic examination, achievement of motor milestones should be evaluated. The infant should be observed in the prone and supine positions. Posture and tone are assessed on pulling to sit, supported sitting, and vertical and ventral suspension. The infant should be able to support himself or herself on arms and hands and rotate within the body axis at the appropriate ages. The emergence and quality of protective postural reactions should be noted.",
"   </p>",
"   <p>",
"    Serial examination using motor milestones can be an effective screening process for CP. In one study, six motor milestones (roll prone to supine, roll supine to prone, sit with support, sit without support, crawl, and cruise) were sequentially evaluated for at least 18 months in 173 infants born at &lt;33 weeks gestational age, of whom 31 (18 percent) developed CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/2\">",
"     2",
"    </a>",
"    ]. Serial screening of these milestones predicted the development of CP better than did any individual milestone. Delays in more than four milestones were especially worrisome. In another report, signs present at four months of age that indicated increased risk of CP were failure to support weight on the forearms in a prone position, sit supported with head erect, or show interest in surroundings or respond socially [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Developmental reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal infants, most developmental reflexes related to posture (tonic labyrinthine, tonic neck, and neck-righting and body-righting reflexes) disappear when the infants are between three and six months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=see_link&amp;anchor=H35#H35\">",
"     \"Neurological examination of the newborn\", section on 'Developmental'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These reflexes often are not appropriately integrated or inhibited in children with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, delay in the disappearance or exaggeration of a developmental reflex may be an early indication of motor disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. An obligatory developmental reflex (a response that persists for as long as the stimulus is applied) is abnormal at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link&amp;anchor=H10929149#H10929149\">",
"     \"Detailed neurologic assessment of infants and children\", section on 'Developmental reflexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tonic labyrinthine response is tested in the supine position. Extension of the neck results in shoulder retraction, leg extension, and either elbow flexion or extension and pronation of the arms. Flexion of the neck results in flexion of the extremities. Infants with an exaggerated tonic labyrinthine response may have opisthotonic posturing or roll over at an age that is earlier than appropriate.",
"   </p>",
"   <p>",
"    Other abnormal signs can be elicited when the infant is held in vertical suspension. During the first few months, the appropriate response is for the baby to assume a sitting position (\"sit in the air\"). An abnormal response is persistent extension of the legs. This may be followed by or associated with an abnormal positive support reaction. The latter is tested by placing the anteromedial areas of the soles on a firm surface, which should result in a few seconds of plantar flexion, then return of the feet to a neutral position. An abnormal response is plantar flexion that is obligate or maintained for more than 30 seconds, especially if accompanied by equinus posturing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific CP syndromes are best recognized after five years of age (",
"    <a class=\"graphic graphic_table graphicRef74533 \" href=\"UTD.htm?29/5/29787\">",
"     table 1",
"    </a>",
"    ). Earlier diagnosis may be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/6\">",
"     6",
"    </a>",
"    ]. These clinical syndromes are discussed in more detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spastic diplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with spastic diplegia often have hypotonia of the lower limbs with delayed functional maturation for several months. Spasticity that involves ankle plantar flexors and hip adductors usually is detected at approximately six months of age. This often results in contractures of the hip flexors and hamstring muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spastic hemiplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemiplegia is characterized by the early appearance of motor asymmetry, often with some retraction of the shoulder on the affected side. The fingers tend to be held in flexion, and with adduction of the thumb. Spasticity initially may be minimal, but usually develops later with decreased abduction at the hip, plantar flexion at the ankle, clawing of the toes, and a flexion-pronation pattern that affects the upper limb.",
"   </p>",
"   <p>",
"    Other early signs are the inability to use both hands in the midline or to reach out with the affected limb. When the infant is placed in the prone position, the affected upper limb provides decreased support, and movement of the affected leg is diminished. When the child is pulled to a sitting position, the affected leg tends to extend. The protective reactions that appear at five to eight months of age are asymmetric.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Spastic quadriplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with spastic quadriplegia typically have moderate or severe psychomotor delay and poor head control. Spasticity may begin by two to three months of age and involves the antigravity muscles, especially the biceps, forearm pronators, wrist flexors, thumb adductors, and finger flexors. Adduction of the thighs and flexion of the hips and knees occur, with equinus of the feet and adduction of the forefoot. Marked adduction of the thighs results in typical scissoring of the legs.",
"   </p>",
"   <p>",
"    Diagnosis of spastic CP usually is easier in the older infant. At approximately 9 to 10 months of age, affected infants who are pulled to sitting are unable to flex the legs and have poor truncal balance. They cannot form a pincer grasp when reaching for an object. Instead, the hand splays and they may achieve an ulnar grasp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dyskinetic CP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early infancy, patients with dyskinetic CP may have reduced spontaneous movement and oromotor incoordination. They may be hypotonic at rest, but tone may be variable with movement or emotion. Primitive reflexes typically persist. Patients typically have extension patterns in the supine position, and flexion with shoulder retraction in the prone position; the head usually is persistently turned to one side [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific tests confirm the diagnosis of CP. Children with unusual features in the history or abnormalities on physical or neurologic examination should be thoroughly evaluated for other conditions. Laboratory studies, including serum concentrations of glucose, ammonia, lactate and pyruvate, plasma amino acid analysis, urine organic acid analysis, and arterial acid-base status, should be obtained to exclude a metabolic disorder (",
"    <a class=\"graphic graphic_algorithm graphicRef51656 \" href=\"UTD.htm?23/54/24417\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with hemiplegic CP or MRI evidence of cerebral infarction, we suggest screening for coagulation abnormalities. This is because up to 40 percent of children with hemiplegic CP have MRI findings of cerebral infarction, suggesting the possibility of an underlying coagulation disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ]. About 50 to 60 percent of patients with hemiplegic CP have at least one prothrombotic coagulation abnormality including factor V Leiden deficiency, protein C deficiency, and elevated lipoprotein-a [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link&amp;anchor=H3#H3\">",
"     \"Stroke in the newborn\", section on 'Arterial ischemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link&amp;anchor=H12#H12\">",
"     \"Stroke in the newborn\", section on 'Coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of the brain can identify a lesion in the majority of cases of CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] and may provide information regarding the timing of the insult (",
"    <a class=\"graphic graphic_algorithm graphicRef51656 \" href=\"UTD.htm?23/54/24417\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    MRI abnormalities in patients with CP include hypoxic-ischemic lesions, such as periventricular leukomalacia, cortical malformations, and lesions of the basal ganglia. The range of abnormalities is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review and practice parameter from the American Academy of Neurology and the Child Neurology Society, abnormalities on MRI were noted in 89 percent of children with CP (range 68 to 100 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"       8",
"      </a>",
"      ]. The yield of MRI depended upon the type of CP (mixed &gt; quadriplegic &gt; hemiplegic &gt; diplegic &gt; ataxic &gt; dyskinetic &gt; hypotonic) and the timing of birth. Scans were abnormal in 99 percent of preterm infants with CP, as compared with 92 percent of term infants in whom the insult occurred up to one month after birth. MRI, in combination with the clinical history, also helped determine whether the injury was prenatal, perinatal, or postnatal in onset.",
"     </li>",
"     <li>",
"      In one report, periventricular white matter injury was detected in 82 percent of 11 children with CP who were born preterm [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/11\">",
"       11",
"      </a>",
"      ]. Three patterns of lesions were identified among 29 children who were born at term: gyral anomalies, isolated periventricular leukomalacia (PVL), and watershed cortical or deep gray nuclear damage. These lesions are consistent with injury in the mid-second trimester; late second or early third trimester; or late third trimester, or perinatal or postnatal period, respectively.",
"     </li>",
"     <li>",
"      In a study of 56 children with bilateral spastic CP, 91 percent had specific pathology on an MRI performed at a mean age of 10.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/13\">",
"       13",
"      </a>",
"      ]. PVL was seen in 42 and 87 percent of term and preterm children, respectively. Other lesions that occurred almost exclusively in the term or late preterm infants were maldevelopment (9 percent) and parasagittal subcorticocortical injury, multicystic encephalomalacia, and basal ganglia lesions (16 percent).",
"     </li>",
"     <li>",
"      Neuroimaging in ataxic CP may be normal or show biparietal or infratentorial lesions. In a series of 29 affected patients studied with computed tomography, abnormalities were identified in the parietal lobes or posterior fossa in 55 and 28 percent, respectively; scans were normal or only slightly abnormal in 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the practice parameter cited above also found that CT scans can identify abnormalities in a large number of children with CP, MRI is preferred because it generally has a higher yield of suggesting both an etiology and the timing of insult leading to CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur in approximately 45 percent of children with CP. Children with CP and suspected seizure activity should undergo electroencephalography (EEG) to diagnose and manage the epilepsy. However, there is no clinical value of performing EEG testing in children with no evidence of seizure activity, and EEG testing is not useful in establishing the cause of CP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features of cerebral palsy\", section on 'Epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9229279\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with unexplained and refractory seizures or movement disorders such as ataxic-spastic gait or dyskinesias, lumbar puncture should be considered to screen for pediatric neurotransmitter disorders (eg, dopa responsive dystonia), and to rule out the low glucose concentrations in the cerebrospinal fluid (hypoglycorrhachia) caused by glucose transporter deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H19#H19\">",
"     \"Classification and evaluation of dystonia\", section on 'Dopa-responsive dystonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Laboratory screening in undiagnosed epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the placenta may indicate infection or chronic pathologic changes due to ischemia. Lesions associated with asphyxia include chronic ischemic change, meconium staining, nucleated red blood cells, intravillous hemorrhages, and chronic ischemic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Metabolic and genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic or genetic disorders are uncommon causes of CP. They have been noted in 0 to 4 percent of patients, but the true incidence is unknown because there have been no prospective studies on this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of CP associated with a metabolic or genetic disorder are associated with atypical complaints, a history of progressive rather than static encephalopathy, findings on neuroimaging that suggest a specific disorder, or a family history of childhood neurologic disorder associated with CP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital brain malformations (eg, lissencephaly, schizencephaly, or pachygyria) in children with CP are increasingly associated with specific genetic disorders. A systematic review of 1426 children with CP found such malformations in 7 percent who had a CT scan, and 12 percent who had MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practice parameter from the American Academy of Neurology and the Child Neurology Society recommends that metabolic and genetic testing be considered if any of the following conditions are present (",
"    <a class=\"graphic graphic_algorithm graphicRef51656 \" href=\"UTD.htm?23/54/24417\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there are features in the history or clinical examination that are atypical for CP, or otherwise suggestive of a genetic or metabolic abnormality",
"     </li>",
"     <li>",
"      If brain imaging reveals a developmental brain malformation (such as lissencephaly, schizencephaly, or pachygyria), or",
"      <span class=\"nowrap\">",
"       frontal/temporal",
"      </span>",
"      atrophy",
"     </li>",
"     <li>",
"      If the clinical history or findings on neuroimaging do not determine a specific structural abnormality (eg, a focal brain lesions or other acquired abnormality)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific genetic and metabolic disorders that may present with symptoms resembling CP include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glutaric aciduria type 1, in which MRI findings include frontal and temporal atrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H33#H33\">",
"       \"Organic acidemias\", section on 'Glutaric aciduria type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Zellweger syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H17#H17\">",
"       \"Peroxisomal disorders\", section on 'Zellweger syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dopa-responsive dystonia, caused by GTP cyclohydrolase deficiency, and is characterized by focal dystonia with onset in early childhood, but may occasionally present as spastic diplegia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H19#H19\">",
"       \"Classification and evaluation of dystonia\", section on 'Dopa-responsive dystonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Miller Dieker lissencephaly, characterized by lissencephaly, microcephaly, seizures, and hypotonia or spasticity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=see_link&amp;anchor=H2157776#H2157776\">",
"       \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17p13.3 deletion including PAFAH1B1 (Miller-Dieker syndrome)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyruvate decarboxylase (dehydrogenase) deficiency, characterized by lactic acidosis, hypotonia, seizures, and spasticity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lesch-Nyhan syndrome, caused by deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT), is usually characterized by hypotonia and dystonia developing during infancy, but may occasionally present as spastic diplegia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H25#H25\">",
"       \"Hyperkinetic movement disorders in children\", section on 'Lesch-Nyhan syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arginase deficiency and other urea cycle disorders, which are characterized by hyperammonemia, encephalopathy, and respiratory alkalosis, and may include spasticity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Holocarboxylase synthetase deficiency, which is a rare and treatable disorder of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      metabolism and presents with generalized hypertonia and developmental delay. Patients also have scaly skin eruptions and episodes of metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) is a diagnosis of exclusion. Typical symptoms and signs of CP (eg, early hypotonia, spasticity, and dystonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    choreoathetosis) may be present in other conditions. These include neurodegenerative diseases, inborn errors of metabolism, developmental or traumatic lesions of the brain or spinal cord, neuromuscular or movement disorders, and neoplasm.",
"   </p>",
"   <p>",
"    Some conditions, especially those that are slowly progressive, may be misdiagnosed as CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, all children with manifestations of CP should be evaluated for a possible underlying cause. The following features raise the possibility of a diagnosis other than CP, such as a neurodegenerative disease or metabolic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history of the neurologic condition",
"     </li>",
"     <li>",
"      Loss of developmental milestones",
"     </li>",
"     <li>",
"      Ataxia, involuntary movements, oculomotor abnormalities, muscle atrophy, or sensory loss",
"     </li>",
"     <li>",
"      Hypotonia associated with weakness",
"     </li>",
"     <li>",
"      Rapid deterioration of neurologic signs",
"     </li>",
"     <li>",
"      Marked worsening during periods of catabolism (fasting or illness)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific signs and symptoms associated with other conditions that may be initially diagnosed as CP are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions with muscle weakness as well as central nervous system involvement include degenerative disorders, such as metachromatic leukodystrophy and pontocerebellar atrophies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .) These infants may be misdiagnosed because CP in early infancy often results in profound hypotonia, which may be mistaken for muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diplegia or quadriplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that may present with diplegia or quadriplegia include urea cycle disorders, dopa-responsive dystonia, and holocarboxylase synthetase deficiency. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Metabolic and genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Degenerative diseases with diplegia or quadriplegia include adrenoleukodystrophy and hereditary progressive spastic paraplegia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13465?source=see_link&amp;anchor=H24#H24\">",
"     \"Pelizaeus-Merzbacher disease\", section on 'Hereditary spastic paraplegia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dystonia and choreoathetosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutaric aciduria type 1, caused by deficiency of riboflavin dependent glutaryl-CoA dehydrogenase, often presents with an episode of metabolic decompensation with ketoacidosis, hyperammonemia, hypoglycemia, and encephalopathy during the first year or later, often accompanied by infection and fever. Affected patients also develop a dystonic movement disorder with preserved cognitive function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H33#H33\">",
"     \"Organic acidemias\", section on 'Glutaric aciduria type 1'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Metabolic and genetic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dopa-responsive dystonia, an unusual form of hereditary progressive dystonia that presents in childhood, may mimic dyskinetic CP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/20\">",
"     20",
"    </a>",
"    ]. The dystonia usually starts in the legs and becomes generalized. Some patients also have hyperreflexia, rigidity, tremor, and other parkinsonian features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dystonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    choreoathetosis also occur in other disorders, including Lesch-Nyhan disease, pyruvate dehydrogenase complex deficiency, and Rett syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link\">",
"     \"Overview of the hereditary ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ataxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia may occur in a number of disorders that could be mistaken for CP. These include ataxia telangiectasia, X-linked spinocerebellar ataxia, and Niemann-Pick disease type C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .) The initial manifestation of ataxia in these conditions may be severe truncal hypotonia and delayed motor milestones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/19\">",
"     19",
"    </a>",
"    ]. Involuntary movements may be associated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bulbar and oromotor dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bulbar and oromotor dysfunction occur in children with CP, and result in difficulty with feeding and speech. However, these conditions usually are less prominent than are other motor findings. Thus, other diagnoses should be considered in patients with profound bulbar and oromotor abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/19\">",
"     19",
"    </a>",
"    ]. One example is bilateral perisylvian syndrome (also known as opercular syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=see_link\">",
"       \"Patient information: Cerebral palsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the practice parameter from the American Academy of Neurology and the Child Neurology Society, which recommends the following approach to the evaluation of the child with cerebral palsy (CP) (",
"    <a class=\"graphic graphic_algorithm graphicRef51656 \" href=\"UTD.htm?23/54/24417\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children should undergo a detailed history and physical examination. It is particularly important to determine that the condition is static rather than progressive or degenerative. This may require repeated examinations over time. It is also important to classify the type of CP (",
"      <a class=\"graphic graphic_table graphicRef74533 \" href=\"UTD.htm?29/5/29787\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Specific syndromes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening for intellectual disability, ophthalmologic abnormalities, hearing impairment, speech and language disorders, and disorders of oral-motor function are warranted as part of the initial assessment, because these problems are commonly associated with CP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical features of cerebral palsy\", section on 'Associated disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An electroencephalogram (EEG) should be performed when there are features suggestive of epilepsy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Electroencephalography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging should be performed to establish an etiology and for prognostic purposes. MRI is preferred to CT scan. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic and genetic testing should be performed if the clinical history or findings on neuroimaging do not determine a specific structural abnormality, or if there are additional and atypical features in the history or clinical examination. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Metabolic and genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with hemiplegic CP or MRI findings of cerebral infarction may have a prothrombotic coagulation disorder. In our practice, we perform a screen for coagulation abnormalities in such patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CP is a diagnosis of exclusion. Typical symptoms and signs of CP may be present in other conditions, including neurodegenerative diseases, inborn errors of metabolism, developmental or traumatic lesions of the brain or spinal cord, neuromuscular or movement disorders, and neoplasm. Features that raise the possibility of a diagnosis other than CP include the following: (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Family history of the neurologic condition",
"     </li>",
"     <li>",
"      Loss of developmental milestones",
"     </li>",
"     <li>",
"      Ataxia, involuntary movements, oculomotor abnormalities, muscle atrophy, or sensory loss",
"     </li>",
"     <li>",
"      Hypotonia associated with weakness",
"     </li>",
"     <li>",
"      Rapid deterioration of neurologic signs",
"     </li>",
"     <li>",
"      Marked worsening of symptoms during periods of catabolism",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/1\">",
"      Burns YR, O'Callaghan M, Tudehope DI. Early identification of cerebral palsy in high risk infants. Aust Paediatr J 1989; 25:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/2\">",
"      Allen MC, Alexander GR. Using motor milestones as a multistep process to screen preterm infants for cerebral palsy. Dev Med Child Neurol 1997; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/3\">",
"      Capute AJ. Identifying cerebral palsy in infancy through study of primitive-reflex profiles. Pediatr Ann 1979; 8:589.",
"     </a>",
"    </li>",
"    <li>",
"     Foley J. Physical aspects. In: Cerebral Palsy and the Young Child, Blencowe SM (Ed), E&amp;S Livingstone, London 1969. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/5\">",
"      Zafeiriou DI, Tsikoulas IG, Kremenopoulos GM. Prospective follow-up of primitive reflex profiles in high-risk infants: clues to an early diagnosis of cerebral palsy. Pediatr Neurol 1995; 13:148.",
"     </a>",
"    </li>",
"    <li>",
"     Scherzer AL, Tsharnuter I. Early Diagnosis and Therapy in Cerebral Palsy, Marcel Dekker, New York 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/7\">",
"      Yokochi K, Shimabukuro S, Kodama M, et al. Motor function of infants with athetoid cerebral palsy. Dev Med Child Neurol 1993; 35:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/8\">",
"      Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/9\">",
"      Senbil N, Y&uuml;ksel D, Yilmaz D, G&uuml;rer YK. Prothrombotic risk factors in children with hemiplegic cerebral palsy. Pediatr Int 2007; 49:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/10\">",
"      Simchen MJ, Goldstein G, Lubetsky A, et al. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 2009; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/11\">",
"      Truwit CL, Barkovich AJ, Koch TK, Ferriero DM. Cerebral palsy: MR findings in 40 patients. AJNR Am J Neuroradiol 1992; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/12\">",
"      Yin R, Reddihough D, Ditchfield M, Collins K. Magnetic resonance imaging findings in cerebral palsy. J Paediatr Child Health 2000; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/13\">",
"      Kr&auml;geloh-Mann I, Petersen D, Hagberg G, et al. Bilateral spastic cerebral palsy--MRI pathology and origin. Analysis from a representative series of 56 cases. Dev Med Child Neurol 1995; 37:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/14\">",
"      Miller G, Cala LA. Ataxic cerebral palsy--clinico-radiologic correlations. Neuropediatrics 1989; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/15\">",
"      Pons R, Collins A, Rotstein M, et al. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord 2010; 25:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/16\">",
"      Altshuler G. Some placental considerations related to neurodevelopmental and other disorders. J Child Neurol 1993; 8:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/17\">",
"      Scheuerle AE, McVie R, Beaudet AL, Shapira SK. Arginase deficiency presenting as cerebral palsy. Pediatrics 1993; 91:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/18\">",
"      Livne M, Gibson KM, Amir N, et al. Holocarboxylase synthetase deficiency: a treatable metabolic disorder masquerading as cerebral palsy. J Child Neurol 1994; 9:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/19\">",
"      Gupta R, Appleton RE. Cerebral palsy: not always what it seems. Arch Dis Child 2001; 85:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/20\">",
"      Nygaard TG, Waran SP, Levine RA, et al. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994; 11:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4104/abstract/21\">",
"      Gropman AL, Barkovich AJ, Vezina LG, et al. Pediatric congenital bilateral perisylvian syndrome: clinical and MRI features in 12 patients. Neuropediatrics 1997; 28:198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6169 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4104=[""].join("\n");
var outline_f4_0_4104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neurobehavioral signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Motor abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Developmental reflexes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spastic diplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spastic hemiplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Spastic quadriplegia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dyskinetic CP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9229279\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Metabolic and genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diplegia or quadriplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dystonia and choreoathetosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ataxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bulbar and oromotor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6169\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6169|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/54/24417\" title=\"algorithm 1\">",
"      Evaluation of a child with CP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6169|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/5/29787\" title=\"table 1\">",
"      Cerebral palsy syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15962?source=related_link\">",
"      Management and prognosis of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=related_link\">",
"      Patient information: Cerebral palsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13465?source=related_link\">",
"      Pelizaeus-Merzbacher disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4105="Unipolar major depression with psychotic features: Acute treatment";
var content_f4_0_4105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar major depression with psychotic features: Acute treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4105/contributors\">",
"     Anthony J Rothschild, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4105/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4105/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/0/4105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14443905\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression with psychotic features is a severe subtype of unipolar major depression (major depressive disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/1\">",
"     1",
"    </a>",
"    ]. The psychotic symptoms are delusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hallucinations that are frequently consistent with depressive themes of guilt and worthlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/2\">",
"     2",
"    </a>",
"    ]. Psychotic depression and nonpsychotic depression differ in their diagnosis, treatment, and prognosis.",
"   </p>",
"   <p>",
"    This topic reviews the acute treatment of unipolar major depression with psychotic features. Maintenance treatment and prognosis are discussed elsewhere. Also discussed separately are the epidemiology, pathogenesis, clinical features, assessment, and diagnosis of psychotic depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8055?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060271\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression with psychotic features is characterized by an episode of unipolar major depression that includes delusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania, mixed mania, or hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/2\">",
"     2",
"    </a>",
"    ]. A major depressive episode is a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide. The clinical presentation and diagnosis of unipolar major depression are discussed further elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary distinction between unipolar major depression with psychotic features and unipolar major depression without psychotic features is that psychotic depression includes [",
"    <a 1ff8 c href=\"UTD.htm?4/0/4105/abstract/2\" lass=\"abstract\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delusions &ndash; False, fixed beliefs",
"     </li>",
"     <li>",
"      Hallucinations &ndash; False sensory perceptions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the symptoms of major depression in unipolar psychotic depression are significantly more numerous and severe than they are in unipolar nonpsychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Further, suicidal ideation, suicide attempts, and comorbid anxiety disorders are more common in psychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and differential diagnosis of unipolar major depression with psychotic features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link&amp;anchor=H175106406#H175106406\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link&amp;anchor=H175106414#H175106414\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link&amp;anchor=H10190933#H10190933\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14442291\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4939142\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of unipolar major depression are treated by internists [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/7\">",
"     7",
"    </a>",
"    ]. However, unipolar psychotic depression is more difficult to treat and most patients are referred to a psychiatrist [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of treating unipolar psychotic depression is remission, which is defined as resolution of both the psychotic symptoms (delusions or hallucinations) and depressive symptoms. Patients whose psychosis resolves and whose depression improves to the point that only one or two symptoms of mild intensity persist are also regarded as remitted. For patients who do not achieve remission, a reasonable goal is response, which is defined as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms. Standardized rating scales such as the clinician-administered Brief Psychiatric Rating Scale (assesses psychosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/9\">",
"     9",
"    </a>",
"    ] and the self-report Patient Health Questionnaire &ndash; Nine Item (assesses depression) (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/10\">",
"     10",
"    </a>",
"    ] can be used to quantify response, but this is not standard clinical practice.",
"   </p>",
"   <p>",
"    Depressive and psychotic symptoms should be monitored regularly with clinical interviews that pay particular attention to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation",
"     </li>",
"     <li>",
"      Suicide plans",
"     </li>",
"     <li>",
"      Psychotic symptoms that place the patient at imminent risk of coming to harm (eg, auditory hallucinations commanding the patient to kill herself)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of assessment generally ranges from daily to monthly, depending upon the severity of persistent symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves may require constant observation. Outpatients who have not achieved substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms are generally seen weekly; those who have improved substantially may be seen every two to four weeks until they remit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13923869\">",
"    <span class=\"h2\">",
"     First line",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating unipolar major depression with psychotic features with either of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antidepressant plus an antipsychotic, or",
"     </li>",
"     <li>",
"      ECT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with treatment guidelines from the American Psychiatric Association [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57129843\">",
"    <span class=\"h3\">",
"     Choosing a treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of low quality studies found that ECT and the combination of an antidepressant plus an antipsychotic each improved symptoms of unipolar psychotic depression to a similar degree [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/13\">",
"     13",
"    </a>",
"    ]; thus, the initial choice for treating unipolar psychotic depression is based upon other factors. Combination pharmacotherapy is generally selected as initial treatment because it is easier to administer, more widely available, and more acceptable to patients compared with ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, because ECT is generally faster than pharmacotherapy, ECT should be used initially for patients with severe psychosis that places the patient at imminent risk of coming to harm (eg, the patient is distracted by hallucinations to the point of unwittingly walking into moving traffic), severe suicidality (eg, active suicidal ideation with a plan and intent), or malnutrition secondary to food refusal. Initial treatment with ECT is also reasonable for patients who prefer it or responded well to it during prior episodes of unipolar psychotic depression. Another factor to consider is cost [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Studies showing that the combination of an antidepressant and an antipsychotic is comparable with ECT for unipolar psychotic depression were generally open-label, and often included nonrandom assignment or consisted of retrospective chart reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with heterogeneous diagnoses were included, and different types of ECT (bilateral and unilateral) were compared with different combinations of tricyclic antidepressants and first-generation antipsychotics prescribed at varying doses for different lengths of time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13924267\">",
"    <span class=\"h3\">",
"     Antidepressant plus antipsychotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/19-23\">",
"     19-23",
"    </a>",
"    ], we prefer the combination of an antidepressant and an antipsychotic rather than antidepressant monotherapy or antipsychot",
"1ff8",
"ic monotherapy for unipolar psychotic depression. This is consistent with multiple practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/11,12,24,25\">",
"     11,12,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85451847\">",
"    <span class=\"h4\">",
"     Choosing a combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor treating unipolar psychotic depression with",
"    <span class=\"nowrap\">",
"     antidepressant/antipsychotic",
"    </span>",
"    combinations that have demonstrated efficacy in randomized trials. The following combinations have shown beneficial effects compared with antidepressant monotherapy, antipsychotic monotherapy, or placebo in well-designed, sufficiently large trials:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"       perphenazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of the combinations have been compared in head-to-head trials.",
"   </p>",
"   <p>",
"    However, it is reasonable to initially treat psychotic depression with a combination that has not been studied in randomized trials. Many alternative combinations are available from existing antidepressants (selective serotonin reuptake inhibitors, tricyclics, serotonin-norepinephrine reuptake inhibitors, and antidepressants with a unique mechanism of action) and antipsychotics (first- and second-generation).",
"   </p>",
"   <p>",
"    We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    as initial pharmacotherapy for unipolar psychotic depression because this combination has been studied in the most patients. Based upon the randomized trial that established the efficacy of this combination, we typically use the following dose schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Increase",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      by 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      by 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every three days as tolerated &nbsp;",
"     </li>",
"     <li>",
"      Attempt to reach",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      dose of at least 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      within seven days of starting treatment",
"     </li>",
"     <li>",
"      Minimum target doses are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      15",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      usually beginning no later than week two",
"     </li>",
"     <li>",
"      Maximum target doses are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      usually beginning no later than week three",
"     </li>",
"     <li>",
"      Allow slower titration or temporary dose reductions of one or both medications if side effects occur; however, subsequent dose increases should be attempted &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elderly patients can initially receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    2.5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The dose is then increased by the same amount every three to five days to a minimum target dose of sertraline 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and olanzapine 15",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and a maximum target dose of sertraline 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and olanzapine 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Three percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    withdrew from the trial because of intolerable side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/19\">",
"     19",
"    </a>",
"    ]. Adverse effects of the combination included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight gain of at least 2.7 kg (54 percent of patients)",
"     </li>",
"     <li>",
"      Sedation (29 percent)",
"     </li>",
"     <li>",
"      Orthostasis (16 percent)",
"     </li>",
"     <li>",
"      One or more falls (16 percent)",
"     </li>",
"     <li>",
"      Significant increases in serum cholesterol, triglyceride, and glucose concentrations from baseline to study termination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H399779851#H399779851\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524651#H76524651\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of an a",
"1ff8",
"ntidepressant plus a phenothiazine antipsychotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    , mesoridazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    ) may cause adverse drug interactions. In a case control study, the medication history was examined in 1814 cases of sudden cardiac death and 1171 controls who survived an acute myocardial infarction; the analyses controlled for risk factors such as hypertension, diabetes, and hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/26\">",
"     26",
"    </a>",
"    ]. Compared with controls, cases were significantly more likely to have been treated with phenothiazines plus any antidepressant (odds ratio 9.6, 95% CI 1.2-80.8).",
"   </p>",
"   <p>",
"    Specific interactions between antidepressants and antipsychotics may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230508\">",
"    <span class=\"h4\">",
"     Duration of therapy and switching drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following protocols used in randomized trials, unipolar psychotic depression is treated with an antidepressant plus an antipsychotic at minimum target doses or higher for four to eight weeks before determining whether the combination is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Intervening adverse effects may necessitate discontinuing one or both drugs sooner than four weeks.",
"   </p>",
"   <p>",
"    If patients do not respond to or tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , we suggest using another combination with demonstrated efficacy in a randomized trial, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus olanzapine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , or amitriptyline plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    . The new combination is started and titrated up with the goal of reaching minimum target doses within two weeks, while the failed combination is concurrently tapered and discontinued over one to two weeks.",
"   </p>",
"   <p>",
"    For patients who do not respond to or tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , it is reasonable to use another selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic, or an antidepressant with a unique mechanism of action. Similarly, if patients do not respond to or tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    , it is reasonable to use another second- or first-generation antipsychotic, except for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , which can cause agranulocytosis. Most authorities and clinicians switch antidepressant classes when starting a new course of combination pharmacotherapy. Antidepressants and antipsychotics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4459881\">",
"    <span class=\"h4\">",
"     Evidence of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized trials show that for patients with unipolar psychotic depression, the combination of an antidepressant and an antipsychotic is more effective than antipsychotic monotherapy or antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of five randomized trials (337 patients with psychotic depression) found that patients were less likely to fail treatment with combination therapy than antidepressant monotherapy (RR 0.76, 95% CI 0.59-0.98); there was mild to moderate heterogeneity across studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/28\">",
"     28",
"    </a>",
"    ]. Discontinuation for any reason was comparable for combination treatment and antidepressant monotherapy, as was the incidence of blurred vision, dry mouth, dizziness, tremor, and constipation. However, combination pharmacotherapy led to higher rates of sedation (RR 2.79, 95% CI 1.14-6.79).",
"   </p>",
"   <p>",
"    In addition, a meta-analysis of four randomized trials (447 patients with psychotic depression) found that patients were less likely to fail treatment with combination therapy than antipsychotic monotherapy (RR 0.73, 95% CI 0.63-0.84); there was little to no heterogeneity across studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/28\">",
"     28",
"    </a>",
"    ]. Discontinuation for any reason was comparable for combination treatment and antipsychotic monothera",
"1ff8",
"py, as was the incidence of somnolence and weight gain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13924275\">",
"    <span class=\"h3\">",
"     Electroconvulsive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT uses two scalp electrodes to administer an electric current to anesthetized patients and induce a tonic-clonic seizure. Initial treatment for most patients with unipolar psychotic depression consists of an antidepressant plus an antipsychotic. However, because ECT is generally faster than pharmacotherapy, clinicians should use ECT initially for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychosis that places the patient at imminent risk of coming to harm (eg, psychotic symptoms prevent the patient from attending to basic needs)",
"     </li>",
"     <li>",
"      Severe suicidality (eg, active suicidal ideation with a plan and intent)",
"     </li>",
"     <li>",
"      Malnutrition secondary to food refusal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who responded well to ECT during prior episodes of unipolar psychotic depression are also good candidates for initial treatment with ECT.",
"   </p>",
"   <p>",
"    Based upon meta-analyses, the efficacy of ECT for treating unipolar major depression with or without psychotic features is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/11,12,29-32\">",
"     11,12,29-32",
"    </a>",
"    ], and a review of meta-analyses and practice guidelines found that psychotic depression may respond better than nonpsychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/29\">",
"     29",
"    </a>",
"    ]. Another review, based upon studies that were generally open-label and often included nonrandom assignment or consisted of retrospective chart reviews, found that approximately 80 percent of patients with psychotic depression responded to ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/32\">",
"     32",
"    </a>",
"    ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrode placement and other aspects of ECT technique for treating unipolar psychotic depression have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients, regardless of indication, remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=see_link\">",
"     \"Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13925748\">",
"    <span class=\"h2\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of unipolar psychotic depression may fail to stabilize the patient&rsquo;s safety and substantially improve the number, intensity, and frequency of psychotic and mood symptoms. Patients resistant to one or two courses of an",
"    <span class=\"nowrap\">",
"     antidepressant/antipsychotic",
"    </span>",
"    combination as initial treatment should receive ECT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/33\">",
"     33",
"    </a>",
"    ]. Conversely, patients who initially receive an unsuccessful course of ECT should receive combination pharmacotherapy. ECT and choosing a pharmacotherapy combination are discussed separately. (See",
"    <a class=\"local\" href=\"#H13924275\">",
"     'Electroconvulsive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H85451847\">",
"     'Choosing a combination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who do not respond to combination pharmacotherapy and who decline or do not have access to ECT, adding both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    plus a specific type of psychotherapy may possibly improve outcomes; however, there is little evidence to support these adjunctive treatments. Other augmentation strategies have not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13926644\">",
"    <span class=\"h3\">",
"     Lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports describe patients with unipolar psychotic depression who initially did not respond to an antidepressant plus an antipsychotic, but subsequently improved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Lithium is added after four to eight weeks of unsuccessful treatment with an antidepressant plus an antipsychotic, at a dose sufficient to achieve a 12-hour serum trough level of 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    At least two to four weeks at therapeutic levels is necessary to determine whether lithium augmentation is beneficial.",
"   </p>",
"   <p>",
"    Adjunctive treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    for unipolar major depression without psychotic features is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14442383\">",
"    <span class=\"h3\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One short-term psychotherapy studied for unipolar major depression with psychotic features is acceptance and commitment therapy, which teaches patients to increase their acceptance of unavoidable distress, to simply notice their psychotic symptoms without considering them as either true or false, and to identify and work toward personally valued goals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A post-hoc analysis of an open-label randomized trial found that in 18 patients with unipolar psychotic depression, symptomatic improvement occurred in significantly more patients who received acceptance and commitment therapy (average three sessions) plus treatment as usual, compared with patients who received treatment as usual alone. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4939053\">",
"    <span class=\"h2\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar psychotic depression that does not respond to one or two courses of an antidepressant plus an antipsychotic, a course of ECT, and adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    and acceptance and commitment therapy should be treated with additional trials of an antidepressant plus an antipsychotic. Most authorities and clinicians switch antidepressant classes when starting a new course of combination pharmacotherapy (eg, switch from a selective serotonin reuptake inhibitor (SSRI) to either a serotonin-norepinephrine reuptake inhibitor or a tricyclic). Patients with chronic, unremitting moderate to severe symptom",
"1ff8",
"s may require close monitoring and supervision within a structured setting (eg, group home or hospital), depending upon the risk of imminent harm to self or others. Choosing a pharmacotherapy combination and switching drugs are discussed separately. (See",
"    <a class=\"local\" href=\"#H85451847\">",
"     'Choosing a combination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H230508\">",
"     'Duration of therapy and switching drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14442390\">",
"    <span class=\"h2\">",
"     Family support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family members should be involved in the care of patients with unipolar psychotic depression, and be educated about the signs and symptoms, treatment, and prognosis of the illness. The family can provide information about symptoms that the patient may not reveal and can encourage adherence to treatment. Family meetings for assessment and treatment of patients with major depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18025?source=see_link\">",
"     \"Family and couples therapy for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129863201\">",
"    <span class=\"h1\">",
"     TIME TO RECOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies show that about 50 percent of patients with unipolar psychotic depression recover within 2 to 3 months, and the large majority of patients recover within 6 to 12 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A five-year observational study of 61 in- or outpatients with unipolar psychotic depression estimated that the median time to recovery from prospectively observed episodes was 10 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A two-year, prospective observational study of 53 patients hospitalized for unipolar psychotic depression estimated that 50 percent recovered within 9 weeks of admission, 75 percent within six months, and 94 percent within 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A one-year, community survey of 92 patients with unipolar psychotic depression found that during prospective follow-up, recovery occurred in 81 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a few patients may remain ill for approximately 10 years or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of recovery may be less in unipolar psychotic depression than nonpsychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In a community survey of 92 patients with unipolar psychotic depression and 532 patients with unipolar nonpsychotic depression, recovery during one year of prospective follow-up occurred in significantly fewer psychotic patients than nonpsychotic patients (81 versus 89 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129863208\">",
"    <span class=\"h2\">",
"     Functional recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social and occupational impairment usually occurs in unipolar psychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. We suggest that patients gradually resume their normal activities following remission of the mood episode. As an example, patients can return to work on a part-time schedule and incrementally increase the hours to full-time.",
"   </p>",
"   <p>",
"    Functional recovery often lags recovery from psychotic and depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. A prospective, two-year observational study of 53 patients with unipolar psychotic depression found that functional recovery (occupational and residential status) occurred in 29 percent, whereas recovery from the mood episode occurred in 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4105/abstract/41\">",
"     41",
"    </a>",
"    ]. Based upon clinical experience, a quick and full recovery of psychosocial functioning is more probable in patients aged 30 to 65 years with good pre-morbid functioning, a first lifetime episode of unipolar psychotic depression, and a good response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14442474\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unipolar major depression with psychotic features is characterized by delusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hallucinations that accompany a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide. (See",
"      <a class=\"local\" href=\"#H1060271\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link&amp;anchor=H175106414#H175106414\">",
"       \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      First-line acute treatment for unipolar major depression with psychotic features is either electroconvulsive therapy (ECT) or combination pharmacotherapy with an antidepressant and an antipsychotic. For patients with mild to moderate disease, we suggest initial treatment with combination pharmacotherapy rather than ECT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination pharmacotherapy is generally easier to administer, more widely available, and more acceptable to patients compared with ECT. (See",
"      <a class=\"local\" href=\"#H13923869\">",
"       'First line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      as initial pharmacotherapy for unipolar psychotic depression because this combination has been studied with the most patients in randomized trials. Reasonable alternatives include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      plus olanzapine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      , or amitriptyline plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"       perphenazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H85451847\">",
"       'Choosing a combination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar psychotic depression that includes severe psychosis or suicidality, or malnutrition secondary to food refusal, we suggest initial treatment with ECT rather than combination pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition, initial treatment with ECT is reasonable for patients who prefer it or responded well to it during prior episodes of unipolar psychotic depression. (See",
"      <a class=\"local\" href=\"#H13923869\">",
"       'First line'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13924275\">",
"       'Electroconvulsive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unipolar psychotic depression wh",
"1ff8",
"o do not respond adequately to one or two courses of combination pharmacotherapy should receive ECT. Conversely, patients initially treated with an unsuccessful course of ECT should receive combination pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H13925748\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients with unipolar psychotic depression recover within 2 to 3 months and the large majority of patients recover within 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H129863201\">",
"       'Time to recovery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Social and occupational impairment usually occurs in unipolar psychotic depression, and functional recovery often lags recovery from psychotic and depressive symptoms. Patients may find it helpful to gradually resume their normal activities following remission of the mood episode. (See",
"      <a class=\"local\" href=\"#H129863208\">",
"       'Functional recovery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/1\">",
"      Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48:1075.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Rothschild AJ. Clinical Manual for Diagnosis and Treatment of Psychotic Depression, American Psychiatric Publishing, Inc., Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/4\">",
"      Gaudiano BA, Young D, Chelminski I, Zimmerman M. Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression. Compr Psychiatry 2008; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/5\">",
"      Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/6\">",
"      Zimmerman M, Mattia JI. Psychotic subtyping of major depressive disorder and posttraumatic stress disorder. J Clin Psychiatry 1999; 60:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/7\">",
"      Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010; 67:1265.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: TheTreatment and Management of Depression in Adults (Updated Edition). National Clinical Practice Guideline 90. National Institute for Health &amp; Clinical Excellence. file://guidance.nice.org.uk/CG90 (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/9\">",
"      Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/10\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Practice guideline for the treatment of major depressive disorder, third edition. Am J Psychiatry 2010; 167:10 (supplement).",
"    </li>",
"    <li>",
"     American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/13\">",
"      Kroessler D. Relative Efficacy Rates for Therapies of Delusional Depression. Convuls Ther 1985; 1:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/14\">",
"      Olfson M, Marcus S, Sackeim HA, et al. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998; 155:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/15\">",
"      Stoskopf C, Horn SD. Predicting length of stay for patients with psychoses. Health Serv Res 1992; 26:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/16\">",
"      Wilson KG, Kraitberg NJ, Brown JH, Bergman JN. Electroconvulsive therapy in the treatment of depression: the impact on length of stay. Compr Psychiatry 1991; 32:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/17\">",
"      Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/18\">",
"      Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996; 19:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/19\">",
"      Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/20\">",
"      Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/21\">",
"      Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010; 121:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/22\">",
"      M&uuml;ller-Siecheneder F, M&uuml;ller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/23\">",
"      Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/24\">",
"      Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/25\">",
"      Leadholm AK, Rothschild AJ, Nolen WA, et al. The treatment of psychotic depression: is there consensus among guidelines and psychiat",
"1ff8",
"rists? J Affect Disord 2013; 145:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/26\">",
"      Honkola J, Hookana E, Malinen S, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 2012; 33:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/27\">",
"      Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry 2006; 188:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/28\">",
"      Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 2012; 73:486.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf (Accessed on May 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/30\">",
"      UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/31\">",
"      Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003; 19:139.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/33\">",
"      Blumberger DM, Mulsant BH, Emeremni C, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res 2011; 45:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/34\">",
"      Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/35\">",
"      Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983; 140:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/36\">",
"      Birkenh&auml;ger TK, van den Broek WW, Wijkstra J, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. J Clin Psychopharmacol 2009; 29:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/37\">",
"      Gaudiano BA, Miller IW, Herbert JD. The treatment of psychotic major depression: is there a role for adjunctive psychotherapy? Psychother Psychosom 2007; 76:271.",
"     </a>",
"    </li>",
"    <li>",
"     Bach P, Guadiano BA, Pankey J et al. Acceptance, mindfulness values and psychosis: applying Acceptance and Commitment Therapy (ACT) to the chronically mentally ill, in Mindfulness-Based Treatment Approaches: Clinician&rsquo;s Guide to Evidence Base and Applications. Edited by Baer RA, New York, Academic Press 2006. p 93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/39\">",
"      Coryell W, Keller M, Lavori P, Endicott J. Affective syndromes, psychotic features, and prognosis. I. Depression. Arch Gen Psychiatry 1990; 47:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/40\">",
"      Tohen M, Strakowski SM, Zarate C Jr, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000; 48:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/41\">",
"      Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/42\">",
"      Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry 1996; 153:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/43\">",
"      Murphy E. The prognosis of depression in old age. Br J Psychiatry 1983; 142:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4105/abstract/44\">",
"      Rothschild AJ, Schatzberg AF. Psychotic Depression: A newly recognized subtype. Clin Neurosci 1993; 1:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16546 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4105=[""].join("\n");
var outline_f4_0_4105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14442474\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14443905\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060271\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14442291\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4939142\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13923869\">",
"      First line",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57129843\">",
"      - Choosing a treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13924267\">",
"      - Antidepressant plus antipsychotic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85451847\">",
"      Choosing a combination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H230508\">",
"      Duration of therapy and switching drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4459881\">",
"      Evidence of efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13924275\">",
"      - Electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13925748\">",
"      Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13926644\">",
"      - Lithium",
"     </a>",
"     &lt;",
"1b72",
"/li&gt;",
"     <li class=\"dashItem\">",
"      <a class=\"outlineLink\" href=\"#H14442383\">",
"       - Psychotherapy",
"      </a>",
"     </li>",
"     <li class=\"bulletItem\">",
"      <a class=\"outlineLink\" href=\"#H4939053\">",
"       Refractory patients",
"      </a>",
"     </li>",
"     <li class=\"bulletItem\">",
"      <a class=\"outlineLink\" href=\"#H14442390\">",
"       Family support",
"      </a>",
"     </li>",
"     <li class=\"plainItem\">",
"      <a class=\"outlineLink\" href=\"#H129863201\">",
"       TIME TO RECOVERY",
"      </a>",
"     </li>",
"     <li class=\"bulletItem\">",
"      <a class=\"outlineLink\" href=\"#H129863208\">",
"       Functional recovery",
"      </a>",
"     </li>",
"     <li class=\"plainItem\">",
"      <a class=\"outlineLink\" href=\"#H14442474\">",
"       SUMMARY AND RECOMMENDATIONS",
"      </a>",
"     </li>",
"     <li class=\"plainItem\">",
"      <a href=\"#references\">",
"       REFERENCES",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18025?source=related_link\">",
"      Family and couples therapy for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41416?source=related_link\">",
"      Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=related_link\">",
"      Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4106="Biology and clinical features of radiation injury in adults";
var content_f4_0_4106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology and clinical features of radiation injury in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Nicholas Dainiak, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/0/4106/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/0/4106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of industrial and medical radiation accidents and the threat of terrorist events involving radioactive material mandate the development and implementation of an appropriate medical response. Medical professionals who would logically be involved in such events include, among others, radiation safety officers, radiation oncologists, nuclear medicine physicians, emergency department physicians, hematologists, medical oncologists, infectious disease specialists, and gastroenterologists. All will be asked to play a significant role in evaluating and treating victims of an accidental or deliberate exposure to radiation. Due to their experience in managing patients with cytopenias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marrow aplasia, hematologists and medical oncologists will most likely be asked to take primary responsibility or a consultative role for the medical treatment of individuals exposed to a moderate or high dose of radiation.",
"   </p>",
"   <p>",
"    However, all physicians, and especially medical triage personnel, must have an understanding of how radiation alters the function of cells, tissues, and organ systems, how radiation levels are quantified, and how victims receiving a significant radiation dose can be recognized and treated. In addition, all medical facilities should have a radiation emergency contingency plan with which their employees are familiar. Emergency personnel and hospital personnel must also be aware of local, state, and national resources that may be employed in the case of a radiological event [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A basic understanding of radiation physics is requisite for understanding the principles of injury and the fundamentals of medical management of those suffering radiation-induced injury. This subject is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features of radiation exposure in children\", section on 'Radiation Physics'",
"    </a>",
"    .) Building on a rudimentary understanding of these principles, the general aspects of radiation biology and the clinical features of radiation injury in the adult will be discussed here.",
"   </p>",
"   <p>",
"    Triage and treatment of adults involved in radiation accidents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=see_link\">",
"     \"Treatment of radiation injury in the adult\"",
"    </a>",
"    .) These subjects are also covered in the Pediatrics section of UpToDate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link\">",
"     \"Clinical features of radiation exposure in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25193?source=see_link\">",
"     \"Management of radiation exposure in children following a nuclear disaster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNITS OF RADIATION DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of radiation (ie, radiation dose) absorbed by the patient's tissues is highly predictive of its biological effects. Such doses are defined as the amount of energy of",
"    <strong>",
"     ionizing",
"    </strong>",
"    radiation deposited per unit of tissue mass at a specific point [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to distinguish ionizing radiation (eg, x-rays, gamma rays, proton beams used for radiation therapy) from non-ionizing radiation (eg, microwaves, radio waves, infrared light). Nonionizing radiation generally causes damage through direct or indirect transfer of thermal (heat) energy; sunburn and microwave heating are classic examples of such exposures. On the other hand, ionizing radiation acts at the cellular level and has the potential to cause structural and chemical damage to vital targets such as nucleic acids and proteins.",
"   </p>",
"   <p>",
"    The terms most often used for quantifying radioactivity, radiation dose, and radiation injury are described in the table (",
"    <a class=\"graphic graphic_table graphicRef74125 \" href=\"UTD.htm?0/22/364\">",
"     table 1",
"    </a>",
"    ). Those that will be employed in this review are defined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Absorbed Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"     rad",
"    </strong>",
"    (radiation absorbed dose) is the traditional unit of absorbed dose, and is defined as the transfer of 100 ergs per gram of tissue. The rad has been superseded in the SI (Syst&egrave;me International) by the",
"    <strong>",
"     Gray",
"    </strong>",
"    (Gy). One Gy, the unit most commonly used to measure radiation therapy dose, is equivalent to 100 rad (1",
"    <span class=\"nowrap\">",
"     joule/kilogram),",
"    </span>",
"    while one cGy is equivalent to 1 rad or 1000 mrad.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dose Equivalent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"     rem",
"    </strong>",
"    (Roentgen equivalent in man) is a unit for the dose equivalent and represents the product of the absorbed dose (in rads) and weighting factors that take into account the differential sensitivity among tissues as well as the biological effectiveness (\"quality factor\") of various sources of ionizing radiation (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Cellular effects of radiation'",
"    </a>",
"    below). The rem has been superseded in the SI by the",
"    <strong>",
"     Sievert",
"    </strong>",
"    (Sv). One Sv is equivalent to 100 rem.",
"   </p>",
"   <p>",
"    For most therapeutic radiation exposures (eg, x-rays, gamma rays) the Sievert and Gray are approximately equal. However, when there is exposure to highly ionizing particles (eg, neutrons, alpha particles) the radiation dose equivalent reflects resulting tissue damage better than the absorbed dose. As an example, the quality factor for x-rays, gamma rays, and beta particles is 1, while that for alpha particles is 20, and can range from 4 to 22 for neutrons, depending on neutron energy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dose rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"dose rate\" refers to the amount of radiation delivered per unit of time and is most often measured in",
"    <span class=\"nowrap\">",
"     rads/hour",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     Gy/hour.",
"    </span>",
"    Geiger counters typically provide an estimate of dose rate that may, in turn, be used to estimate the degree of hazard in a particular environment (eg, accident scene, patient clothing or bodily wastes). Common, hand-held Geiger counters are suitable for monitoring radioactive sources emitting gamma rays, but more specialized equipment is required for sources emitting certain low energy beta particles, neutrons, and alpha particles.",
"   </p>",
"   <p>",
"    For cases involving exposure to x-rays, gamma rays and beta particles, a reduction in the radiation dose rate results in a decreased radiation response. For example, it is believed that the carcinogenic effect of these radiations delivered at a lower dose rate is less than that of the same total dose delivered at a higher dose rate. Similarly, a dose of 1 Gy delivered over 1 minute might cause signs and symptoms of acute radiation injury, whereas the same dose delivered over 100 days would not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Examples of possible radiation exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average annual dose to persons residing in the United States is approximately 3.6 mSv (360 mrem) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/4\">",
"     4",
"    </a>",
"    ]. This corresponds to an absorbed dose of approximately 3.6 mGy (360 mrad). With the caveat that the absorbed dose includes radiation from not only x-rays but also alpha particles, the dose estimates provided below are reported in rads and Gy rather than as dose equivalents in",
"    <span class=\"nowrap\">",
"     Sv/rems.",
"    </span>",
"   </p>",
"   <p>",
"    The majority of this dose (55 percent) is due to exposure to radon daughter products from the earth and construction materials, with iatrogenic sources of radiation (eg, medical imaging studies), cosmic radiation, and natural radiation from endogenous sources (eg, the naturally occurring radioactive isotope of potassium, potassium-40) contributing the majority of the rest.",
"   </p>",
"   <p>",
"    The following examples describe the ranges of doses that might be seen with various exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A standard chest x-ray delivers a dose of 6 to 11 mrad (0.06 to 0.11 mGy). A two-view mammogram delivers a dose of 72 mrad (0.72 mGy). A full body CT and standard chest CT deliver doses of 1000 mrad (10 mGy) and 700 mrad (7mGy), respectively. These relatively high radiation doses associated with CT have prompted concern for cancer risk, particularly in children. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link&amp;anchor=H244757#H244757\">",
"       \"Radiation-related risks of imaging studies\", section on 'Pediatrics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interventional cardiologists working in a high-volume catheterization laboratory may have collar badge exposures exceeding 600 mrad (6 mGy) per year [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema with 10 spot images delivers a dose of approximately 0.7 rem (700 mrad, 7 mGy). Similar doses (7 to 8 mGy) are delivered from a CT scan of the chest or a PET scan, while a combined",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scan is estimated to deliver a dose of 25 mrad (0.25 mGy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been estimated that no worker exposed at the Fukushima reactor accident in Japan has received a radiation dose greater than 25,000 mrad (250 mGy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For comparison, the exposure dose from a round-trip airplane flight from New York to Los Angeles is 5 mrad (0.05 mGy), and the exposure dose from an airport screening is 0.001 to 0.005 mrad (0.01 to 0.05 mGy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/11\">",
"       11",
"      </a>",
"      ]. The annual exposure dose from consumer products such as cathode television sets, smoke detectors, and Coleman lanterns is 10 mrad (0.1 mGy); from rocks and soil (depending on geographic location) is 28 mrad (0.28 mGy); and from radon gas in poorly ventilated basements is 200 mrad (2 mGy). Since all organic matter and water contain radioactive elements, radioactivity in food and water consumed by the average person in a year is approximately 30 mrad (0.3 mGy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The biologic effect of radiation doses higher than those received after routine medical imaging procedures are outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lowest radiation dose resulting in an observable effect on bone marrow depression in man, with a resultant decrease in blood cell counts, is in the range of 10 to 50 rem (100 to 500 mSv, 0.1 to 0.5 Gy).",
"     </li>",
"     <li>",
"      Cataracts have occurred in atomic bomb survivors in a dose-response manner with ocular doses as low as 0.4 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/13\">",
"       13",
"      </a>",
"      ]. The hazard ratio for an ocular dose of 3 Gy was 2.3 (95% CI 1.6-3.2). This represents an increase in incidence from 108 per 10,000 person years in the unexposed to 189 per 10,000 person years in individuals with ocular doses of &ge;3 Gy.",
"     </li>",
"     <li>",
"      The lowest total body dose at which the first deaths may be seen following exposure to ionizing radiation is in the range of 1.0 to 2.0 Gy (1000 to 2000 mSv). Depending upon the type of support given, 50 percent of people exposed to a dose of 3 to 4 Gy will be expected to die of radiation-induced injury. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lethal dose of radiation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is virtually no chance of survival following a total body exposure in excess of 10 to 12 Gy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of radiation-induced carcinogenesis and other adverse health effects from medical imaging is controversial and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=see_link&amp;anchor=H8#H8\">",
"     \"Radiation dose and risk of malignancy from cardiovascular imaging\", section on 'Health risks of radiation exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lethal dose of radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of the dose associated with death in 50 percent of those similarly exposed (ie, the LD 50) have been made in various scenarios. As an example, virtually all survivors of the explosion of a nuclear device at Hiroshima had estimated exposures of less than 3 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/14\">",
"     14",
"    </a>",
"    ]. Depending on the incident, estimates for the LD 50 have ranged from 1.4 Gy among atomic bomb survivors in Japan to 4.5 Gy following uniform total-body exposure to external photons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Several factors determine the lethality of ionizing radiation. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose rate &mdash; doses received over a shorter period of time cause more damage.",
"     </li>",
"     <li>",
"      Distance from the source &mdash; For point sources of radiation, the dose rate decreases as the square of the distance from the source (inverse square law).",
"     </li>",
"     <li>",
"      Shielding &mdash; Shielding can reduce exposure, depending upon the type of radiation and the material used [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/17\">",
"       17",
"      </a>",
"      ]. As examples, alpha particles can be stopped by a sheet of paper or a layer of skin, beta particles by a layer of clothing or less than one inch of a substance such as plastic, and gamma rays by inches to feet of concrete or less than one inch of lead. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features of radiation exposure in children\", section on 'Ionizing radiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Available medical therapy &mdash; The availability of supportive therapy (eg, antibiotics, transfusion, use of cytokines, hematopoietic cell transplantation) is critical for those exposed to moderately high doses of radiation. These subjects are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=see_link\">",
"       \"Treatment of radiation injury in the adult\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon an analysis of all available data, the LD 50 at 60 days (LD",
"    <span class=\"nowrap\">",
"     50/60)",
"    </span>",
"    for humans has been estimated to be approximately 3.5 to 4.0 Gy in persons managed without supportive care, 4.5 to 7 Gy when antibiotics and transfusion support are provided, and potentially as high as 7 to 9 Gy in patients with rapid access to intensive care units, reverse isolation, and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/18-21\">",
"     18-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RADIATION DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation dose from external exposure can be assessed by physical, biological, and clinical dosimetric techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical dosimetry can provide an estimate of individual dose, using a whole-body radiation dosimeter. While sensitive and precise measurements of dose can be made, few whole-body dosimeters are available for rapid assessment of dose. Reconstruction of dose can be made with considerable sensitivity, using environmental measurements combined with time-integrated activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Measurements of radioactivity in the air, plants, buildings, and ground are combined with an individual activity over time to reconstruct a dose for the purpose of epidemiological studies. However, this is a time-consuming process that is impractical in an emergency situation, particularly when there are many potentially exposed persons.",
"   </p>",
"   <p>",
"    Estimation of internal radiation dose from the deposition of radioactive materials, such as alpha emitters (eg, plutonium, americium, californium), and beta-gamma emitters (eg, cesium, cobalt, iodine) into the lungs, gastrointestinal tract, and other tissues, requires detection with special instrumentation (such as ion chambers and spectroscopes). In this case, measurements are made on body fluids (blood, urine, saliva), nasal swipes, fecal samples,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expired air [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biologic and clinical markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual \"biomarkers\" for evaluation of radiation exposure have been sought from the beginning of the nuclear age. Currently, the three most clinically useful markers are the time to onset of emesis, lymphocyte depletion kinetics, and chromosomal aberrations (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ). These will be described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chromosomal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A landmark observation was the observation that the frequency of chromosomal aberrations (eg, dicentrics, chromosomal rings) in lymphocytes correlated well with radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/25\">",
"     25",
"    </a>",
"    ]. In this setting, the formation of dicentrics involves the end-to-end joining of two separate chromosomes both damaged by ionizing radiation, resulting in a chromosome containing two centromeres. Ring formation involves a break in the arm of a single damaged chromatid, followed by rejoining to form a ring and a fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=see_link&amp;anchor=H6#H6\">",
"     \"Chromosomal translocations, deletions, and inversions\", section on 'Translocations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At low doses, chromosomal breakage results from the passage of a single charged particle through the cell's nucleus, damaging one or more chromosomes in the process, and is a linear function of dose. At high doses, chromosomal breaks are caused by the passage of multiple charged particles, resulting in an interaction that is a quadratic function of dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of chromosomal aberrations is currently the \"gold standard\" for biodosimetry. Their detection is facilitated by the application of hybridization probes for centromeres and automated metaphase detectors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The sample is not drawn until 24 hours after the exposure. For triage purposes, as few as 20 metaphases may be scored to provide a preliminary estimate of dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/29\">",
"     29",
"    </a>",
"    ]. However, such testing typically requires several days of processing time, including sample collection, cell separation and incubation, metaphase finding, and scoring of dicentrics and ring forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Biological dosimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of biological dosimetry include the determination of absolute lymphocyte counts, lymphocyte depletion kinetics, interphase aberrations (eg, premature chromosome condensation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/30\">",
"     30",
"    </a>",
"    ]), and electron spin resonance of dental enamel. Of these methods, monitoring the decrease in absolute lymphocyte count has been found to be the most practical method to assess the radiation dose within hours or days following a radiation exposure (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A simple algorithm has been developed for estimating whole-body dose in the range from 0.5 to 10 Gy from acute exposure to gamma radiation, using the rate of decline in circulating lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of documenting clinical signs and symptoms has been emphasized in assigning risk from radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/33\">",
"     33",
"    </a>",
"    ]. These include the time of onset and intensity of nausea and vomiting, the appearance and type of skin changes, development of anorexia and fatigue, and the severity of depression in circulating blood counts, including the absolute lymphocyte, neutrophil, and platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of these clinical features, the time to emesis and lymphocyte depletion kinetics are dose-related and are amenable to quantitative analysis with respect to dose (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/37\">",
"     37",
"    </a>",
"    ]. As an example, at doses &gt;6 Gy, virtually all victims will develop vomiting, with the time to vomiting being inversely proportional to the absorbed dose. However, at doses &lt;4 Gy, vomiting is less common and its",
"    <span class=\"nowrap\">",
"     presence/absence,",
"    </span>",
"    and timing cannot be reliably used to estimate dose. A reassessment of reported times to emesis showed a relative error of 200 percent for the prediction of a dose of 2Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international consensus document developed with the assistance of the World Health Organization has recommended that clinicians use as many sources of information on radiation dose as available in order to assess prognosis and guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/39\">",
"     39",
"    </a>",
"    ]. Whenever possible, incorporation of data from three key elements (ie, time to onset of vomiting, lymphocyte depletion kinetics, and chromosome aberrations) should be sought for the most accurate assignment of prognosis and selection of therapy (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ). As a practical matter, however, only the time of onset of vomiting and lymphocyte depletion may be available within the first 24 hours following exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CELLULAR EFFECTS OF RADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation may interact directly with intracellular targets or may interact with other molecules (eg, water) to produce free radicals that, in turn, reach and damage a target (eg, DNA, mRNA, proteins, plasma membrane). Depending upon the amount of ionization deposited along a unit length of track of radiation, the chance of achieving a \"hit\" on a critical cellular target will vary. Low linear energy transfer (LET) sources of radiation (eg, x-rays, gamma-rays) produce sparse ionization, while high LET radiation sources (eg, alpha particles, neutrons) are characterized by dense ionization.",
"   </p>",
"   <p>",
"    The following observations have been made concerning the effects of ionizing radiation on human tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiosensitivity varies directly with the rate of cellular proliferation. Rapidly dividing cells are more profoundly affected (see below).",
"     </li>",
"     <li>",
"      Radiosensitivity varies directly with the number of future divisions. Long-lived gonadal and hematopoietic stem cells fall into this category.",
"     </li>",
"     <li>",
"      Radiosensitivity varies indirectly with the degree of morphologic and functional differentiation. As an example, cells at the growth plate in bone, which have not yet developed into bone or cartilage, are more sensitive than those of the diaphysis. Accordingly, growth arrest of bone is commonly seen after radiation exposure to the growth plate in children, as may occur in the treatment of malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variation in sensitivity to radiation is an inherited genetic trait, although candidate gene studies have been largely unsuccessful in identifying the genetic variants underlying most phenotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While all tissues composed of short-lived cells are directly and indirectly affected by radiation, the most critically affected tissues in adults include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spermatocytes in the testis",
"     </li>",
"     <li>",
"      Hematopoietic precursor cells in the bone marrow",
"     </li>",
"     <li>",
"      Crypt cells in the intestines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon the dose and dose rate, effects on these cells are primarily exerted through inhibition of cell renewal and triggering of cell death (apoptosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/42\">",
"     42",
"    </a>",
"    ]. However, most cell types do not manifest evidence of damage until mitosis occurs, and several divisions may ensue before actual cell death.",
"   </p>",
"   <p>",
"    Survival curves for normal clonogenic hematopoietic cells have been derived using the spleen colony forming unit (CFU-S) assay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/43\">",
"     43",
"    </a>",
"    ]. A single-exponential radiation survival curve is evident for murine hematopoietic stem cells, with 37 percent surviving a dose of 0.95 Gy. Such mitotically active cells have a limited ability to divide after a whole body exposure greater than 2 to 3 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, some CFU-S appear to be extremely radioresistant, perhaps because they are in a resting or G(0) phase, surviving doses as high as 6 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Such radioresistant stem cells may play a role in spontaneous hematologic recovery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the hematopoietic response observed in exposed individuals receiving cytokine therapy. In addition, hematopoietic reconstitution may occur from unirradiated (or relatively under-irradiated) areas of bone marrow that have been partially shielded from the source of radiation by physical materials (eg, lead, other metals), heavy clothing, or other body tissues.",
"   </p>",
"   <p>",
"    Based on a mathematical model, it has been suggested that an absolute neutrophil count less than 200 to",
"    <span class=\"nowrap\">",
"     300/microL",
"    </span>",
"    at five to six days following radiation exposure indicates that no stem cells remain from which a spontaneous regeneration could occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/46\">",
"     46",
"    </a>",
"    ]. Such patients would therefore be candidates for hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=see_link&amp;anchor=H51#H51\">",
"     \"Treatment of radiation injury in the adult\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dose-dependent effects on various organs have also been identified. They are of two types, deterministic and stochastic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A deterministic effect is one in which the severity is determined by the dose (eg, depression of blood counts). A dose threshold (ie, a dose below which an effect is not seen) is characteristic of this effect. As an example, the threshold absorbed dose for a \"deterministic effect\" on bone marrow (0.5 Gy) is lower than that for all other organs, except for the testis (0.15 Gy).",
"     </li>",
"     <li>",
"      A stochastic effect represents an outcome for which the probability of occurrence (rather than severity) is determined by the dose. An example is radiation-induced carcinogenesis, which occurs after a prolonged and variable delay (latency) after exposure. These effects do not have an apparent threshold dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms underlying deterministic and stochastic effects remain unknown. Studies showing the impact of radiation on gene function may shed light in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In addition, studies employing cDNA microarrays and protein arrays may help to identify gene expression and protein profiles that may ultimately serve as biomarkers for an exposure to radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sources of data on radiation effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial understanding of the acute effects of total-body radiation is derived from analysis of the clinical course of individuals exposed to radiation after the detonation of two atomic bombs over Japan in 1945, as well as radiation accidents that have occurred throughout the world since that time. In some cases, this includes a large affected population (eg, the Marshallese exposed in 1954 and individuals in the former Soviet Union and Europe exposed during the Chernobyl nuclear power plant disaster in 1986). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Chernobyl reactor explosion in the former Soviet Union resulted in high levels of exposure, with 28 people receiving doses &gt;6 Gy, 23 receiving 4 to 6 Gy, and 53 receiving 2 to 4 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/53\">",
"       53",
"      </a>",
"      ]. There were 115 cases of acute radiation syndrome and 28 deaths.",
"     </li>",
"     <li>",
"      In 1987, in Goiania, Brazil, an abandoned Cesium-137 teletherapy source was breached, with hundreds of people exposed to gamma and beta radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/54\">",
"       54",
"      </a>",
"      ]. There were 48 hospitalizations for radiation injury and four deaths.",
"     </li>",
"     <li>",
"      In contrast, the reactor breach at Three Mile Island in the United States was calculated to result in no more than 50 to 70 mrem of additional exposure to any individual within range [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other cases, relatively low numbers of individuals have been exposed. The registry of serious radiation accidents maintained by the Radiation Emergency Assistance",
"    <span class=\"nowrap\">",
"     Center/Training",
"    </span>",
"    Site",
"    <span class=\"nowrap\">",
"     (REAC/TS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/56\">",
"     56",
"    </a>",
"    ] has been updated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/57\">",
"     57",
"    </a>",
"    ]. Since December 1990, over 50 accidents have occurred worldwide, involving more than 650 individuals. Of these, more than 250 had a significant exposure and more than 30 have died. This information is periodically updated at Advanced Radiation Research Workshops in Europe and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHASES OF ACUTE RADIATION INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irradiation of human cells leads to acute as well as delayed effects, which may involve every major organ system. Chronic changes, which may take many months or years to become evident, include the development of malignancy (eg, thyroid cancer, leukemia), growth retardation in children, cataracts, infertility, and fetal abnormalities. These stochastic effects of ionizing radiation will not be discussed here.",
"   </p>",
"   <p>",
"    The ensuing damage results from the sensitivity of cells to radiation, with the most rapidly dividing cells being the most sensitive to the acute effects of radiation. The inherent sensitivity of these cells results in a constellation of clinical syndromes that occur within a predictable range of doses after a whole-body or significant partial-body exposure. Symptoms arising from such exposures are referred to as radiation sickness or acute radiation syndrome (ARS). Classically, the threshold dose for ARS is a whole-body or significant partial-body irradiation of greater than 1 Gy delivered at a relatively high dose rate.",
"   </p>",
"   <p>",
"    Acute changes, which are seen within the first two months following exposure, include signs and symptoms resulting mainly from damage to the skin, central nervous system, lung, gastrointestinal tract, and hematopoietic tissues. Classic clinical syndromes associated with ARS include the hematopoietic, gastrointestinal, and cerebrovascular (formerly known as cardiovascular and central nervous) syndromes, although there is significant clinical overlap.",
"   </p>",
"   <p>",
"    Local radiation injury, sometimes called the Cutaneous Syndrome (CS), is especially common and important in patients with ARS consequent to a non-uniform exposure. The CS may include changes ranging from epilation to radionecrosis (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Cutaneous syndrome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The presence of ARS complicates the management of CS, due to poor wound healing, infections, and bleeding, while the converse is also true. As an example, severe CS dramatically affected the course of victims of the Chernobyl accident, and was the main cause of death in more than half of the lethal cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are four main phases to the acute radiation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prodromal phase usually occurs in the first 48 hours following exposure, but may develop up to six days after exposure.",
"     </li>",
"     <li>",
"      The latent phase is a short period characterized by improvement of symptoms. However, this effect is transient, lasting for several days to a month. The duration of this phase is inversely related to the dose of radiation received, and may be absent at the highest, fatal doses.",
"     </li>",
"     <li>",
"      The stage of manifest illness may last for weeks, and is characterized by intense immunosuppression. It is the most difficult to manage. If the person survives this stage, recovery is likely.",
"     </li>",
"     <li>",
"      Death or recovery phase &mdash; Those patients who recover will require close follow-up for the first year, owing to the risk for unusual infections, as aberrant immune reconstitution is probable in those with significant exposure. Survivors will require life-long follow-up to monitor for long-term complications, such as organ dysfunction and carcinogenesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The onset, duration, and dominant pattern of the acute radiation syndrome depend upon the dosage of radiation received (",
"    <a class=\"graphic graphic_table graphicRef53570 \" href=\"UTD.htm?28/5/28764\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/64\">",
"     64",
"    </a>",
"    ]. As examples, the prodromal syndrome is often minimal in those exposed to doses of &le;1 Gy, while those exposed to doses of 10 to 20 Gy may have a rapid compression of phases and proceed from the prodromal phase to death in two days or less.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prodromal phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early symptoms resulting from an acute total-body exposure constitute the prodromal radiation syndrome. The time of onset, duration of symptoms and signs, and mortality rate are all dependent on the magnitude of radiation dose and the presence or absence of additional injury (such as trauma or burns). These early symptoms include anorexia, apathy, nausea, vomiting, diarrhea, fever, tachycardia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    headache. The following general observations concerning the relationship between this phase and the absorbed dose include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prodromal syndrome is generally mild or absent at total body doses of 1 Gy or less.",
"     </li>",
"     <li>",
"      Patients whose symptoms begin more than two hours after exposure were probably exposed to doses &lt;2 Gy. They can be expected to fully recover within one month, although long-term sequelae may develop.",
"     </li>",
"     <li>",
"      Onset of symptoms within the first two hours usually indicates significant and potentially lethal exposures exceeding 2 Gy. At these doses, sloughing of the gastrointestinal epithelium also occurs (ie, the gastrointestinal syndrome), adding to the symptomatology (see below). At doses between 2 to 10 Gy, it is difficult to establish a prognosis based solely on the existence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of the prodromal syndrome.",
"     </li>",
"     <li>",
"      At high doses (eg, 10 to &gt;20 Gy), prodromal symptoms occur in virtually all patients within minutes of exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]. These gradually merge into loss of consciousness and hypotension, components of the cerebrovascular syndrome. Death often occurs within a few days to weeks after such exposures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, a rapid and severe prodromal response is the harbinger of a poor clinical outcome that may be later complicated by a severe form of the gastrointestinal and hematopoietic syndromes. As noted previously, the time of onset of vomiting in the prodromal phase, when present, can be used to estimate radiation dose (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ), (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Biological dosimetry'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Evaluation of signs and symptoms specific to these organ systems is required for triage of victims, selection of therapy, and determination of prognosis. These component syndromes are discussed below. It is important to emphasize the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all patients who present with the cerebrovascular syndrome will die. Those who live long enough will also develop a severe form of the gastrointestinal and hematologic syndromes before death.",
"     </li>",
"     <li>",
"      Those patients who do not present with the cerebrovascular syndrome but develop the gastrointestinal syndrome may survive with appropriate medical support. However, all will also develop the hematologic syndrome if they survive long enough. Presentation with mild gastrointestinal symptoms limited to one or two episodes of diarrhea with associated abdominal pain is accompanied by virtually certain recovery.",
"     </li>",
"     <li>",
"      Those with minimal gastrointestinal signs and symptoms may still develop the hematologic syndrome, with a potentially fatal outcome. Those with mild to moderate prodromal symptoms, absence of the gastrointestinal syndrome, and minimal evidence of bone marrow suppression have an estimated survival in excess of 90 percent.",
"     </li>",
"     <li>",
"      The cutaneous syndrome may develop in any of the above scenarios and will complicate management. Consultation with specialists in CS is necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cerebrovascular syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebrovascular syndrome, also called the neurovascular syndrome or CNS syndrome, results from localized changes in the central nervous system. These include impaired capillary circulation with damage to the blood-brain barrier, interstitial edema, acute inflammation, petechial hemorrhages, inflammation of the meninges, and hypertrophy of perivascular astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/68\">",
"     68",
"    </a>",
"    ]. Paroxysmal spike and wave discharges may be evident on the EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/69\">",
"     69",
"    </a>",
"    ], and the presence of swelling and edema may be documented by CT scans and MRI of the head.",
"   </p>",
"   <p>",
"    In general, cerebrovascular symptoms only occur at whole-body doses in excess of 10 Gy. Its stages from prodrome through to death are usually compressed (",
"    <a class=\"graphic graphic_table graphicRef53121 \" href=\"UTD.htm?32/44/33484\">",
"     table 4",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early presence, within minutes of exposure, of fever, hypotension, and major impairment of cognitive function, along with severe prodromal symptoms (eg, anorexia, nausea, vomiting) suggests that the victim has been exposed to a supralethal dose of radiation (ie, more than 20 to 30 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those with lesser, but still fatal, exposures to the central nervous system, in the range of 10 to 20 Gy, present with persistent and severe nausea and vomiting, accompanied by headache, neurologic deficits, and abnormal cognition. Signs and symptoms include disorientation, confusion, loss of balance, and seizures. Physical examination may show papilledema, ataxia, and reduced or absent deep tendon and corneal reflexes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be a latent period of a few hours in which there is apparent improvement, but within five to six hours watery diarrhea, secondary to severe gastrointestinal syndrome (see below), respiratory distress, fever, and cardiovascular collapse ensue. The final picture, which may mimic that of sepsis, includes hypotension, cerebral edema, increased intracranial pressure, and cerebral anoxia, with death in about two days time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gastrointestinal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal syndrome typically develops within five days of the initial exposure (",
"    <a class=\"graphic graphic_table graphicRef70498 \" href=\"UTD.htm?29/14/29931\">",
"     table 5",
"    </a>",
"    ). At doses &lt;1.5 Gy, only the prodromal phase of nausea, vomiting, and gastric atony are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More severe symptoms develop at doses between 5 and 12 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/72\">",
"     72",
"    </a>",
"    ], secondary to loss of intestinal crypt cells and breakdown of the mucosal barrier, with sloughing of the epithelial cell layer and denudation of the bowel wall. These changes result in crampy abdominal pain, diarrhea, nausea and vomiting, gastrointestinal bleeding with resultant anemia, and abnormalities of fluid and electrolyte balance. This early phase is often followed by a latent phase lasting five to seven days, during which symptoms abate. Vomiting and severe diarrhea accompanied by high fever make up the manifest illness. Systemic effects at this time may include malnutrition from malabsorption.",
"   </p>",
"   <p>",
"    Impaired barrier function of the gastrointestinal tract results in the passage of bacteria and their toxins through the intestinal wall into the bloodstream, predisposing to infection and sepsis, which may be further compromised by immunosuppression and cytopenias secondary to development of the hematopoietic syndrome (see below).",
"   </p>",
"   <p>",
"    Other severe complications include ulceration and necrosis of the bowel wall, leading to stenosis, ileus, and perforation. In the latter case, recovery is most unlikely, as radiosensitive stem cells in the crypts of the gastrointestinal tract are permanently damaged. Consequently, there is no replacement of cells that are lost from the surface of the villi through the sloughing process, precluding recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/31,73\">",
"     31,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, mild gastrointestinal symptoms limited to one or two episodes of diarrhea with associated abdominal pain are accompanied by virtually certain recovery, provided that the hematopoietic syndrome that follows is reversible (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hematopoietic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematopoietic syndrome develops at doses exceeding 1 Gy and is rarely clinically significant at doses &lt;1 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/3,66,67,70,72\">",
"     3,66,67,70,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitotically active hematopoietic precursors have a limited capacity to divide after whole-body doses greater than 2 to 3 Gy. In addition to inducing apoptosis, whose effect is not seen before the first cell cycle following radiation exposure, radiation alters recirculation properties of lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/46,74,75\">",
"     46,74,75",
"    </a>",
"    ]. Neutropenia and thrombocytopenia reach a nadir at two to four weeks and may persist for months. Anemia inevitably ensues, due to the combined effects of gastrointestinal blood loss from the gastrointestinal syndrome, hemorrhage into organs and tissues secondary to thrombocytopenia, and, ultimately, bone marrow aplasia.",
"   </p>",
"   <p>",
"    In the ensuing weeks to months after exposure, hypoplasia or aplasia of the bone marrow occurs, resulting in pancytopenia, predisposition to infection, bleeding, and poor wound healing, all of which may contribute to death in the absence of appropriate supportive care.",
"   </p>",
"   <p>",
"    Two important points warrant discussion here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhomogeneity of dose, afforded by partial shielding or a more ventral exposure may imply bone marrow sparing. Indeed, most active bone marrow sites are present dorsally, in the spine, dorsal ribs, and pelvis. Such sparing may contribute to the reestablishment of hematopoiesis.",
"     </li>",
"     <li>",
"      Selectively radioresistant subpopulations of stem cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      accessory cells exist. These may play an important role in recovery of hematopoiesis after exposure to doses as high as 6 Gy, albeit with a reduced capacity for self-renewal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lymphocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphopenia is common and occurs before depression of the other cellular elements, and may develop within the first 6 to 24 hours after exposure to a moderate or high dose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/31,76,77\">",
"     31,76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary immune deficiency due to miscellaneous causes\", section on 'Ionizing radiation'",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 50 percent decline in the absolute lymphocyte count within the first 24 hours after exposure, followed by a further more severe decline within 48 hours, characterizes a potentially fatal exposure in the range of 5 to 10 Gy.",
"     </li>",
"     <li>",
"      An absolute lymphocyte count that remains within 50 percent of normal during the first week following exposure suggests an exposure of &lt;1 Gy and a survival probability in excess of 90 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, there is a highly predictable relationship between the absolute lymphocyte count and absorbed dose (",
"    <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"     table 2",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Biologic and clinical markers'",
"    </a>",
"    above). However, since lymphopenia can also result from stresses accompanying burns and trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/78-80\">",
"     78-80",
"    </a>",
"    ], it is always important to examine more than one biodosimetry element (eg, prodromal symptoms, lymphocyte dicentrics) whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Neutrophil counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the profound lymphocytopenia that occurs shortly after exposure, the absolute neutrophil count and the total white blood cell count become nearly identical. The initial neutrophil nadir occurs at approximately one week following exposure, after which there may be an abortive, transient rise in the absolute neutrophil count following exposure to doses less than 5 Gy. Presence of this abortive rise may indicate a survivable exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/81\">",
"     81",
"    </a>",
"    ]. As noted above, a more profound and longer-lasting neutrophil nadir occurs at two to four weeks post-exposure, and may last for many weeks (",
"    <a class=\"graphic graphic_figure graphicRef65095 \" href=\"UTD.htm?16/2/16431\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanism for the transient neutrophilia is unknown but may be related to demargination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enhanced release of preformed neutrophils from marrow. In addition, radiation is known to cause endothelial cell damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death, resulting in interruption of the marrow-peripheral blood barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the overall levels of lymphocyte, neutrophil, and platelet counts, as well as the presence or absence of infection and blood loss, the relative severity of toxicity to the hematopoietic system can be evaluated (",
"    <a class=\"graphic graphic_table graphicRef51611 \" href=\"UTD.htm?16/21/16732\">",
"     table 6",
"    </a>",
"    ). Approaches to therapy for different levels of severity, including the use of transfusions, antibiotics, colony-stimulating factors, and allogeneic hematopoietic cell transplantation, are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=see_link\">",
"     \"Treatment of radiation injury in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cutaneous syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous syndrome may develop early following exposure (eg, one to two days). However, it may take years before becoming fully manifest. Unlike the syndromes discussed above, which are related to the whole body radiation dose, the localized dose to the skin is critical for determining the type of skin lesions that occur.",
"   </p>",
"   <p>",
"    Early lesions include erythema, edema, and dry desquamation of the skin (",
"    <a class=\"graphic graphic_table graphicRef62805 \" href=\"UTD.htm?5/28/5580\">",
"     table 7",
"    </a>",
"    ). Such lesions may be isolated or may appear simultaneously in several locations, depending on the amount of skin receiving direct exposure. More advanced lesions include bullae, moist desquamation, ulceration, and onycholysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Target cells of radiation reside at multiple levels within the skin (ie, epidermis, dermis, hair follicle canals, subcutaneous tissues). Hence, the severity of the cutaneous reaction depends upon the depth dose distribution of the radiation source [",
"    <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/68\">",
"     68",
"    </a>",
"    ]. Ulceration may be limited to the epidermis or may involve deeper structures, such as the dermis, subcutaneous tissue, and even muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone. Estimated dose responses to localized skin exposures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blisters and bullae appear 1 to 3 weeks after localized exposure to doses of &gt;30 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/15,84\">",
"       15,84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Moist desquamation and ulceration are seen with localized doses of 20 to 25 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/0/4106/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The estimated threshold for erythema is a localized exposure dose of 10 to 15 Gy",
"     </li>",
"     <li>",
"      Epilation occurs 10 to 20 days after a single localized exposure to 3 to 4 Gy or greater",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17710551\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biology and clinical features of radiation injury in adults are discussed in this review, including an understanding of radiation dose units, how such doses are assessed, the cellular effects of radiation, and the various phases of acute radiation injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Radiation units",
"      </strong>",
"      &mdash; The terms most often used for quantifying radioactivity, radiation dose, and radiation injury are described in the table (",
"      <a class=\"graphic graphic_table graphicRef74125 \" href=\"UTD.htm?0/22/364\">",
"       table 1",
"      </a>",
"      ). Examples are given of possible radiation exposures and levels of radiation at which biologic changes are to be expected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Units of radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       The patient&rsquo;s radiation dose",
"      </strong>",
"      &mdash; The three most clinically useful markers of absorbed radiation dose are the time to onset of emesis, lymphocyte depletion kinetics, and chromosomal aberrations (",
"      <a class=\"graphic graphic_table graphicRef82508 \" href=\"UTD.htm?7/34/7725\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessment of radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Biologic effects",
"      </strong>",
"      &mdash; The most critically affected tissues in adults include spermatocytes in the testis, hematopoietic precursor cells in the bone marrow, and crypt cells in the intestines. Radiation effects are primarily exerted through inhibition of cell renewal and triggering of cell death (apoptosis). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cellular effects of radiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Phases of radiation injury",
"      </strong>",
"      &mdash; The main phases of the acute radiation syndrome (prodromal, latent, manifest illness, and death or recovery) depend mostly on the radiation dose (",
"      <a class=\"graphic graphic_table graphicRef53570 \" href=\"UTD.htm?28/5/28764\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Phases of acute radiation injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Prodromal phase",
"      </strong>",
"      &mdash; Early prodromal symptoms include anorexia, apathy, nausea, vomiting, diarrhea, fever, tachycardia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headache. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prodromal phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Organ system involvement",
"      </strong>",
"      &mdash; Cerebrovascular (",
"      <a class=\"graphic graphic_table graphicRef53121 \" href=\"UTD.htm?32/44/33484\">",
"       table 4",
"      </a>",
"      ), gastrointestinal (",
"      <a class=\"graphic graphic_table graphicRef70498 \" href=\"UTD.htm?29/14/29931\">",
"       table 5",
"      </a>",
"      ), hematopoietic (",
"      <a class=\"graphic graphic_table graphicRef51611 \" href=\"UTD.htm?16/21/16732\">",
"       table 6",
"      </a>",
"      ), and cutaneous (",
"      <a class=\"graphic graphic_table graphicRef62805 \" href=\"UTD.htm?5/28/5580\">",
"       table 7",
"      </a>",
"      ) toxicity can be expected, depending upon the dose of radiation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/1\">",
"      Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140:1037.",
"     </a>",
"    </li>",
"    <li>",
"     Mettler FA Jr, Royal HD, Drum DE. Radiation accidents. In: Textbook of pediatric emergency medicine, 4th ed, Fleisher GR, Ludwig S (Eds), Lippincott, Philadelphia 2000. p.965.",
"    </li>",
"    <li>",
"     Hall EJ. Radiobiology for the Radiologist, 5th ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     National Research Council, Committee on the Biological effects of Ionizing Radiation. Health Effects of Exposure to Low Levels of Ionizing Radiation, BEIR V. Washington, DC: National Academy Press 1990.",
"    </li>",
"    <li>",
"     Chinsoo Cho L, Glatstein E. Radiation Injury. In: Harrison's Principles of Internal Medicine, Fauci AS, Braunwald E, Isselbacher KL, et al. (Eds), McGraw-Hill, New York 1998. p.2559.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/6\">",
"      Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/7\">",
"      McKetty MH. Study of radiation doses to personnel in a cardiac catheterization laboratory. Health Phys 1996; 70:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/8\">",
"      Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005; 46:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/9\">",
"      Christodouleas JP, Forrest RD, Ainsley CG, et al. Short-term and long-term health risks of nuclear-power-plant accidents. N Engl J Med 2011; 364:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/10\">",
"      Gale RP. Fukushima not a repeat of Chernobyl: A doctor's analysis of nuclear accidents. Cancer Lett 2011; 37:13:April 1.",
"     </a>",
"    </li>",
"    <li>",
"     Rapiscan Systems. Rapiscan Secure 1000 Single Pose. www.rapiscansystems.com/rapiscan-secure-1000-single-pose.html (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     Doses in our daily lives. United States Nuclear Regulatory Commission. www.nrc.gov/about-nrc/radiation/around-us-daily-lives.html (Accessed on October 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/13\">",
"      Neriishi K, Nakashima E, Akahoshi M, et al. Radiation dose and cataract surgery incidence in atomic bomb survivors, 1986-2005. Radiology 2012; 265:167.",
"     </a>",
"    </li>",
"    <li>",
"     Schull WJ. Effects of atomic radiation: A half-century of studies from Hiroshima and Nagasaki, J Wiley, New York 1996.",
"    </li>",
"    <li>",
"     Rotblat J. Acute mortality in nuclear war. In: The Medical Implications of Nuclear War, Soloman F, Marston RQ (Eds), Institute of Medicine, National Academy of Sciences, Washington, DC 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/16\">",
"      Mole RH. The LD50 for uniform low LET irradiation of man. Br J Radiol 1984; 57:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/17\">",
"      Reeves GI. Radiation injuries. Crit Care Clin 1999; 15:457.",
"     </a>",
"    </li>",
"    <li>",
"     Lushbaugh CC. Reflections on some recent progress in human radiobiology. In: Advances in Radiation Biology, Augenstein LC, Mason R, Zelle M (Eds), Academic Press, New York 1969. p.277.",
"    </li>",
"    <li>",
"     Vriesendorp HM, Van Bekkum DW. Susceptibility to total-body irradiation. In: Response to Total-Body Irradiation in Different Spe, Broerse JJ, MacVittie T (Eds), Martinus Nijhoff, Amsterdam 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/20\">",
"      Anno GH, Young RW, Bloom RM, Mercier JR. Dose response relationships for acute ionizing-radiation lethality. Health Phys 2003; 84:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/21\">",
"      Saenger EL. Radiation accidents. Ann Emerg Med 1986; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Bouville A, Anspaugh L, Beebe GQ. What is desirable and feasible in dose reconstruction for application in epidemiological studies?. In: The Radiological Consequences of the Chernobyl Accident, Karaglou A, Desmetg G, Kelly GN, et al. (Eds), Office for Official Public of the European Communities, Luxembourg 1996. p.995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/23\">",
"      Brooks AL. Biomarkers of exposure, sensitivity and disease. Int J Radiat Biol 1999; 75:1481.",
"     </a>",
"    </li>",
"    <li>",
"     Management of Persons Accidentally Contaminated with Radionuclides. NCRP Report No.65, Bethesda, MD: National Council on Radiation Protection and Measurements 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/25\">",
"      Bender MA, Gooch PC. Somatic chromosome aberrations induced by human whole-body irradiation: the \"Recuplex\" criticality accident. Radiat Res 1966; 29:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/26\">",
"      Bender MA. Cytogenetics research in radiation biology. Stem Cells 1995; 13 Suppl 1:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/27\">",
"      Kolanko CJ, Pyle MD, Nath J, et al. In situ detection of a PCR-synthesized human pancentromeric DNA hybridization probe by color pigment immunostaining: application for dicentric assay automation. Biotech Histochem 2000; 75:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/28\">",
"      Pantelias GE, Maillie HD. Direct analysis of radiation-induced chromosome fragments and rings in unstimulated human peripheral blood lymphocytes by means of the premature chromosome condensation technique. Mutat Res 1985; 149:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/29\">",
"      Lloyd DC, Edwards AA, Moquet JE, Guerrero-Carbajal YC. The role of cytogenetics in early triage of radiation casualties. Appl Radiat Isot 2000; 52:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/30\">",
"      Prasanna PG, Escalada ND, Blakely WF. Induction of premature chromosome condensation by a phosphatase inhibitor and a protein kinase in unstimulated human peripheral blood lymphocytes: a simple and rapid technique to study chromosome aberrations using specific whole-chromosome DNA hybridization probes for biological dosimetry. Mutat Res 2000; 466:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/31\">",
"      Goans RE, Holloway EC, Berger ME, Ricks RC. Early dose assessment in criticality accidents. Health Phys 2001; 81:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/32\">",
"      Goans RE, Holloway EC, Berger ME, Ricks RC. Early dose assessment following severe radiation accidents. Health Phys 1997; 72:513.",
"     </a>",
"    </li>",
"    <li>",
"     Fliedner TM, Friesecke I, Beyrer K. Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome, The British Institute of Radiology, Oxford 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/34\">",
"      Wald N. Diagnosis and therapy of radiation injuries. Bull N Y Acad Med 1983; 59:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/35\">",
"      Hartmann A, Bojar H, Zamboglou N, et al. [The significance of clinical prodromes for dosage estimation after whole-body radiation exposure]. Strahlenther Onkol 1994; 170:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/36\">",
"      Gottl&ouml;ber P, Kr&auml;hn G, Peter RU. [Cutaneous radiation syndrome: clinical features, diagnosis and therapy]. Hautarzt 2000; 51:567.",
"     </a>",
"    </li>",
"    <li>",
"     Goans RE. Clincal care of the radiation-accident patient: patient presentation, assessment and initial diagnosis. In: The Medical Basis for Radiation-accident preparedness: The clinical care of victims, Ricks RC, Berger ME, O'Hara FM (Eds), Parthenon Publishing Group, Boca Raton, FL 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/38\">",
"      Demidenko E, Williams BB, Swartz HM. Radiation dose prediction using data on time to emesis in the case of nuclear terrorism. Radiat Res 2009; 171:310.",
"     </a>",
"    </li>",
"    <li>",
"     Dainiak N, Gent RN, Carr Z, et al. Medical management of acute radiation syndrome: an international consensus and evidence based recommendations. Manuscript submitted for publication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/40\">",
"      Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/41\">",
"      Barnett GC, West CM, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/42\">",
"      Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/43\">",
"      McCulloch EA, Till JE. The sensitivity of cells from normal mouse bone marrow to gamma radiation in vitro and in vivo. Radiat Res 1962; 16:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/44\">",
"      van Bekkum DW. Radiation sensitivity of the hemopoietic stem cell. Radiat Res 1991; 128:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/45\">",
"      Inoue T, Hirabayashi Y, Mitsui H, et al. Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. Exp Hematol 1995; 23:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/46\">",
"      Fliedner TM, Tibken B, Hofer EP, Paul W. Stem cell responses after radiation exposure: A key to the evaluation and prediction of its effects. Health Phys 1996; 70:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/47\">",
"      Amundson SA, Bittner M, Meltzer P, et al. Physiological function as regulation of large transcriptional programs: the cellular response to genotoxic stress. Comp Biochem Physiol B Biochem Mol Biol 2001; 129:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/48\">",
"      Amundson SA, Do KT, Shahab S, et al. Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat Res 2000; 154:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/49\">",
"      Goldberg Z, Schwietert CW, Lehnert B, et al. Effects of low-dose ionizing radiation on gene expression in human skin biopsies. Int J Radiat Oncol Biol Phys 2004; 58:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/50\">",
"      Amundson SA, Fornace AJ Jr. Gene expression profiles for monitoring radiation exposure. Radiat Prot Dosimetry 2001; 97:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/51\">",
"      Dainiak N, Schreyer SK, Albanese J. The search for mRNA biomarkers: global quantification of transcriptional and translational responses to ionising radiation. BJR Suppl 2005; 27:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/52\">",
"      Sreekumar A, Nyati MK, Varambally S, et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 2001; 61:7585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/53\">",
"      Gale RP. Immediate medical consequences of nuclear accidents. Lessons from Chernobyl. JAMA 1987; 258:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/54\">",
"      Roberts L. Radiation accident grips Goi&acirc;nia. Science 1987; 238:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/55\">",
"      Gerusky TM. Three Mile Island: assessment of radiation exposures and environmental contamination. Ann N Y Acad Sci 1981; 365:54.",
"     </a>",
"    </li>",
"    <li>",
"     Ricks RC. The radiation-accident patient in the new millennium: past history and future threats. In: The Medical Bases for Radiation-Accident Preparedness: The Clinical Care of Victims, Ricks RC, Berger ME, O'Hara FM (Eds), The Parthenon Publishing Group, Boca Raton, FL 2002. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/57\">",
"      Dainiak N, Ricks RC. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl 2005; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/58\">",
"      Fliedner TM, Feinendergen LE, Hopewell JW. Chronic irradiation: tolerance and failure in complex biological systems. Br J Radiol 2002; suppl 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     Fliedner TM, Meineke V, Dainiak N, et al. Radiation-Induced Multi-Organ Involvement and Failure: A Challenge for Pathogenetic, Diagnostic and Therapeutic Approaches and Research, British Insitute of Radiology, Ulm 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/60\">",
"      Petrova A, Gnedko T, Maistrova I, et al. Morbidity in a large cohort study of children born to mothers exposed to radiation from Chernobyl. Stem Cells 1997; 15 Suppl 2:141.",
"     </a>",
"    </li>",
"    <li>",
"     The Radiological Consequences of the Chernobyl Accident, Karaoglou A, Desmet G, Kelly GN, Menzel HG (Eds), Luxembourg: Office of the European Communities, 1996.",
"    </li>",
"    <li>",
"     Barabanova AV. Acute radiation syndrome with cutaneous syndrome. In: The Medical Basis for Radiation-Accident Preparedness, Ricks RC, Berger ME, O'Hara FM Jr (Eds), The Parthenon Publishing Group, New York 2002. p.217.",
"    </li>",
"    <li>",
"     Guidance for radiation accident management www.orau.gov/reacts/guidance.htm (Accessed on August 10, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/64\">",
"      Darte JM, Little WM. Management of the acute radiation syndrome. Can Med Assoc J 1967; 96:196.",
"     </a>",
"    </li>",
"    <li>",
"     Lushbaugh CC. Human radiation tolerance. In: Bioastronautics Data Book. NASA-S-30006, Parker J Jr (Ed), National Aeronotics and Space Administration, Washington, DC 1973. p.421.",
"    </li>",
"    <li>",
"     Wald N. Radiation Injury. In: Cecil Textbook of Medicine, Wyngaarden JB, Smith LH Jr (Eds), WB Saunders, Philadelphia 1982. p.2228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/67\">",
"      Anno GH, Baum SJ, Withers HR, Young RW. Symptomatology of acute radiation effects in humans after exposure to doses of 0.5-30 Gy. Health Phys 1989; 56:821.",
"     </a>",
"    </li>",
"    <li>",
"     Fliedner TM, Friesecke I, Beyrer K. Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome, Institute of Radiology, Oxford 2001.",
"    </li>",
"    <li>",
"     Gangloff H. Hippocampal spike activity following low doses of irradiation. In: Response of the Nervous System to Ionizing Radiation, Haley TJ, Snider RS (Eds), Little Brown, Boston 1964. p.221.",
"    </li>",
"    <li>",
"     Medical Consequences of Nuclear Warfare. Walker RI, Cerveny RJ (Eds), Office of the Surgeon General, Falls Church, VA 1989. Available at: www.afrri.usuhs.mil (Accessed on August 10, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/71\">",
"      Dubois A, Walker RI. Prospects for management of gastrointestinal injury associated with the acute radiation syndrome. Gastroenterology 1988; 95:500.",
"     </a>",
"    </li>",
"    <li>",
"     Chinsoo Cho L, Glatstein E. Radiation Injury. In: Harrison's Principles of Internal Medicine, Fauci AS, Braunwald E Isselbacher KL, et al (Eds), McGraw-Hill, New York 1998. p.2559.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/73\">",
"      Husebye E, Hauer-Jensen M, Kj&oslash;rstad K, Skar V. Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. Dig Dis Sci 1994; 39:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/74\">",
"      Albanese J, Dainiak N. Ionizing radiation alters Fas antigen ligand at the cell surface and on exfoliated plasma membrane-derived vesicles: implications for apoptosis and intercellular signaling. Radiat Res 2000; 153:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/75\">",
"      Stodtmeister R, Sandkuhler S, Fliedner TM. Uber die pathogenese akuter knochenmarkatrophie bei ratten nach ganzkorperbestrahlung mit schnellen elektronen. Folia Haematologica 1956; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     Andrews GA, Auxier JA, Lushbaugh CC. The importance of dosimetry to the medical management of persons accidentally exposed to high levels of radiation. In: Personnel Dosimetry for Radiation Accidents, IAEA, Vienna, Vienna 1965. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/77\">",
"      ANDREWS GA, CLOUTIER RJ. ACCIDENTAL ACUTE RADIATION INJURY. THE NEED FOR RECOGNITION. Arch Environ Health 1965; 10:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/78\">",
"      Barlow Y. T lymphocytes and immunosuppression in the burned patient: a review. Burns 1994; 20:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/79\">",
"      Cheadle WG, Pemberton RM, Robinson D, et al. Lymphocyte subset responses to trauma and sepsis. J Trauma 1993; 35:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/80\">",
"      Lebedev MY, Sholkina MN, Utkina TM, et al. Immunophenotype of Peripheral Blood Lymphocytes in Patients with Burns. Russ J Immunol 2001; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/81\">",
"      Vorobiev AI. Acute radiation disease and biological dosimetry in 1993. Stem Cells 1997; 15 Suppl 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/82\">",
"      Rezvani M, Hopewell JW, Wilkinson JH, et al. Time- and dose-related changes in the thickness of skin in the pig after irradiation with single doses of thulium-170 beta particles. Radiat Res 2000; 153:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/0/4106/abstract/83\">",
"      Peter RU. Cutaneous radiation syndrome &mdash; clinical and therapeutic aspects. Rad Protect Bull 1996; 183:19.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Management of Radiation Accidents, 2nd ed, Gusev I, Guskova AK, Mettler Fa Jr (Eds), CRC Press, Boca Raton, FL 2001.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8367 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4106=[""].join("\n");
var outline_f4_0_4106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17710551\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNITS OF RADIATION DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Absorbed Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dose Equivalent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dose rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Examples of possible radiation exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lethal dose of radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ASSESSMENT OF RADIATION DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biologic and clinical markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chromosomal changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Biological dosimetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CELLULAR EFFECTS OF RADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sources of data on radiation effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHASES OF ACUTE RADIATION INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prodromal phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cerebrovascular syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gastrointestinal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hematopoietic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Neutrophil counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cutaneous syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17710551\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8367|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/2/16431\" title=\"figure 1\">",
"      Serial WBC after radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/22/364\" title=\"table 1\">",
"      Radiation terms defined",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/34/7725\" title=\"table 2\">",
"      Radiation biodosimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/5/28764\" title=\"table 3\">",
"      Phases radiation injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/44/33484\" title=\"table 4\">",
"      Radiation toxicity cerebrovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29931\" title=\"table 5\">",
"      Radiation toxicity gastrointest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/21/16732\" title=\"table 6\">",
"      Radiation toxicity hematopoietic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/28/5580\" title=\"table 7\">",
"      Radiation tox cutaneous",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17689?source=related_link\">",
"      Clinical features of radiation exposure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25193?source=related_link\">",
"      Management of radiation exposure in children following a nuclear disaster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38170?source=related_link\">",
"      Treatment of radiation injury in the adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_0_4107="Diseases associated with achalasia-like motility disorders";
var content_f4_0_4107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases associated with achalasia-like motility disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Malignancy, especially gastric carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chagas disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurofibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple endocrine neoplasia, type 2B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile Sj&ouml;gren's syndrome with achalasia and gastric hypersecretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic idiopathic intestinal pseudo-obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anderson-Fabry disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4107=[""].join("\n");
var outline_f4_0_4107=null;
var title_f4_0_4108="Factors associated with trial of labor after cesarean delivery";
var content_f4_0_4108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors associated with trial of labor after cesarean delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factors resulting in an increased likelihood of successful TOLAC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Prior vaginal birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Spontaneous labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Advanced cervical dilation on admission",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        Factors resulting in a decreased likelihood of successful TOLAC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; African American or Hispanic ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Increased maternal age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Single marital status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Less than 12 years education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Delivery at rural or private hospital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Recurrent indication for initial cesarean delivery",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        Non-medical factors affecting TOLAC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; American College of Obstetricians and Gynecologist guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; American Society of Anesthesiologist guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Physician and hospital professional liability concerns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Physician preference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patient preference and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Patient access to TOLAC",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4108=[""].join("\n");
var outline_f4_0_4108=null;
var title_f4_0_4109="Echo pericardial disease";
var content_f4_0_4109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for echocardiography in pericardial disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Patients with suspected pericardial disease, including effusion, constriction, or effusive-constrictive process.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Patients with suspected bleeding in the pericardial space, eg, trauma, perforation, etc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Follow-up study to evaluate recurrence of effusion or to diagnose early constriction. Repeat studies may be goal directed to answer a specific clinical question.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Pericardial friction rub developing in acute myocardial infarction accompanied by symptoms such as persistent pain, hypotension, and nausea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Follow-up studies to detect early signs of tamponade in the presence of large or rapidly accumulating effusions. A goal-directed study may be appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Echocardiographic guidance and monitoring of pericardiocentesis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Class IIb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Postsurgical pericardial disease, including postpericardiotomy syndrome, with potential for hemodynamic impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. In the presence of a strong clinical suspicion and nondiagnostic TTE, TEE assessment of pericardial thickness to support a diagnosis of constrictive pericarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Routine follow-up of small pericardial effusion in clinically stable patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Follow-up studies in patients with cancer or other terminal illness for whom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        management would not be influenced by echocardiographic findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Assessment of pericardial thickness in patients without clinical evidence of constrictive pericarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Pericardial friction rub in early uncomplicated myocardial infarction or early postoperative period after cardiac surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ACC/AHA classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class I:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Class II:",
"        </strong>",
"        Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Class IIa:",
"        </strong>",
"        Weight of evidence/opinion is in favor of usefulness/efficacy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <strong>",
"         Class IIb:",
"        </strong>",
"        Usefulness/efficacy less well established by evidence/opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Class III:",
"        </strong>",
"        Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4109=[""].join("\n");
var outline_f4_0_4109=null;
var title_f4_0_4110="Flt 1 and sFlt 1";
var content_f4_0_4110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Flt-1 and sFlt-1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Protein structure of vascular endothelial growth factor receptor (VEGF) and placental growth factor receptor (PIGF) Flt-1 and sFlt-1 are illustrated. Flt-1 has 7 immunoglobulin domains (lgG) which are thought to mediate ligand binding to VEGF and PIGF. sFlt-1 protein has a unique 31 AA C-terminus region derived from alternative splicing and lacks the transmembrane and cytoplasmic domains.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of S Ananth Karumanchi MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4110=[""].join("\n");
var outline_f4_0_4110=null;
var title_f4_0_4111="Genetic loci T2 DM";
var content_f4_0_4111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Genetic loci associated with type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronological accounting of the discovery of type 2 diabetes-associated genes, plotted by year of definitive publication and approximate effect size. Within each group,",
"    <em>",
"     darker colors",
"    </em>",
"    indicate biological candidate genes",
"    <em>",
"     (PPARG, KCNJ11, HNF1B, WFS1, HNF4A, HNF1A, and ENPP1)",
"    </em>",
"    , and",
"    <em>",
"     lighter colors",
"    </em>",
"    denote loci identified via agnostic genome-wide approaches. In",
"    <em>",
"     gray",
"    </em>",
"    are genes implicated in type 2 diabetes by considerable functional and genetic evidence but for which genome-wide statistical evidence of association has not been reached.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Florez JC. The genetics of type 2 diabetes: A realistic appraisal in 2008. J Clin Endocrine Metab 2008; 93:4633. file://jcem.endojournals.org/. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_0_4111=[""].join("\n");
var outline_f4_0_4111=null;
